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Chapter 1. 
 
Introduction 
 
 
1. Amphiphilic molecules: structure, classification and 
biological role 
 
Amphiphilic (from the Greek αμφις, amphis: both and φιλíα, philia: love, friendship) is 
a term describing a chemical compound possessing both hydrophilic (water-loving, polar) 
and hydrophobic (fat-loving) properties (Figure 1). Such a compound is called amphiphilic 
or amphipathic. This forms the basis for a number of 
areas of research in chemistry and biochemistry, 
notably that of lipid polymorphism. The lipophilic 
groups of the amphiphiles are typically long 
hydrocarbon residues such as a long chain of the form 
CH3(CH2)n
 
The hydrophilic groups can be classified in various categories: 
, with n > 4. [1-3] 
1. Charged groups 
• Anionic (R = lipophilic part): 
 Carboxylates: RCOO
 Sulfate groups: ROSO
- 
3
 Phosphate groups: ROPO
- 
3
2-, 
• Cationic: 
present in phospholipids 
 Amines: RNH3
2. Neutral (uncharged groups): examples are 
+ 
alcohols with large R groups, such as 
diacyl glycerol (DAG), and oligoethyleneglycols with long alkyl chains. 
In Figure 2 same examples of amphiphilic molecules are reported: 
Figure 1. Schematic representation of 
an amphiphile molecule. 
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Anionic 
OSO3-Na+  
Sodium dodecyl sulfate (SDS) 
Cationic 
NH3+  
Ammonium dodecane 
Neutral 
O
O
OH
O
O
 
1-Palmitoyl-2-oleoyl-glycerol 
Figure 2. Some examples of amphiphilic molecules. 
 
Amphiphiles orientate their domain with the highest affinity for the solvent 
toward the solvent molecules, while the other part of the molecule tends to fold so to 
avoid contact with the solvent. In this way amphiphilic molecules align according to well-
defined patterns and give rise to a variety of different self-aggregates. The shape 
(=morphology) of the aggregates is determined by the ratio between the size of the 
hydrophilic and the hydrophobic part as well as the nature of the solvent. Scanning 
electron microscopy and other techniques have revealed various morphologies: micellar 
rods (A), micelles (B), bilayers (C), vesicles (D) and inverted aggregates (E), as shown in 
Figure 3. 
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Figure 3. Possible self-aggregation modes of amphiphilic molecules. 
 
For example, in water solution the polar heads are exposed to the solvent and the 
hydrophobic tails are not in contact with the solvent; in this way the amphiphiles are able 
to solubilize in water a large number of hydrophobic guest molecules (oils), otherwise 
insoluble in polar solvents, by encapsulation of the guest within the micelle core (Figure 
4). This property is used in detergents. [3] 
 
 
Figure 4. Solubilization of hydrophobic molecules in water. 
 
Amphiphilic molecules are very common in nature. The phospholipids are an 
example of naturally occurring amphiphiles. They are a major component of all cell 
membranes as they can form lipid bilayers which enclose the cytoplasm and other 
contents of a cell. Most phospholipids contain a glycerol backbone, a phosphate group, 
and a structurally simple organic molecule such as choline. The hydrophilic head contains 
the negatively charged phosphate group, and may contain other polar groups. The 
hydrophobic tail usually consists of long fatty acid hydrocarbon chains. When placed in 
water, phospholipids form a variety of structures depending on the specific properties of 
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the phospholipids. These specific properties allow phospholipids to play an important role 
in the phospholipid bilayers. In cell membranes, the phospholipids often occur in 
combination with other molecules (e.g., proteins, glycolipids, cholesterol). Lipid bilayers 
are obtained when hydrophobic tails line up one against the other, forming a membrane 
with hydrophilic heads on both sides facing the water (Figure 5). [3-4] 
 
 
A 
 
B 
Figure 5. (A) Phospholipids structure; (B) Phospholipid bilayer (cell membrane). 
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2. Nucleolipids: a class of amphiphilic molecules 
 
In recent years, nucleic acids features have been used in the development of 
numerous artiﬁcial structures, including oligonucleotide [5-7] and nucleolipid analogs. [8-
10] In these biomimetic approaches, two fundamental objectives have been pursued in 
combining nucleic acid and lipid families: 
 i) the development of new therapeutic strategies; 
ii) the construction of new supramolecular assemblies. [11] 
 
2.1 Natural nucleolipids 
 
Nucleolipids are hybrid molecules composed of a lipid covalently linked to a 
nucleobase, a nucleoside or an oligonucleotide. Hybrid lipid–nucleoside structures occur 
in eukaryotic and prokaryotic cells. Tunicamicyns for instance possess antimicrobial, 
antifungal, antiviral and antitumor activities. [12-13] Cytidinediphosphate diacylglycerol 
coenzyme (CDP-DAG, Figure 6), a diphosphorylated nucleolipid (or liponucleotide), is 
present in mammalian cells and plays a central role in the metabolism of phosphoinosides 
and cardiolipins. [14] CDP-DAG and its analogue 2’-deoxy-CDP-DAG are also present in 
prokaryotic cells as key intermediates in the synthesis of all glycerophospholipids. In 
addition to their biochemical function, nucleolipids are unique in terms of molecular 
structure (containing different structural motifs, i.e. lipid, phosphate, sugar, heterocyclic 
moieties) and biophysical properties. Consequently, nucleolipid analogs have been 
investigated as anticancer drugs and pro-drugs. [11] 
                                                                                                                                                Chapter 1 
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Figure 6. Chemical structures of CDP-DAG and synthetic amphipatic nucleotides. 
 
2.2 Artificial nucleolipids 
 
Nucleotides are natural substrates of transcriptase or reverse transcriptase. 
Accordingly, many analogs have been designed to block the enzymatic elongation of RNA 
chains and are used as anti-tumor or antiviral drugs. [11] Given their inherent toxicity, 
many prodrugs of these chemotherapeutic agents have been evaluated over the years. 
[15-20] Since the 80’s, several research groups have devoted their efforts to combine the 
pharmacological activity of nucleosides with the aggregation properties of vesicle-forming 
lipids. It is well known that liposome-forming species can produce effective drug carrier 
systems, capable of incorporating large amounts of lipophilic drugs in aqueous solutions 
and efficiently transport them within cells by endocytosis (Figure 7). If the carrier system 
is covalently linked to the drug, a very efficient prodrug may be obtained, which, by self-
structuring into liposomes, is expected to undergo only minimal leakages of the lipidic 
prodrug from the delivery system, thus ensuring an efﬁcient transport and, in parallel, 
protecting the drug from enzymatic degradation. This simple concept is the basis for the 
increasing interest towards nucleolipids. 
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Figure 7. Transport of a drug into a cell by liposome formulation. 
 
2.3 Supramolecular assemblies of nucleolipids 
 
Nucleolipids, in contrast to classical detergents, possess a highly informative polar 
head (A, T, C, G, U or analogs) with additional H-bonding and π-stacking capabilities that 
can speciﬁcally base -pair with other nucleobases. The interplay between these specific 
base pairing interactions, [5-7] and the unique aggregation properties of lipids is very 
attractive for the design of supramolecular assemblies with new and interesting 
properties. These concepts of molecular recognition with nucleolipids were initially 
applied to a supramolecular ﬁlm at the air–water interface. [8,21,22] More recently, base-
pairing between complementary nucleolipids at mesoscopic interfaces such as those 
found in vesicular and micellar systems have been investigated. [8,9,23–28] Nucleolipid–
nucleolipid interactions have been studied in different types of supramolecular systems 
including micelles, [29] vesicles, [30] and monolayers. [31-32] For these purposes a 
variety of synthetic strategies have been used to prepare nucleolipids. [15,33,34] 
Since 2002, Barthélémy and coworkers have been designing novel amphiphilic 
structures derived from nucleobases. They have investigated how modifications within 
the molecular structure of the nucleolipid (hydrophobization of the 2’ and/or 3’ position 
in contrast to the classical 5’-modiﬁcation) affect their physico-chemical and self-
assembling properties. A large number of novel amphiphilic nucleolipids have been 
therefore synthesized, which can be classified according to their charge:  
1) nonionic (compounds I1–3), [35,36] 
2) zwitterionic (phosphocholine derivatives, I4–6), [37,38] 
3) anionic [39] (single chain nucleotides I7) 
4) cationic compounds (I8 and I9
 
). [40-41] 
Examples of nucleolipid structures described in the literature are shown in Figure 8: 
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Figure 8. Left, examples of synthetic amphiphilic nucleolipids (I). Right, TEM and SEM images showing 
examples of different nucleolipid self-assemblies: nano-ﬁbers, vesicles, and microspheres. [11] 
 
The wide possibility to finely modulate the physico-chemical properties and three-
dimensional structures of nucleolipids as a function of the nature of the inserted 
decorations renders these artificial compounds new, powerful tools for innovative 
developments both in biomedical applications and in material science. 
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Chapter 2. 
 
Synthesis and Characterization of Novel Nucleolipid 
Nanovectors as Molecular Carriers for Potential 
Applications in Drug Delivery 
 
 
1. Introduction: the prodrugs 
 
The development of prodrugs — chemically modified versions of the 
pharmacologically active agent that must undergo an in vivo transformation to release 
the active drug — is now a well established strategy to improve the physico-chemical, 
biomedical or pharmacokinetic properties of pharmacologically relevant compounds, and 
thereby increase the developability and usefulness of a potential drug (Figure 1). [1–9] 
For example, prodrugs provide possibilities to overcome various barriers to drug 
formulation and delivery, such as poor aqueous solubility, chemical instability, insufficient 
oral absorption, rapid pre-systemic metabolism, inadequate brain penetration, toxicity 
and local irritation. Prodrugs can also improve drug targeting, and the development of a 
prodrug of an existing drug with improved properties may represent a life-cycle 
management opportunity. In most cases, prodrugs are simple chemical derivatives that 
require only one or two chemical or enzymatic transformation steps to yield the active 
parent drug. In some cases, a prodrug may consist of two pharmacologically active drugs 
that are coupled together in a single molecule so that each drug acts as a promoiety for 
the other; such derivatives are called co-drugs. [10,11] Prodrugs have also been referred 
to as reversible or bioreversible derivatives, latentiated drugs or biolabile drug-carrier 
conjugates, [12–14] but the term prodrug is now standard. A bioprecursor prodrug is a 
prodrug that does not contain a carrier or promoiety, but results from a molecular 
modification of the active agent itself. This modification (for example, an oxidation or 
reduction) generates a new compound that can be transformed metabolically or 
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chemically, with the resulting compound being the active agent (it can also be referred to 
as an active metabolite). Finally, soft drugs, which are often confused with prodrugs, also 
find applications in tissue targeting. However, in contrast to prodrugs, soft drugs are 
active drugs that are designed to undergo a predictable and controllable deactivation or 
in vivo metabolism once their therapeutic effect is achieved. [15–17] Currently, 5–7% of 
the drugs approved worldwide can be classified as prodrugs, and approximately 15% of all 
new drugs approved in 2001 and 2002 were prodrugs. [2,6]  
 
 
Figure 1.  A simplified representative illustration of the prodrug concept. The drug–promoiety is the 
prodrug that is typically pharmacologically inactive. In broad terms, the barrier can be thought of as any 
liability or limitation of a parent drug that prevents optimal (bio)pharmaceutical or pharmacokinetic 
performance, and which has to be overcome for the development of a marketable drug. The drug and 
promoiety are covalently linked via bioreversible groups that are chemically or enzymatically labile, such as 
those shown here. The ‘ideal’ prodrug yields the parent drug with high recovery ratios, with the promoiety 
being non-toxic. [1] 
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2. Aims of the work 
 
In recent years a number of amphiphilic nucleoside-based nanoaggregates have 
been proposed as transfection agents. In this frame, Berti and coworkers reported a 
promising strategy for the base-specific recognition between micelles composed of 
dioctanoylphosphatidyluridine, a negatively charged amphiphile, and short oligoadenylic 
acids. [18-21] Extensive and detailed highlights on this field have been recently presented 
by Gissot et al. [22] In this review several examples of nucleoside- or nucleotide- and 
oligonucleotide-based amphiphiles along with their peculiar properties are presented, 
which in principle may result into efficient pro-drugs. Insertion of functional reporter 
groups into amphiphilic nucleolipids in principle further expands the potential of this 
therapeutic strategy, allowing specific recognition/interaction with drugs. The complex 
between the functional nucleolipid and the drug can be ad hoc designed, so that rapid 
self-assembly is realized to give stable super-aggregates such as micelles, vesicles, 
liposomes, etc.  
Nanostructuring in pseudo-physiological conditions leads to efficient cell uptake 
through the phospholipid bilayers and also confers protection to the drug from 
extracellular enzymatic degradation. On the other hand, full reversibility - within the cells-  
of the chemical bonds connecting the nucleoside decorations may be a powerful strategy 
to prevent toxicity, thus opening the way to a completely new approach for drug delivery. 
In this chapter we present the design, synthesis and physico-chemical characterization of 
novel nucleolipids along with the investigation of their cytotoxic profile by in vitro 
experiments.  
The new described nucleolipids are characterized by: 
• thymidine or uridine selected as the central scaffold;  
• one pyridine-methyl group (linker) on the nucleobase as the ligand to 
successively attach the effective drug [a Ru(III) complex, which will be 
discussed in detail in Chapter 3]; 
• one hydrophilic oligo(ethylene glycol) unit in position 5’; 
• one or two (in the case of uridine) lipophilic oleyl or cholesteroxyacetyl 
groups covalently anchored in position 3’, or 2’ and 3’.  
A schematic representation of the novel derivatives here proposed is shown in Figure 2. 
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B = Purine or pyrimidine base
 
Figure 2. Representation of the new amphiphilic nucleolipids here described.  
 
Specifically, as optimized substrates inspired to a prototype previously described 
by Paduano and Ruffo, [23] the nucleolipids here synthesized - depicted in Figure 3 - are: 
3-(4-pyridylmethyl)-3’-O-oleyl-5’-O-(monomethoxy)triethylene glycol-acetyl-thymidine 
(ToThy, 1a), 3-(4-pyridylmethyl)-3’-O-oleyl-5’-O-(benzyloxy)hexaethylene glycol-acetyl-
thymidine (HoThy, 1b), 3-(4-pyridylmethyl)-2’,3’-di-O-oleyl-5’-O-(benzyloxy)hexaethylene 
glycol-acetyl-uridine (DoHu, 1c) and 3-(4-pyridylmethyl), 3’-O-cholesteroxyacetyl, 5’-O-
(monomethoxy)triethylene glycol-acetyl-thymidine (ToThyChol, 1d). [24,25] 
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Figure 3. Functional nucleolipids: ToThy (1a), HoThy (1b), DoHu (1c) and ToThyChol (1d). 
 
The physico-chemical characterization of these systems has been addressed to the 
study of the aggregation behaviour and of the morphology of the aggregates they form 
both in pure water and in pseudo-physiological conditions by means of dynamic light 
scattering (DLS) and small-angle neutron scattering (SANS). Cell culture experiments were 
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performed in order to get an insight into the in vivo potential of the developed 
nanocarriers on the basis of rightly interpreted in vitro results.  
Nowadays a major concern of nanomedicine consists in understanding the 
contingent toxicity, and, more generally, the environmental impact of nanomaterials. 
Extensive research efforts are devoted to developing drug-transporting devices to target 
cells without affecting healthy ones and without showing undesired side effects. Hence, 
detailed biochemical and toxicological investigations are crucial to determine the 
feasibility of effective applications in biotechnological platforms for the new developed 
nanoaggregates. For this reason – in parallel with a detailed microstructural 
characterization of these systems, designed as new nanovectors - we focused on in vitro 
bioscreening by useful and standardised tumor and non tumor in vitro models, aiming at 
verifying if these nucleolipid aggregates affect cell growth and viability. 
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3. Results and discussion 
 
3.1 Synthesis of functional nucleosides ToThy, HoThy, DoHu and 
ToThyChol 
 
The design of functional amphiphilic nucleosides 1a-d (Figure 3)  –  following a 
previous work by Paduano and Ruffo [23] - was based on the usage of thymidine or 
uridine as the central scaffold, anchoring three diverse structural motifs: [24,25]  
1) one pyridine-methyl arm, inserted at the N-3 position, as the functional reporter 
group, useful for successive manipulations and/or metal complexation;  
2) one (in the case of thymidine derivatives 1a, 1b and 1d) or two (in the case of  
uridine analog 1c) lipophilic residues, attached at the ribose secondary hydroxyl 
group(s) to induce self-assembly in aqueous solutions;  
3) one hydrophilic oligo(ethylene glycol) chain, linked at the 5’-OH ribose moiety; 
the role of the oligo(ethylene glycol) was here intended not only to optimize the 
“hydrophilic/lipophilic balance” within the hybrid molecules, but also – at a 
functional level - to prevent extracellular enzymatic degradation by the 
reticuloendothelial system.  
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Scheme 1. Synthetic scheme for the preparation of thymidine analogues 1a and 1b. Reaction conditions: a) 
4-(bromomethyl)pyridine, K2CO3, DMF, 12 h, 60 °C; b) oleic acid, or cholesteroxy-acetic acid (18), DCC, 
DMAP, CH2Cl2, 12 h, r.t.; c) 1% TCA in CH2Cl2, 1 h, r.t.; d) CH3O-TEG acetic acid (11), or BnO-HEG acetic acid 
(14), DCC, DMAP, CH2Cl2, 4 h, r.t. 
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Scheme 2. Synthetic scheme for the preparation of uridine analog 1c. Reaction conditions: a) 4-
(bromomethyl)pyridine, K2CO3, DMF, 12 h, 60 °C; b) oleic acid, DCC, DMAP, CH2Cl2, 12 h, r.t.; c) 1% TCA in 
CH2Cl2, 2 h, r.t.; d) BnO-HEG acetic acid (14), DCC, DMAP, CH2Cl2, 3 h, r.t. 
 
The pyridine residue, attached through a methylene linker, was here selected as the 
ligand allowing, in a successive step, for transition metals trapping into stable complexes 
(the synthesis and properties of which are discussed in detail in Chapter 3). 
The synthesis of target molecules ToThy, HoThy, DoHu and ToThyChol was realized by a 
straightforward and high yielding strategy. Insertion of the pyridine moiety on the 
pyrimidine nucleobases was achieved in almost quantitative yields by treatment of the 5’-
DMT protected nucleosides 2 or 6, respectively, with 4-(bromomethyl)pyridine in DMF 
using K2CO3
i) insertion of the fatty acid chain at the secondary hydroxyls to give 4, 8 and 15, 
respectively; ii) detritylation, yielding 5, 9 and 16, respectively, and, finally, iii) 
conjugation with the oligoethylene glycol chains at the 5’-end to give the target 
compounds 1a, 1b, 1c and 1d. In all cases, the hydrophilic and lipophilic components were 
attached to the sugar hydroxyl moieties through ester linkages, which are cleanly formed 
by classical DCC activation of the selected carboxylic acids. These chemical bonds are 
typically stable in neutral and extracellular media, but can be rapidly degraded in cells by 
esterases. For the lipophilic component, oleic acid and cholesteroxy-acetic acid were 
chosen as suitable building blocks due to both their structural similarity with lipid 
membranes constituents and easy availability. The synthesis of cholesteroxy-acetic acid 
 as the base (Schemes 1 and 2). After a simple work-up, not requiring column 
chromatography, the alkylated nucleosides 3 and 7 were then subjected to the following 
reactions: 
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was performed starting from cholesterol, that was first converted into ester 17 by 
reaction with tert-butyl bromoacetate and NaH in THF, followed by treatment with formic 
acid, assuring tert-butyl removal and recovery of target acid 18 in almost quantitative 
yields (Scheme 3). 
 
HO
H H
O
H H
O
t-BuO
O
H H
HOOC
a b
17 18  
Scheme 3. Synthetic scheme for the preparation of cholesteroxy-acetic acid (18). 
Reaction conditions: a) NaH, tert-butyl bromoacetate, THF, 12 h, r.t.; b) HCOOH, 2 h, r.t. 
 
After DMT removal, the nucleobase-alkylated nucleolipids 5, 9 and 16 were decorated 
with different hydrophilic groups at their primary OH groups. For a fine tuning of their 
hydrophilic/lipophilic balance, oligo(ethylene glycol) chains of different length were 
adopted. The starting materials were (monomethoxy)triethylene glycol (CH3
10 11
12 13 14
a b
a b c
CH3O(CH2CH2O)3H CH3O(CH2CH2O)3CH2COOt-Bu CH3O(CH2CH2O)3CH2COOH
HO(CH2CH2O)6H BnO(CH2CH2O)6H BnO(CH2CH2O)6CH2COOt-Bu BnO(CH2CH2O)6CH2COOH
O-TEG) and 
hexaethylene glycol (HEG). These compounds were elaborated into acetic acid derivatives 
11 and 14 (Scheme 4), following a straightforward and high yielding procedure, essentially 
similar to the synthetic scheme exploited to obtain cholesteroxy-acetic acid 18 from 
cholesterol. In the case of hexaethylene glycol, an additional step of benzylation to cap 
one OH group was required, leading to alcohol 12, so to allow high yields in the following 
coupling with tert-butyl bromoacetate in the presence of NaH, furnishing ester 13. After 
an acid treatment with formic acid, esters 10 and 13 were cleanly converted into target 
acids 11 and 14, respectively, which were then coupled at the 5’-OH end of 5, 9 or 16 , 
finally giving 1a, 1b, 1c and 1d in good overall yields (41-48 % for 4 steps). 
 
Scheme 4. Synthetic scheme for the preparation of carboxylic acids 11 and 14. Reaction conditions for 11: 
a) NaH, tert-butyl bromoacetate, THF, 12 h, r.t.; b) HCOOH, 2 h, r.t. Reaction conditions for 14: a) NaH, 
BnBr, THF, 12 h, r.t.; b) NaH, tert-butyl bromoacetate, THF, 12 h, rt.; c) HCOOH, 2 h, r.t. 
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3.2 Characterization of the aggregates formed by ToThy, HoThy, DoHu 
and ToThyChol 
 
The characterization of the aggregates formed by ToThy, HoThy, DoHu and 
ToThyChol was accomplished in collaboration with the research group of Prof. Luigi 
Paduano of the Department of Chemistry “Paolo Corradini” in Naples.  
The aggregation capabilities for all the systems were investigated by a combined 
use of DLS (Dynamic Light Scattering) and SANS (Small Angle Neutron Scattering) to 
obtain information about the dimension and morphology of the aggregates. DLS 
experiments were conducted in H2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O and in pseudo-physiological conditions to measure 
the diffusion coefficients and hydrodynamic radii of the aggregates. As reported in Figure 
4, we can observe that while ToThy and ToThyChol present a mono-modal distribution 
both in water and in pseudo-physiological conditions, HoThy and DoHu show a bimodal or 
monomodal distribution of the aggregates depending on the environmental conditions. In 
pure water, DLS measurements showed the presence of two migrating species with 
different mean diffusion coefficients and in turn two aggregates size distributions were 
observed. 
 
 
Figure 4. Examples of the hydrodynamic radii distribution of the aggregates formed by nucleolipids in pure 
water (a) and in pseudo-physiological conditions (b). For all cases the concentration was 0.2 mmol kg-1
  In pseudo-physiological conditions all the systems show only a single distribution 
and, notably, for ToThy a sensible reduction of the particles size has been observed. In 
this system, as well as in pure water, the size of the aggregates of the investigated 
. 
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samples was found to be quite constant in the concentration range explored. The 
overview of these experimental results suggests that in pure water the molecules here 
presented, with the exception of ToThy and ToThyChol, show some tendency to form two 
aggregates with different morphology. This is very clear for DoHU where two 
dimensionally different aggregates are detected by DLS whereas for HoThy the presence 
of small aggregates is less evident. In both cases these supramolecular species show a 
hydrodynamic radius larger than the length of the molecule in a fully extended 
conformation. In fact, in the case of spherical micelles, the radius should be of the same 
order of the fully extended molecule, i.e. ~ 3.5 nm for HoThy and DoHu, well below the 
measured values (80-90 nm). On this basis, the small aggregates formed by HoThy and 
DoHu systems can be described as rod-like micelles. In contrast, in pseudo-physiological 
conditions all the systems exclusively show the presence of bigger aggregates, i.e. 
vesicles, while the distribution ascribable to the micelles disappears. This is confirmed by 
SANS results that do not reveal the presence of any correlation peak due to small 
aggregates and suggest the contemporary presence of a population of single and 
multilamellar vesicles, while for ToThyChol the aggregates are ascribed to rod-like 
micelles (see Table 1). As a general consideration, in pseudo-physiological conditions the 
radius of the vesicles is reduced with respect to that measured in pure water, though 
their size distribution broadens. This was also observed in other systems based on 
amphiphilic molecules carrying oligo(ethylene glycol) moieties in the head group. In fact, 
the presence of salts forces the molecules to aggregate in shape of vesicles, due to 
unfavorable interactions between the alkyl chains and the solvent, and the ethylene 
glycol chains and the solvent as well. The presence of salts increases the polar nature of 
the solvent and promotes the formation of a better packed structure of the alkyl chains, 
so that it is less accessible to ionic species. This is reinforced by the unfavorable 
interactions between the oligo(ethylene glycol) moieties and the salts. [26] 
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System in pseudo-physiological 
conditions, conc. 0.2 mmol kg
Morphology 
-1 
τ (nm) N d (nm) 
ToThy Vesicle 4.4±0.2 2±1 12±3 
HoThy Vesicle 5.0±0.1 4±1 24±3 
DoHu Vesicle 5.2±0.3 3±1 20±5 
ToThyChol Micelle - - 6±2 
Table 1. SANS results for the investigated systems.  
τ = layer thickness; N = number of consecutive bilayers; d = distance from the center of two consecutive 
bilayers. 
 
 
 
 
a b 
 
Figure 5. Schematic representation of the aggregates morphology.  
a) Multilamellar vesicles; b) rod-like micelles.  
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3.3 Bioactivity and in vitro cytotoxicity  
 
Biochemical and toxicological investigations were performed to screen and validate 
the new developed technological platform. In particular, we focused on the evaluation of 
cell growth and viability following the administration of the nucleolipid aggregates on 
different cultured tumor and non-tumor cell lines. For comparison, in the same 
experimental conditions, we evaluated the bioactivity of conventional POPC-based 
liposomes, which are currently used in a broad range of pharmaceutical applications for 
systemic drug delivery and for which no adverse effects have been reported to date.  
As depicted in Table 2, DoHu, HoThy and ThoThyChol aggregates do not show 
toxicological relevance within the used cell line panel, even when administered at high 
concentrations (250 µM) for 72 h. These results are similar to those obtained from POPC 
bioscreening. The related IC50 values (see Table 2) were higher than 103 µM for all the 
examined cell populations. Typically, IC50 values of this magnitude indicate the absence of 
bioactivity and would suggest the theoretical safety of these nanoaggregates towards 
biostructures, thus allowing to use them in a wide range of concentrations. Conversely, 
ToThy showed a weak but significant biological activity. In fact, even though at high 
concentrations (250 µM), a noteworthy cytotoxicity was observed toward certain tumor 
cells as neuroblastoma (SH-SY5Y cell line), glioma (C6 cell line) and cervical cancer (HeLa 
cell line). This activity was associated with IC50 values ranging from 65 to 180 µM, 
indicating some ability to interfere with cell viability and/or proliferation (Figure 5). As a 
consequence, the ToThy nucleolipidic aggregate appears unsuitable for drug delivery 
applications because of its intrinsic cytotoxicity. However, this is not a surprising result 
since hybrid molecules as nucleolipids, besides occurring in eukaryotic and prokaryotic 
cells in which they play a central role in some metabolic pathways, frequently show 
biological features like antimicrobial, antifungal, antiviral and antitumor activities. [27-30] 
Indeed, several research groups have tried in the past to use the pharmacologically active 
nucleolipids as therapeutic agents and/or as pro-drugs. [31-33] In addition, the 
occurrence of cytotoxic and antiproliferative activities can be probably related to 
aggregate stability, uptake and internalization pathways. Future studies, aimed at 
understanding the mechanisms behind the bioactivity showed by ToThy, will provide 
precious information to obtain a picture of the structure-activity relationships of these 
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nucleolipids, so to develop a second generation of nucleolipids with improved 
biochemical and biotechnological properties. In this frame, considering that 
neuroblastoma and glioma cells were the most sensitive to ToThy treatments, the design 
of nucleolipid derivatives endowed with a certain degree of cell and tissue specificity may 
also be envisaged, which is a perspective of paramount importance in the research of 
supramolecular devices with specific in vivo target recognition.  
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Figure 5. Examples of cell growth and viability evaluations performed on the indicated cell lines treated for 
72 h with POPC (■), ToThy (○), HoThy ( ) and DOHU (•) nanovectors 
 
IC50 (µM) 
Nanovectors Cell lines 
 3T3-L1 C6 CaCo-2 HeLa SH-SY5Y 
POPC >10 > 103 >103 >103 >103 
ToThy 
3 
475 ± 35 130 ± 20 380 ± 25 180 ± 20 65 ± 15 
HoThy >10 >103 >103 >103 >103 
DoHu 
3 
>10 >103 >103 >103 >103 
ToThyChol 
3 
>10 >103 >103 >103 >103 3 
 
                            Table 2. IC50 values for the investigated nanovectors. 
Here tested cell lines: 3T3-L1, murine embryonic fibroblasts (non cancer cells); HeLa, human cervical cancer 
cells; C6, rat glioma cells; CaCo-2, human epithelial colorectal adenocarcinoma cells; SH-SY5Y, human 
neuroblastoma cells. 
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To the best of our knowledge, this is one of the first cytotoxicity investigations 
performed on amphiphilic nucleolipids. [34,35] Since the cytotoxicity of DoHu, HoThy and 
ToThyChol was shown to be virtually null, the supramolecular systems obtained can be 
regarded as promising tools, leading to new types of functional, biocompatible materials, 
as well as vehicles for biomolecules transport and drug delivery. Therefore, these results 
show nanocarriers based on HoThy, DoHu and ToThyChol nucleolipids as realistic, 
effective alternatives to conventional lipid-based micelles. 
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4. Conclusions 
 
According to the large number of recent publications, amphiphilic hybrid 
molecules based on nucleolipids are attracting increasing interest in a variety of 
biotechnological fields, with relevant applications both in the design of artificial molecular 
devices and in novel therapeutic strategies. In this context, we here described the design, 
synthesis and supramolecular organization of three novel synthetic nucleolipids (here 
named ToThy, HoThy, DoHu and ToThyChol), as well as a preliminary investigation of their 
cytotoxic activity on a panel of tumor and non-tumor cell lines. Using thymidine and 
uridine as the central, polyfunctional scaffold, insertion of one oligo(ethylene glycol) 
residue and one or two lipophilic chains on the ribosidic moiety confer to these 
nucleolipids the desired amphiphilic behaviour in aqueous solutions. A pyridine-methyl 
arm was also introduced on the nucleobase as a functional ligand, available for successive 
complexation with transition metals, useful for diagnostic and therapeutic applications. 
Studies on the synthesis, biophysical characterization and biological evaluation of Ru(III) 
complexes of these molecules are reported in the Chapter 3. 
ToThy, HoThy, DoHu, ToThyChol nucleolipids, prepared in few, straightforward 
and high yielding synthetic steps, showed the desired distinctive features of nanocarriers, 
being mainly organized as multilayer vesicles or large micelles in pseudo-physiological 
conditions. For in vivo applications, a vesicular nanocarrier is more efficient than a 
micellar one due to the bigger size, with a more efficient delivery effect obtained if the 
aggregates size is within the 50-1000 nm range. [36] As determined by DLS and SANS 
measurements, the hydrodynamic radii of ToThy, HoThy and DoHu vesicular carriers are 
between 50 and 400 nm. In pure water, HoThy and DoHu also form cylindrical micelles. 
For ToThyChol we observed in pseudo-physiological conditions the formation of rod-like 
micelles. 
Bioscreening investigations revealed for HoThy, DoHu and ToThyChol the 
complete absence of significant cytotoxicity and toxicological effects on both normal and 
tumor cells. Given the utmost importance of delivering drugs and targeting specific cells, 
these nucleolipid-based amphiphiles with no associated cytotoxicity are very attractive 
candidate carriers, rationally designed to incorporate metal-based drugs in stable 
complexes. Conversely, due to the emergence of some cytotoxicity, further investigations 
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will be addressed to the elucidation of the molecular basis of ToThy bioactivity. Taken 
together, these results clearly indicate a novel and promising approach for the 
development of specific nanocarrier devices, consisting of finely tunable multifunctional 
materials with a versatile, ad hoc tailored chemical structure. 
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4. Experimental section 
 
General Methods 
All the reagents were of the highest commercially available quality and were used 
as received. TLC analyses were carried out on silica gel plates from Merck (60, F254). 
Reaction products on TLC plates were visualized by UV light and then by treatment with a 
10 % Ce(SO4)2/H2SO4 aqueous solution. For column chromatography, silica gel from 
Merck (Kieselgel 40, 0.063-0.200 mm) was used. NMR spectra were recorded on Bruker 
WM-400, Varian Gemini 200 and Varian Inova 500 spectrometers, as specified. All the 
chemical shifts are expressed in ppm with respect to the residual solvent signal. Peak 
assignments have been carried out on the basis of standard 1H-1
5’-O-(4,4′-dimethoxytriphenylmethyl)thymidine (2) (350 mg, 0.64 mmol) was dissolved 
in 5 ml of dry DMF. K
H COSY and HSQC 
experiments. The following abbreviations were used to explain the multiplicities: s = 
singlet; d = doublet; t = triplet; q = quartet; m = multiplet; b = broad; dd = double doublet. 
For the ESI MS analyses, a Waters Micromass ZQ instrument – equipped with an 
Electrospray source – was used in the positive and/or negative mode. MALDI TOF mass 
spectrometric analyses were performed on a PerSeptive Biosystems Voyager-De Pro 
MALDI mass spectrometer in the Linear mode using 3,4-dihydroxybenzoic acid as the 
matrix. 
 
Synthesis of 3-(4-pyridylmethyl)-3’-O-oleyl-5’-O-(4,4′-dimethoxytriphenylmethyl) - 
thymidine (4). 
 
2CO3 (267 mg, 1.93 mmol) and 4-(bromomethyl)pyridine 
hydrobromide (245 mg, 0.97 mmol) were then added to the reaction mixture, left at 60 °C 
under stirring. After 12 h, TLC analysis indicated the presence of a single product in the 
reaction mixture. Alkylated compound 3 was not isolated, but directly converted into its 
3’-conjugated derivative 4. To this purpose, the solvent was removed under reduced 
pressure and the residual solid was taken up in DCM, washed with water, dried over 
anhydrous Na2SO4 and concentrated in vacuo. Successively, the residue was dissolved in 
4 ml of dry DCM and then DMAP (117 mg, 0.96 mmol), oleic acid (304 µL, 0.96 mmol) and 
DCC (198 mg, 0.96 mmol) were sequentially added. After stirring for 12 h at room 
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temperature the reaction mixture was concentrated under reduced pressure; the crude 
product was purified by chromatography on a silica gel column using n-hexane/AcOEt 
(7:3, v/v, containing 1% of TEA) as eluent, yielding desired compound 4 in 64% for the two 
steps (368 mg, 0.41 mmol). 
4: oil: Rf = 0.8 (CHCl3/CH3OH, 95:5, v/v). 
1H NMR (CDCl3, 500 MHz): δ 8.53 [d, J = 6.0 Hz, 2H, (2x Hα Py)]; 7.64 (s, 1H, H-6); 7.37-
6.82 (overlapped signals, 15H, 2x Hβ Py and aromatic protons of DMT); 6.45 (dd, J = 8.0 
and 6.5 Hz, 1H, H-1'); 5.45 (m, 1H, H-3'); 5.34 (m, 2H, H-9 and H-10 oleic acid); 5.10 (s, 2H, 
-CH2Py); 4.11 (m, 1H, H-4'); 3.78 [s, 6H, 2x (-OCH3) of DMT]; 3.46 (m, 2H, H2-5'); 2.44 (m, 
2H, H-2'); 2.30 (apparent t, J = 8.0 and 7.5 Hz, 2H, CH2-2 oleic acid); 2.00-1.26 [overlapped 
signals, 26H, 13x (-CH2- oleic acid)]; 1.41 (s, 3H, CH3-Thy); 0.87 (t, J = 6.5 and 6.5 Hz, 3H, 
CH3-18 oleic acid). 
13C NMR (CDCl3, 100 MHz): δ 173.0 (C=O ester); 163.0 (C-4); 158.4, 144.0, 133.8, 127.9, 
127.0 and 113.2 (aromatic carbons of DMT); 150.8 (C-2); 149.8 (2x Cα Py); 145.3 (Cγ Py); 
135.0 (C-6); 129.9 and 129.5 (C-9 and C-10 oleic acid); 123.4 (2x Cβ Py); 110.7 (C-5); 87.0 
(quaternary carbon of DMT); 85.0 (C-1'); 84.0 (C-4'); 74.8 (C3'); 63.5 (C-5'); 55.1 [2x (OCH3) 
of DMT]; 43.4 (-CH2Py); 37.9 (C-2'); 34.0, 31.7, 29.5, 29.1, 28.9, 27.0, 24.6 and 22.5 
(aliphatic carbons of oleic acid); 13.9 (CH3-18 oleic acid); 12.2 (CH3-Thy). 
MALDI-MS (positive ions): calculated for C55H69N3O8 899.51; found m/z: 901.93 (M+H
+). 
 
Synthesis of 3-(4-pyridylmethyl)-3’-O-oleyl-thymidine (5).  
 
4 (237 mg, 0.26 mmol) was dissolved in 3 ml of a 1% TCA solution in DCM and stirred for 1 
h at room temperature. The solution was then concentrated in vacuo and purified by 
chromatography on a silica gel column eluted with CHCl3/CH3OH (99:1, v/v), giving the 
desired compound 5 in almost quantitative yields (155 mg, 0.26 mmol). 
5: oil: Rf = 0.4 (CHCl3/CH3OH, 95:5, v/v). 
1H NMR (CDCl3, 500 MHz): δ 8.67 [d, J = 4.0 Hz, 2H, (2x Hα Py)]; 7.63 (s, 1H, H-6); 7.57 [d, J 
= 5.0 Hz, 2H, (2x Hβ Py)]; 6.29 (dd, J = 7.5 and 7.0 Hz, 1H, H-1'); 5.34 (overlapped signals, 
3H, H-3', H-9 and H-10 oleic acid); 5.19 (s, 2H, -CH2Py); 4.08 (m, 1H, H-4'); 3.93 (m, 2H, H2-
5'); 2.40 (m, 2H, CH2-2 oleic acid); 2.33 (m, 2H, H-2'); 2.01 (m, 2H, CH2-8 oleic acid); 1.96 
(s, 3H, CH3-Thy); 1.62 (m, 2H, CH2-11 oleic acid); 1.28 [m, 22H, 11x (-CH2- oleic acid)]; 0.88 
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(apparent t, J = 6.0 and 7.5 Hz, 3H, CH3-18 oleic acid). 
13C NMR (CDCl3, 50 MHz): δ 173.4 (C=O ester); 162.9 (C-4); 150.7 (C-2); 146.1 (2x Cα Py); 
145.0 (Cγ Py); 134.8 (C-6); 129.9 and 129.6 (C-9 and C-10 oleic acid); 124.8 (2x Cβ Py); 
110.5 (C-5); 86.4 (C-1'); 85.1 (C-4'); 74.2 (C3'); 62.4 (C-5'); 43.4 (-CH2Py); 37.3 (C-2'); 34.0, 
31.8, 29.5, 29.4, 29.2, 28.9, 27.0, 24.7 and 22.6 (aliphatic carbons of oleic acid); 14.0 (CH3-
18 oleic acid); 13.2 (CH3-Thy). 
MALDI-MS (positive ions): calculated for C34H51N3O6 597.38; found m/z: 596.19 (M+H
+); 
618.57 (M+Na+); 635.86 (M+K+) 
 
Synthesis of 3-(4-pyridylmethyl)-3’-O-oleyl-5’-O-(monomethoxy)triethylene glycol 
acetyl-thymidine (1a). 
 
5 (88 mg, 0.15 mmol) was dissolved in 1.5 ml of dry DCM and then DMAP (27 mg, 0.22 
mmol), carboxylic acid 11 (49 mg, 0.22 mmol) and DCC (46 mg, 0.22 mmol) were added. 
The reaction mixture, left under stirring for 4 h at room temperature, was then 
concentrated under reduced pressure; the crude product was purified by 
chromatography on a silica gel column eluted with n-hexane/AcOEt (1:9, v/v), giving the 
desired compound 1a in 67% yield (80 mg, 0.10 mmol). 
1a: oil: Rf = 0.5 (CHCl3/CH3OH, 95:5, v/v). 
1H NMR (CDCl3, 500 MHz, 0.06 M): δ 8.53 [d, J = 4.0 Hz, 2H, (2x Hα Py)]; 7.36-7.34 
[overlapped signals, 3H, H-6 and (2x Hβ Py)]; 6.35 (dd, J = 6.0 and 6.0 Hz, 1H, H-1'); 5.33 
(m, 2H, H-9 and H-10 oleic acid); 5.20 (m, 1H, H-3'); 5.11 (s, 2H, -CH2Py); 4.42 (m, 2H, H2-
5'); 4.26-4.13 (overlapped signals, 3H, H-4' and -OCH2COO-C5’); 3.73-3.50 [overlapped 
signals, 12H, 3x (-O-CH2-CH2-O-)]; 3.35 (s, 3H, CH3O-TEG); 2.42-2.24 (m, 2H, H-2'); 2.31 
(m, 2H, CH2-2 oleic acid); 2.00 (overlapped signals, 4H, CH2-8 and CH2-11 oleic acid); 1.95 
(s, 3H, CH3-Thy); 1.60 (m, 2H, CH2-3 oleic acid); 1.29-1.23 [overlapped signals, 20H, 10x (-
CH2- oleic acid)]; 0.86 (apparent t, J = 6.0 and 7.0 Hz, 3H, CH3-18 oleic acid). 
13C NMR (CDCl3, 50 MHz): δ 173.1 (C=O oleic acid ester); 169.7 (C=O TEG ester); 162.8 (C-
4); 150.7 (C-2); 149.0 (2x Cα Py); 146.2 (Cγ Py); 133.4 (C-6); 129.9 (C-9 and C-10 oleic acid); 
129.5 (2x Cβ Py); 110.7 (C-5); 85.4 (C-1'); 82.0 (C-4'); 74.1 (C-3'); 71.8, 71.0, 70.5 and 70.4 
(O-CH2-CH2-O-TEG); 68.6 (--OCH2COO-C5’); 64.1 (C-5'); 58.9 (CH3O-TEG); 43.5 (-CH2Py); 
36.9 (C-2'); 33.9 (CH2-2 oleic acid); 31.7 (CH2-8 and CH2-11 oleic acid); 29.5, 29.4, 29.2, 
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28.9, 27.0, 24.6 and 22.5 (aliphatic carbons of oleic acid); 14.0 (CH3-18 oleic acid); 13.1 
(CH3-Thy). 
MALDI-MS (positive ions): calculated for C43H67N3O11 801.48; found m/z: 802.89 (M+H
+); 
824.93 (M+Na+); 840.90 (M+K+). 
 
Synthesis of 3-(4-pyridylmethyl)-3’-O-oleyl-5’-O-(benzyloxy)hexaethylene glycol-acetyl-
thymidine (1b). 
 
5 (64 mg, 0.11 mmol) was dissolved in 1.0 ml of dry DCM and then DMAP (20 mg, 0.16 
mmol), carboxylic acid 14 (50 mg, 0.13 mmol) and DCC (34 mg, 0.16 mmol) were 
sequentially added. The reaction mixture was stirred for 4 h and then the solvent was 
removed in vacuo; the crude product was purified by chromatography on a silica gel 
column with AcOEt as eluent, giving the desired compound 1b in 64% yields (69 mg, 0.070 
mmol). 
1b: oil: Rf = 0.6 (AcOEt/CH3OH, 98:2, v/v). 
1H NMR (CDCl3, 500 MHz, 0.06 M): δ 8.53 (overlapped signals, 2H, 2x Hα Py); 7.35-7.26 
(overlapped signals, 8H, H-6, 2x Hβ Py and 5x aromatic protons of Bn); 6.36 (dd, J = 6.0 
and 6.0 Hz, 1H, H-1'); 5.36 (m, 2H, H-9 and H-10 oleic acid); 5.21 (m, 1H, H-3'); 5.10 (s, 2H, 
-CH2Py); 4.56 (s, 2H, -CH2-Ph); 4.44 (m, 2H, H2-5'); 4.26-4.15 (overlapped signals, 3H, H-4' 
and -OCH2COO-C5’); 3.74-3.57 [overlapped signals, 24H, 6x (-O-CH2-CH2-O-)]; 2.42-2.24 
(m, 2H, H-2'); 2.32 (m, 2H, CH2-2 oleic acid); 2.00 (overlapped signals, 4H, CH2-8 and CH2-
11 oleic acid); 1.96 (s, 3H, CH3-Thy); 1.61 (m, 2H, CH2-3 oleic acid); 1.30-1.25 [overlapped 
signals, 20H, 10x (-CH2- oleic acid)]; 0.87 (apparent t, J = 6.5 and 7.0 Hz, 3H, CH3-18 oleic 
acid). 
13C NMR (CDCl3, 50 MHz): δ 173.1 (C=O oleic acid ester); 169.7 (C=O HEG ester); 162.8 (C-
4); 150.7 (C-2); 149.8 (2x Cα Py); 145.2 (Cγ Py); 138.2 (-CH2-Ph); 133.2 (C-6); 129.9 (C-9 
and C-10 oleic acid); 129.5 (2x Cβ Py); 128.2 and 127.6 (aromatic carbons of Bn); 110.7 (C-
5); 85.4 (C-1'); 82.0 (C-4'); 74.0 (C-3'); 73.1 (-CH2Ph); 71.0, 70.5 and 69.3 (O-CH2-CH2-O-
HEG); 68.6 (-OCH2COO-C5’); 64.1 (C-5'); 43.5 (-CH2Py); 37.0 (C-2'); 34.0 (CH2-2 oleic acid); 
31.7 (CH2-8 and CH2-11 oleic acid); 29.6, 29.4, 29.2, 29.0, 27.1, 24.6 and 22.5 (aliphatic 
carbons of oleic acid); 14.0 (CH3-18 oleic acid); 13.1 (CH3
ESI-MS (positive ions): calculated for C
-Thy). 
55H83Cl4N3O14, 1009.6; found m/z: 1010.8 (M+H
+); 
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1048.7 (M+K+). 
 
 
Synthesis of 3-(4-pyridylmethyl)-2’,3’-di-O-oleyl-5’-O-(4,4′-dimethoxytriphenylmethyl)-
uridine (8). 
 
5’-O-(4,4′-dimethoxytriphenylmethyl)uridine 6 (326 mg, 0.59 mmol) was dissolved in 5 ml 
of dry DMF. K2CO3  (370 mg, 2.68 mmol) and 4-(bromomethyl)pyridine hydrobromide 
(450 mg, 1.77 mmol) were added and the reaction mixture was left under stirring at 60 
°C. After 12 h, TLC analysis indicated the presence of a single product in the reaction 
mixture. Alkylated compound 7 was not isolated, but directly converted into its 2’,3’-bis-
conjugated derivative 8. To this purpose, the solvent was removed in vacuo and the 
residual solid was taken up in DCM, washed with water, dried over anhydrous Na2SO4 
and then concentrated under reduced pressure. Successively the residue was dissolved in 
2.5 ml of dry DCM and then DMAP (216 mg, 1.77 mmol), oleic acid (473 µL, 1.49 mmol) 
and DCC (365 mg, 1.77 mmol) were sequentially added to the reaction mixture. After 12 h 
under stirring at room temperature, the solvent was removed in vacuo and the crude 
product was purified by chromatography on a silica gel column with n-hexane/AcOEt (6:4, 
v/v, containing 1% of TEA) as eluent, affording pure compound 8 in 60% yields for the two 
steps (416 mg, 0.36 mmol).  
8: oil: Rf = 0.4 (n-hexane/AcOEt, 1:1, v/v). 
1H NMR (CDCl3, 500 MHz): δ 8.52 [d, J = 5.5 Hz, 2H, (2x Hα Py)]; 7.76 (d, J = 8.5 Hz, 1H, H-
6); 7.38-6.83 (overlapped signals, 15H, aromatic protons of DMT and 2x Hβ Py); 6.18 (d, J 
= 5.5 Hz, 1H, H-1'); 5.57 (overlapped signals, 2H, H-2' and H-3'); 5.43 (d, J = 8.0 Hz, 1H, H-
5); 5.36-5.31 [overlapped signals, 4H, 2x (H-9 and H-10 oleic acid)]; 5.05 (m, 2H,-CH2Py); 
4.21 (m, 1H, H-4'); 3.78 [s, 6H, 2x (-OCH3) of DMT]; 3.48 (m, 2H, H2-5'); 2.29 [m, 4H, 2x 
(CH2-2 oleic acid)]; 1.99 [overlapped signals, 8H, [2x (CH2-8) and 2x (CH2-11) oleic acid]; 
1.59 [overlapped signals, 4H, 2x (CH2-3 oleic acid)]; 1.94-1.91, 1.71-1.65, 1.39-1.05 
[overlapped signals, 40H, 2x (10x -CH2- oleic acid)]; 0.92-0.86 [overlapped signals, 6H, 2x 
(CH3-18 oleic acid)]. 
13C NMR (CDCl3, 50 MHz): δ 172.4 and 172.2 (C=O esters); 162.0 (C-4); 158.7, 130.1, 
130.0, 129.6, 128.1, 127.2, 123.1 and 113.3 (aromatic carbons of DMT and 2x Cα Py); 
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149.8 (2x Cβ Py); 145.2 (Cγ Py); 143.8 (C-2); 138.1 (C-6); 134.8 and 134.6 (C-9 and C-10 
oleic acid); 102.3 (C-5); 87.5 (C-1'); 86.7 (quaternary carbon of DMT); 82.0 (C-4'); 73.1 and 
70.6 (C-2' and C3'); 62.3 (C-5'); 55.2 [2x (-OCH3) of DMT]; 43.2 (-CH2Py); 33.9 and 33.7 [2x 
(-CH2-2 oleic acid)]; 31.8, 29.7, 29.5, 29.3, 29.1, 29.0, 27.2, 24.7, 24.6 and 22.6 (aliphatic 
carbons of oleic acid); 14.1 [2x (CH3-18 oleic acid)]. 
ESI-MS (positive ions): calculated for C72H99N3O10, 1165.7; found m/z: 1167.0 (M+H
+); 
1205.0 (M+K+). 
 
Synthesis of 3-(4-pyridylmethyl)-2’,3’-di-O-oleyl-uridine (9).  
 
Nucleoside 8 (400 mg, 0.34 mmol) was dissolved in 6 ml of a 1% TCA solution in DCM and 
stirred for 2 h at room temperature. The solution was then concentrated in vacuo and 
purified by chromatography on a silica gel column with n-hexane/AcOEt (3:7, v/v) as 
eluent, yielding the desired compound 9 in almost quantitative yields (290 mg, 0.34 
mmol). 
9: oil: Rf = 0.4 (AcOEt/n-hexane, 3:2, v/v). 
1H NMR (CDCl3, 500 MHz): δ 8.69 [broad signal, 2H, (2x Hα Py)]; 7.79 (d, J = 8.0 Hz, 1H, H-
6); 7.59 [broad signal, 2H, (2x Hβ Py)]; 5.97 (d, J = 5.5 Hz, 1H, H-1'); 5.89 (d, J = 8.0 Hz, 1H, 
H-5); 5.49-5.44 (overlapped signals, 2H, H-2' and H-3'); 5.36-5.29 [overlapped signals, 4H, 
2x (H-9 and H-10 oleic acid)]; 5.18 (m, 2H, -CH2Py); 4.21 (m, 1H, H-4'); 3.99-3.84 (m, 2H, 
H2-5'); 2.35 and 2.29 [t’s, J = 7.5 and 7.5 Hz, 2H each, 2x (CH2-2 oleic acid)]; 1.99 
[overlapped signals, 8H, 2x (CH2-8) and 2x (CH2-11) oleic acid]; 1.59 [overlapped signals, 
4H, 2x (CH2-3 oleic acid)]; 1.31-1.26 [overlapped signals, 40H, 2x (10x -CH2- oleic acid)]; 
0.89-0.86 [overlapped signals, 6H, 2x (CH3-18 oleic acid)]. 
13C NMR (CDCl3, 50 MHz): δ 172.7 and 171.2 [2x (C=O esters)]; 162.1 (C-4); 151.0 (2x Cα 
Py); 145.4 (Cγ Py); 143.8 (C-2); 139.6 (C-6); 130.0 and 129.6 (C-9 and C-10 oleic acid); 
125.3 (2x Cβ Py); 102.3 (C-5); 88.8 (C-1'); 83.6 (C-4') ; 73.0 and 70.9 (C-2' and C3'); 60.4 (C-
5'); 43.2 (-CH2Py); 33.9 [overlapped signals, 2x (-CH2-2 oleic acid)]; 31.8, 29.7, 29.5, 29.3, 
29.1, 29.0, 27.2, 24.8 and 22.6 (aliphatic carbons of oleic acid); 14.1 and 14.0 [2x (CH3-18 
oleic acid)]. 
ESI-MS (positive ions): calculated for C51H81N3O8, 863.6; found m/z: 864.8 (M + H
+). 
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Synthesis of 3-(4-pyridylmethyl)-2’,3’-di-O-oleyl-5’-O-(benzyloxy)hexaethylene glycol-
acetyl-uridine (1c). 
 
Nucleoside 9 (67 mg, 0.078 mmol) was dissolved in 1 ml of dry DCM and then DMAP (15 
mg, 0.12 mmol), carboxylic acid 14 (40 mg, 0.09 mmol) and DCC (24 mg, 0.16 mmol) were 
sequentially added. The reaction mixture was stirred for 3 h and then the solvent was 
removed in vacuo; the crude product was purified by chromatography on a silica gel 
column with AcOEt as eluent, yielding the desired compound 1c in 80% yields (80 mg, 
0.063 mmol). 
1c: oil: Rf = 0.6 (AcOEt/CH3OH, 98:2, v/v). 
1H NMR (CDCl3, 500 MHz): δ 8.53 [d, J = 5.5 Hz, 2H, (2x Hα Py)]; 7.54 (d, J = 8.5 Hz, 1H, H-
6); 7.34-7.26 [overlapped signals, 7H, (2x Hβ Py) and (5x aromatic proton of Bn)]; 6.07 (d, J 
= 6.0 Hz, 1H, H-1'); 5.89 (d, J = 8.5 Hz, 1H, H-5); 5.39-5.37 (overlapped signals, 2H, H-2' and 
H-3'); 5.34 [overlapped signals, 4H, 2x (H-9 and H-10 oleic acid)]; 5.07 (m, 2H,-CH2Py); 
4.56 (s, 2H, -CH2-Ph); 4.42-4.37 (m, 2H, H2-5'); 4.34 (m, 1H, H-4'); 4.25 (s, 2H, -OCH2CO-
HEG); 3.74-3.63 [overlapped signals, 24H, 6x (-O-CH2-CH2-O-)]; 2.35 and 2.26 [t’s, J = 7.5 
Hz, 2H each, 2x (CH2-2 oleic acid)]; 2.01 and 1.99 [overlapped signals, 8H, [2x (CH2-8) and 
2x (CH2-11) oleic acid]; 1.58 [overlapped signals, 4H, 2x (CH2-3 oleic acid)]; 1.30-1.26 
[overlapped signals, 40H, 2x (10 x -CH2- oleic acid)]; 0.89-0.86 [overlapped signals, 6H, 2x 
(CH3-18 oleic acid)]. 
13C NMR (CD3OD, 50 MHz): δ 172.6, 170.4 and 163.0 (C=O esters); 158.7 (C-4); 151.2 (2x 
Cα Py); 149.1 (Cγ Py); 147.3 (C-2); 140.1 (C-6); 138.5 (-CH2-Ph); 129.8 (C-9 and C-10 oleic 
acid); 129.6 (2x Cβ Py); 128.2, 127.7 and 127.5 (aromatic carbons of Bn); 101.2 (C-5); 89.4 
(C-1'); 80.5 (C-4'); 73.0 and 70.8 (C-2' and C-3'); 70.4 (-CH2Ph); 69.5 (O-CH2-CH2-O- HEG); 
68.4 (-OCH2CO- HEG); 63.3 (C-5'); 43.1 (-CH2Py); 33.6 [overlapped signals, 2x(-CH2-2 oleic 
acid)]; 31.9, 29.7, 29.5, 29.2, 29.1, 27.0, 25.6, 24.9 and 22.6 (aliphatic carbons of oleic 
acid); 13.3 [2x (CH3-18 oleic acid)]. 
ESI-MS (positive ions): calculated for C72H113N3O16, 1275.8; found m/z: 1277.2 (M+H
+); 
1315.1 (M+K+). 
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Synthesis of tert-butyl (monomethoxy)triethylene glycol acetate (10). 
 
Monomethoxytriethylene glycol (1.5 g, 9.13 mmol) was dissolved in 6 ml of dry THF and 
NaH 60% p.p. (730 mg, 18.3 mmol) and then tert-butyl bromoacetate (3.37 ml, 22.8 
mmol) were sequentially added. The solution was stirred at room temperature for 12 h, 
then CH3OH (1 ml) was added and the solvent removed in vacuo. The crude product, 
dissolved in CHCl3 and filtered on celite, was then purified by chromatography on a silica 
gel column with CHCl3 as eluent, yielding the desired ester 10 in 98% yields (2.5 g, 8.96 
mmol).  
10: oil: Rf = 0.6 (CHCl3/CH3OH, 95:5, v/v). 
1H NMR (CDCl3, 400 MHz): δ 3.91 (s, 2H, -CH2COO-tert-butyl); 3.60-3.44 [overlapped 
signals, 12H, 3x (-O-CH2-CH2-O-)]; 3.27 (s, 3H, CH3O-); 1.37 [s, 9H, 3x (CH3 tert-butyl)]. 
13C NMR (CDCl3, 100 MHz): δ 169.3 (C=O ester); 81.0 (quaternary carbon of tert-butyl); 
68.7 (-CH2COO-tert-butyl); 71.6 and 70.2 [3x (-O-CH2-CH2-O-)]; 58.6 (CH3O-); 27.7 [3x 
(CH3 tert-butyl)]. 
MALDI-MS (positive ions): calculated for C13H26O6 278.17; found m/z: 279.37 (M+H
+); 
301.40 (M+Na+); 317.38 (M+K+). 
 
Synthesis of (monomethoxy)triethylene glycol acetic acid (11).  
 
Ester 10 (630 mg, 2.26 mmol) was dissolved in 1.5 ml of formic acid and stirred at room 
temperature for 2 h. The solvent was then removed in vacuo and the residue was 
coevaporated three times with CHCl3 (3x 3 ml), yielding the desired carboxylic acid 11 in 
99% yields (500 mg, 2.25 mmol). 
11: oil: Rf = 0.4 (CHCl3/CH3OH, 95:5, v/v). 
1H NMR (CDCl3, 500 MHz): δ 4.13 (s, 2H, -CH2COOH); 3.70-3.50 [overlapped signals, 12H, 
3x (-O-CH2-CH2-O-)]; 3.34 (s, 3H, CH3O-). 
13C NMR (CDCl3, 125 MHz): δ 170.9 (C=O carboxylic acid); 71.6, 70.6 and 70.3 [3x (-O-CH2-
CH2-O-)]; 68.3 (-CH2COOH); 58.7 (CH3O-). 
MALDI-MS (positive ions): calculated for C9H18O6 222.11; found m/z: 223.5 (M+H
+). 
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Synthesis of (monobenzyloxy)hexaethylene glycol (12). 
 
Hexaethylene glycol (2.0 g, 7.1 mmol) was dissolved in 8 ml of dry THF and NaH 60% p.p. 
(170 mg, 4.25 mmol) and then benzylbromide (3.37 ml, 22.8 mmol) were sequentially 
added. The reaction mixture was stirred at room temperature for 12 h, then CH3OH (1 ml) 
was added and the solvent removed in vacuo. The crude product was dissolved in CHCl3, 
filtered on celite and then purified by chromatography on a silica gel column with 
AcOEt/CH3OH (9:1, v/v) as eluent, yielding the desired compound 12 in 65% yields (1.7 g, 
4.6 mmol).  
12: oil: Rf = 0.5 (AcOEt/CH3OH, 9:1, v/v). 
1H NMR (CDCl3, 200 MHz): δ 7.34-7.33 (overlapped signals, 5H, aromatic protons); 4.56 (s, 
2H, -CH2-Ph); 3.66-3.60 [overlapped signals, 24H, 6x (-O-CH2-CH2-O-)]. 
13C NMR (CDCl3, 50 MHz): δ 138.2, 128.3, 127.7 and 127.6 (aromatic carbons); 73.2 (-CH2-
Ph); 72.5, 70.6, 70.2 and 69.4 [5x (-O-CH2-CH2-O-) and (-O-CH2-CH2-OH)]; 61.7 (O-CH2-
CH2-OH). 
ESI-MS (positive ions): calculated for C19H32O7, 372.2; found m/z: 373.2 (M+H
+); 395.1 
(M+Na+). 
 
Synthesis of tert-butyl (monobenzyloxy)hexaethylene glycol acetate (13).  
 
Alcohol 12 (155 mg, 0.42 mmol) was dissolved in 1 ml of dry THF and NaH 60% p.p. (33 
mg, 0.83 mmol) and then tert-butyl bromoacetate (154 µL, 1.0 mmol) were sequentially 
added. The reaction mixture was stirred at room temperature for 12 h, then few drops of 
CH3OH were added and the solvent removed in vacuo. The crude product was dissolved 
in CHCl3, filtered on celite and then purified by chromatography on a silica gel column 
eluted with AcOEt, yielding the desired compound 13 in 86% yields (175 mg, 0.36 mmol).  
13: oil: Rf = 0.6 (AcOEt/CH3OH, 95:5, v/v). 
1H NMR (CDCl3, 200 MHz): δ 7.34-7.32 (overlapped signals, 5H, aromatic protons); 4.56 [s, 
2H, -CH2-Ph]; 4.01 (s, 2H, -CH2COO-tert-butyl); 3.69-3.64 [overlapped signals, 24H, 6x (-O-
CH2-CH2-O-)]; 1.46 [s, 9H, 3x (CH3 tert-butyl)]. 
13C NMR (CDCl3, 50 MHz): δ 169.6 (C=O); 138.3, 128.3, 127.7 and 127.5 (aromatic carbons 
of Bn); 81.4 (quaternary carbon of tert-butyl); 73.2 (-CH2-Ph); 70.6 and 69.4 [6x (-O-CH2-
CH2-O-)]; 69.0 (-CH2COO-t-Bu); 28.1 [3x (CH3 tert-butyl)]. 
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ESI-MS (positive ions): calculated for C25H42O9, 486.3; found m/z: 509.2 (M+Na
+); 525.2 
(M+K+). 
 
Synthesis of (monobenzyloxy)hexaethylene glycol acetic acid (14). 
 
Ester 13 (95 mg, 0.19 mmol) was dissolved in 1.5 ml of HCOOH and stirred at room 
temperature for 2 h. The solvent was then removed in vacuo and the residue was 
coevaporated three times with CHCl3 (3x 3 ml), yielding the desired compound 14 in 
almost quantitative yields (82 mg, 0.19 mmol). 
14: oil: Rf = 0.2 (AcOEt/CH3OH, 95:5, v/v). 
1H NMR (CD3OD, 200 MHz): δ 7.36-7.33 (overlapped signals, 5H, aromatic protons); 4.55 
[s, 2H, -CH2-Ph]; 4.12 (s, 2H, -CH2COOH); 3.66-3.62 [overlapped signals, 24H, 6x (-O-CH2-
CH2-O-)]. 
13C NMR (CD3OD, 50 MHz): δ 174.0 (C=O); 139.7, 129.4, 129.0 and 128.7 (aromatic 
carbons); 74.1 (-CH2-Ph); 71.7, 71.6 and 70.6 [6x (-O-CH2-CH2-O-)]; 69.1 (-CH2COOH). 
ESI-MS (positive ions): calculated for C21H34O9, 430.2; found m/z: 431.1 (M+H
+); 453.1 
(M+Na+); 459.1 (M+K+
5’-O-(4,4′-dimethoxytriphenylmethyl)thymidine (2) (396 mg, 0.73 mmol) was dissolved in 
5 mL of dry DMF. K
). 
 
Synthesis of 3-(4-pyridylmethyl), 3’-O-cholesteroxyacetyl, 5’-O-(4,4’-dimethoxy-
triphenylmethyl)thymidine (15) 
 
2CO3 (302 mg, 2.18 mmol) and 4-(bromomethyl)pyridine 
hydrobromide (276 mg, 1.09 mmol) were sequentially added to the reaction mixture, left 
under stirring at 60 °C. After 12 h, TLC analysis indicated the presence of one main 
product in the reaction mixture. Alkylated compound 3 was not isolated, but directly 
converted into its 3’-conjugated derivative 15. To this purpose, the solvent was removed 
and the residual solid was taken up in DCM, washed with water, dried over anhydrous 
Na2SO4 and concentrated in vacuo. Successively the residue was dissolved in 3 mL of dry 
DCM and then DMAP (32 mg, 0.266 mmol), cholesteroxy-acetic acid 18 (118 mg, 0.266 
mmol) and DCC (55 mg, 0.266 mmol) were sequentially added. The reaction mixture was 
stirred for 12 h at room temperature and then the solvent was removed in vacuo; the 
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crude product was purified by chromatography on a silica gel column with n-
hexane/AcOEt (1:1, v/v, containing 1% of TEA) as eluent, yielding the desired compound 
15 in 19% yields for the two steps (144 mg, 0.14 mmol).  
15: oil: Rf= 0.3 (AcOEt/n-hexane 1:1, v/v). 
1H-NMR (CDCl3, 500 MHz): significant signals at δ 8.57 (d, J = 4.5 Hz, 2H, 2x HαPy); 7.66 
(s, 1H, H-6); 7.49 (d, J = 4.5 Hz, 2H, 2x HβPy); 7.36-6.82 (overlapped signals, 13H, aromatic 
protons of DMT); 6.44 (dd, J = 6.0 and 5.5 Hz, 1H, H-1’); 5.53 (d, J = 5.0 Hz, 1H, H-3’); 5.36 
(m, 1H, H-6 Chol); 5.15 (s, 2H, -CH2-Py); 4.13 (overlapped signals, 3H, -CH2C=O and H-4’); 
3.79 [s, 6H, 2x (-OCH3) of DMT]; 3.47 (m, 2H, H-5’); 3.23 (m, 1H, H-3 Chol); 2.48 (m, 2H, H-
2’); 1.42 (s, 3H, CH3-Thy); 0.99 (s, 3H, CH3-19 Chol); 0.91 (d, J = 6.5 Hz, 3H, CH3-21 Chol); 
0.86 (coincident d’s, J = 4.5 Hz, 6H, CH3-26 and CH3-27 Chol); 0.67 (s, 3H, CH3-18 Chol). 
13C-NMR (CDCl3, 50 MHz): significant signal δ 170.3 (C=O); 163.0 (C-4); 158.7, 144.1, 
133.8, 130.0, 128.0, 127.2 and 113.3 (aromatic carbons of DMT); 150.8 (C-2); 149.9 (2x 
CαPy); 145.4 (C Py); 140.2 (C-5 Chol); 135.1 (C-6); 123.5 (2x CβPy); 122.1 (C-6 Chol) 110.8 
(C-5); 87.0 (quaternary carbon of DMT); 85.0 (C-1’); 83.9 (C-4’); 80.1 (C-3 Chol); 75.6 (C-
3’); 65.4 (-CH2C=O); 63.5 (C-5’); 55.2 [2x (-OCH3) of DMT]; 43.5 (-CH2Py); 38.6 (C-2’); 22.7 
and 22.5 (C-27 and C-26 Chol); 19.2 (C-19 Chol); 18.6 (C-21 Chol); 12.3 (CH3-Thy); 11.8 (C-
18 Chol). 
ESI-MS (positive ions): calculated for C66H83N3O9: 1061.61 found m/z: 1062.93 (M+H
+); 
1101.02 (M+K+). 
 
Synthesis of 3-(4-pyridylmethyl), 3’-O-cholesteroxy-acetyl thymidine (16) 
 
15 (140 mg, 0.13 mmol) was dissolved in 3 mL of a 1% TCA solution in DCM and stirred for 
1 h at room temperature. The reaction mixture was then concentrated in vacuo and 
purified by chromatography on a silica gel column with CHCl3/CH3OH (99:1, v/v) as 
eluent, giving the desired compound 16 in almost quantitative yields (100 mg, 0.13 
mmol).  
16: oil: Rf= 0.4 (AcOEt/n-hexane 7:3, v/v). 
1H-NMR (CDCl3, 500 MHz): significant signals at δ 8.55 (d, J = 4.5 Hz, 2H, 2x HαPy); 7.55 (s, 
1H, H-6); 7.36 (d, J = 4.5 Hz, 2H, 2x HβPy); 6.27 (dd, J = 6.5 and 7.5 Hz, 1H, H-1’); 5.45 (m, 
1H, H-3’); 5.36 (m, 1H, H-6 Chol); 5.12 (s, 2H, -CH2-Py); 4.15 (s, 2H, -CH2C=O); 4.11 (bs, 1H, 
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H-4’); 3.94 (bs, 2H, H-5’); 3.24 (m, 1H, H-3 Chol); 2.42 (m, 2H, H-2’); 1.95 (s, 3H, CH3-Thy); 
1.00 (s, 3H, H-19); 0.91 (d, J = 6.5 Hz, 3H, H-21 Chol); 0.86 (concident d’s, J = 4.5 Hz, 6H, H-
26 and H-27 Chol); 0.67 (s, 3H, H-18 Chol). 
13C-NMR (CDCl3, 50 MHz): significant signals δ 170.6 (C=O); 163.0 (C-4); 150.8 (C-2); 149.2 
(2x CαPy); 146.2 (CγPy); 140.2 (C-5 Chol); 134.6 (C-6); 123.6 (2x CβPy); 122.1 (C-6 Chol) 
110.4 (C-5); 86.1 (C-1’); 85.1 (C-4’); 80.2 (C-3 Chol); 75.3 (C-3’); 65.3 (-CH2C=O); 62.1 (C-
5’); 43.4 (-CH2Py); 38.6 (C-2’); 22.7 and 22.5 (C-27 and C-26 Chol); 19.2 (C-19 Chol); 18.6 
(C-21 Chol); 13.1 (CH3-Thy); 11.8 (C-18 Chol). 
ESI-MS (positive ions): calculated for C45H65N3O7: 759.48; found m/z: 760.88 (M+H
+); 
799.08 (M+K+). 
 
Synthesis of 3-(4-pyridylmethyl), 3’-O-cholesteroxy-acetyl, 5’-O-monomethoxytri-
ethylene glycol acetyl thymidine (1d, ToThyChol). 
 
16 (96 mg, 0.13 mmol) was dissolved in 2 mL of dry DCM and then DMAP (46 mg, 0.38 
mmol), carboxylic acid 14 (41 mg, 0.18 mmol) and DCC (38 mg, 0.18 mmol) were 
sequentially added. The reaction mixture was stirred for 12 h at room temperature and 
the solvent was then removed in vacuo; the crude product was purified by 
chromatography on a silica gel column eluted with n-hexane/acetone (1:1, v/v), giving the 
desired compound 1d in 85% yields (106 mg, 0.11 mmol).  
6: oil: Rf= 0.3 (AcOEt). 
1H-NMR (CDCl3,500 MHz): significant signals at δ 8.55 (bs, 2H, 2x HαPy); 7.36 (bs, 3H, H-6 
and 2x HβPy); 6.36 (dd, J = 5.5 and 9.0 Hz, 1H, H-1’); 5.37 (bs, 1H, H-6 Chol), 5.30 
(apparent d, J = 5.0 Hz, 1H, H-3’); 5.12 (s, 2H, -CH2-Py); 4.43 (AB part of an ABX system, J = 
12.0 and 3.5 Hz, 2H, H-5’a and H-5’b); 4.24 (s, 2H, -CH2C=O TEG); 4.16 (overlapped signals, 
3H, -CH2C=O and H-4’); 3.76-3.50 (overlapped signals, 12H, 3x –OCH2-CH2O-); 3.36 (s, 3H, 
-OCH3); 3.24 (m, 1H, H-3 Chol); 2.42 (m, 2H, H-2’); 1.96 (s, 3H, CH3-Thy); 1.00 (s, 3H, CH3-
19); 0.91 (d, J = 6.5 Hz, 3H, CH3-21 Chol); 0.86 (coincident d’s, J = 4.5 Hz, 6H, CH3-26 and 
CH3-27 Chol); 0.67 (s, 3H, CH3-18 Chol). 
13C-NMR (CDCl3, 125 MHz): significant signals δ 170.6 (C=O Chol ester); 169.7 (C=O TEG 
ester); 162.8 (C-4); 150.7 (C-2); 149.0 (2x CαPy); 146.0 (CγPy); 140.1 (C-5 Chol); 133.5 (C-
6); 123.7 (2x Cβ Py); 122.1 (C-6 Chol); 110.8 (C-5); 85.4 (C-1’); 81.9 (C-4’); 80.2 (C-3 Chol); 
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74.8 (C-3’); 71.8, 71.0, 70.7 and 70.4 (carbons of TEG); 68.7 (-CH2C=O TEG); 65.3 (-CH2C=O 
Chol); 64.0 (C-5’); 58.9 (-OCH3); 43.5 (-CH2Py); 38.6 (C-2’); 22.7 and 22.5 (C-27 and C-26 
Chol); 19.2 (C-19 Chol); 18.6 (C-21 Chol); 13.1 (CH3-Thy); 11.8 (C-18 Chol). 
ESI-MS (positive ions): calculated for C54H81N3O12 963.58; found m/z: 963.97 (M+H
+); 
985.97 (M+Na+); 1002.1 (M+K+
Synthesis of tert-butyl cholesteroxy-acetate (17) 
). 
Cholesterol (963 mg, 2.5 mmol) was dissolved in 4 mL of dry THF and NaH 60% p.p. (200 
mg, 4.98 mmol) and then tert-butyl bromoacetate (920 µL, 6.22 mmol) were sequentially 
added to the reaction mixture taken at 0 °C. After 24 h at room temperature, the reaction 
was quenched by addition of CH3OH (2 mL) and the solvent removed in vacuo. The 
residual solid was taken up in DCM, washed with water, dried over anhydrous Na2SO4 
and concentrated in vacuo. The residue was then purified by chromatography on a silica 
gel column using n-hexane/AcOEt (9:1, v/v) as eluent, yielding the desired compound 17 
in 31 % yields (392 mg, 0.77 mmol).  
17: amorphous solid: Rf= 0.8 (AcOEt/n-hexane 1:3, v/v). 
1H-NMR (CDCl3, 200 MHz): significant signals at δ 5.36 (d, J = 5.0 Hz, 1H, H-6); 4.20 (s, 2H, 
CH2C=O); 3.23 (m, 1H, H-3); 2.31 (m, 2H, H2-4); 1.48 (s, 9H, CH3t-Bu); 1.02 (s, 3H, H-19); 
0.91 (d, J = 6.5 Hz, 3H, H-21); 0.86 (coincident d’s, J = 4.5 Hz, 6H, H-26 and H-27); 0.67 (s, 
3H, H-18). 
13C-NMR (CDCl3, 50 MHz): significant signals at δ 170.1 (C=O); 140.6 (C-5); 121.8 (C-6); 
81.3 (C quaternary of t-Bu); 79.8 (C-3); 66.1 (CH2C=O); 28.1 (3x CH3t-Bu); 22.8 and 22.5 
(C-27 and C-26); 19.3 (C-19); 18.7 (C-21); 11.8 (C-18). 
ESI-MS (positive ions): calculated for C33H56O3 500.42; found m/z: 521.25 (M+Na
+); 
537.45 (M+K+
Synthesis of cholesteroxy-acetic acid (18) 
). 
Ester 17 (300 mg, 0.59 mmol) was dissolved in 3.0 mL of formic acid and stirred at room 
temperature for 2 h. The solvent was then removed in vacuo and the residue 
coevaporated three times with CHCl3 (3x 3 mL), yielding the desired compound 18 in 
almost quantitative yields (266 mg, 0.59 mmol).  
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8: oil: Rf= 0.2 (AcOEt/n-hexane 1:3, v/v). 
1H-NMR (CDCl3,200 MHz): significant signals at δ 5.34 (d, J = 4.4 Hz, 1H, H-6); 4.17 (s, 2H, 
CH2C=O); 3.28 (m, 1H, H-3); 0.91 (d, J = 6.5 Hz, 3H, H-21); 0.86 (coincident d’s, J = 4.5 Hz, 
6H, H-26 and H-27); 0.68 (s, 3H, H-18). 
13C-NMR (CDCl3, 50 MHz): significant signals at δ 175.3 (C=O); 140.1 (C-5); 122.2 (C-6); 
80.3 (C-3); 65.1 (CH2C=O); 22.8 and 22.5 (C-26 and C-27); 19.3 (C-19); 18.7 (C-21); 11.8 (C-
18). 
ESI-MS (positive ions): calculated for C29H48O3 444.36; found m/z: 464.72 (M+Na
+); 
480.88 (M+K+). 
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Chapter 3. 
 
Synthesis and Characterization of Novel Amphiphilic 
Nucleolipid Complexes of Ruthenium (III) as Potential 
Anticancer Agents 
 
 
1. Introduction: Ruthenium(III) complexes as anticancer 
drugs 
 
In the last decades, research has proposed a growing number of antineoplastic 
agents. Among these, transition metal-based complexes represent, nowadays, a very 
important class of chemotherapeutics, intensively used for clinical treatments. The 
anticancer activity of the most important of these, Cisplatin, was discovered in 1969 [1] 
and in thirty years this complex became one of the most used drugs in the treatment of 
some tumoral diseases, such as testicular, breast, uterine and ovarian cancers. Ever since, 
a large variety of Cisplatin analogues have been tested and some of them have been 
approved as drugs, such as Carboplatin and Oxaliplatin. [2] 
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Although these heavy metal agents are active against a variety of cancers, their 
use is associated with severe side effects including gastrointestinal symptoms (nausea, 
vomiting, diarrhea, abdominal pain), renal tubular injury, neuromuscular complications, 
and ototoxicity. In addition, the use of platinum is limited in many tumor types by primary 
and acquired resistance to this agent. [3] This has led to an ongoing quest for the 
                                                                                                                                          Chapter 3 
47 
 
discovery of non-platinum metals that may extend the spectrum of activity of metal-
based drugs [4]. 
A possible improvement of the antitumoral drug properties is represented by the 
efficacy toward the formation and growth of metastases. In fact, many tumors can 
develop metastases often very extended at the diagnosis time, making scarcely effective 
the surgical treatment. [5] If the primary tumor can be surgically removed, the 
pharmacological therapy seems to be the best choice for the metastases treatment, 
because of their wide delocalization. [6] On the other hand, unlike the primary tumor 
cells, metastases are not responsive to several chemotherapeutics, probably because of 
their different proliferation kinetics. [7,8] This is the reason why many widely employed 
drugs show only limited effects on metastatic disease attack. These limitations have 
prompted the research to develop more effective and less toxic metal-based antitumor 
agents.  
In this perspective, ruthenium complexes have attracted much interest as a 
promising alternative to platinum, showing a remarkable anti-tumoral and anti-metastatic 
activity, together with lower toxicity. Ruthenium, a transition metal of the platinum group 
(group 8B of the Periodic Table), was first hypothesized to exert its anticancer effects by 
direct interaction with DNA as observed with platinum. However, it is now known that 
ruthenium shows a number of differences with respect to platinum. [9] First, ruthenium 
appears to accumulate preferentially in neoplastic masses rather than normal tissues 
possibly by using transferrin to enter into tumors. [10] It has been proposed that 
transferrin–ruthenium complexes are actively transported into neoplastic tissues 
containing high transferrin receptor densities. Once bound to the transferrin receptor, it 
is assumed that the complex liberates ruthenium that is then internalized by the tumor. 
[11] Secondly, ruthenium remains in its relatively inactive Ru(III) oxidation state until it 
reaches the tumor site. In this environment, where there is a lower oxygen content and 
higher acidity compared to normal tissues, reduction to the more reactive Ru(II) occurs. 
[12] This reaction, termed “activation-by-reduction”, not only results in selective tumor 
targeting but may also direct cytotoxic activity toward hypoxic tumors that are more likely 
to be resistant to chemotherapy and radiations. [13] 
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The most promising and remarkable Ru-based complexes have been described by 
Sava and Alessio. [14-20] Since the beginning of 90’s, Sava and Alessio have been 
pioneers in studying the perspectives of transition-metal complexes as potential 
anticancer agents, in particular discovering a very active Ru complex, NAMI-A. Such 
compound, together with KP1019, developed by Keppler et al., recently passed Phase I 
clinical trials with good outcome. [21] 
 
 
 
  
NAMI-A KP1019 
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2. Design of novel Ruthenium(III) complexes 
 
A large number of studies on Ru complexes have been published in recent years; 
in all cases, scarce stability in aqueous media of these compounds, undergoing 
replacement of the chloride ligands with hydroxide ions and/or water molecules and 
further consequent degradation processes, has been observed. To overcome these 
drawbacks, an innovative approach to vehiculate in cells transition metal-containing 
drugs for anticancer therapy has been very recently proposed in the literature by 
Paduano and Ruffo, based on the use of amphiphilic nanovectors carrying Ruthenium 
complexes. [22,23] As a continuation of this work, the synthesis and characterization of a 
mini-library of novel Ru-containing nucleolipids is here described.  
As widely known, amphiphilic self-assembly allows an efficient bottom-up strategy 
in order to obtain nanosized aggregates whose size and shape are quite easily tunable. 
Further benefits related to the use of nanostructures concern:  
i) the possibility to transport a larger quantity of the metal inside the blood stream;  
ii) the possibility to obtain “stealth” aggregates, which are not detected by the 
human immune system, thus specifically increasing their residence time in the 
blood;  
iii) the possibility to obtain aggregates selectively captured by specific tumoral cells 
lines by inserting within ruthenium aggregates some "marker" molecules, able to 
be recognized by protein receptors over-expressed by the tumoral cells;  
iv) the possibility to tune the shape and size of the aggregates by acting either on 
their molecular structure or on physico-chemical parameters, such as pH and ionic 
strength. These effects may be very useful in a stimuli-responsive scenario. 
 
With these aims in mind, we have used the functionalized nucleolipids ToThy, 
HoThy, DoHu and ToThyChol (the preparation of which has been discussed in Chapter 2) 
to synthesize and characterize a series of amphiphilic Ru complexes, designed as 
spontaneously self-aggregating systems in structures such as micelles, liposomes or even 
more complex structures.  
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Figure 1. Functional nucleolipids: ToThyRu, HoThyRu, DoHuRu and ToThyCholRu. 
 
The functional nucleolipids reported in Figure 1 have been built starting from a 
pyrimidinic 2’-deoxyribonucleoside (Thymidine, in the case of ToThyRu, HoThyRu and 
ToThyCholRu) or ribonucleoside (Uridine, for DoHuRu). The nucleoside has been chosen 
as the poly-functional main scaffold, allowing high diversification. In fact one or two oleic 
acid chains have been inserted onto the nucleoside, as well as a poly(ethylene oxide) 
chain able to make the aggregates more resistant toward the enzymatic degradation. 
Finally, a residue of pyridine - as a chelating moiety able to complex Ru(III) ions - has been 
attached together with the metallic species.  
The use of hybrid molecules carrying a double functionality, i.e. nucleosides and 
lipid chains, has gained a considerable interest because of the capability of these 
molecules to mimic the molecular organizations of the biological systems, as well as for 
the possibility to form a wide variety of supramolecular systems such as 
liposomes/vesicles, cubic phases, ribbons, etc. [24-26] 
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Furthermore, the use of formulations of Ru complexes with phospholipids allows 
to modulate the metal amount to be administered, as well as to preserve nanoaggregates 
from degradation. In fact, double chained phospholipids in aqueous solutions adopt an 
ordered arrangement by forming double layers in which Ru complexes are easily lodged. 
Among phospholipids, palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, POPC, is 
particularly interesting being one of the main components of cell membranes. 
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2.1 Synthesis of Ruthenium complexes ToThyRu, HoThyRu, DoHuRu 
and ToThyCholRu 
 
The synthesis of ruthenium complexes ToThyRu, HoThyRu, DoHuRu and 
ToThyCholRu was accomplished in one step starting from the corresponding nucleosidic 
nanovectors ToThy, HoThy, DoHu and ToThyChol described in Chapter 2. The reaction 
was carried out by mixing the nucleolipid and the ruthenium salt [RuCl4(DMSO)2]
-
Na
+
, 
prepared following literature procedures, [27] in the same molar ratio in the appropriate 
solvent (anhydrous CH2Cl2 or CH3CN) and heated at 40 °C for 4 h, as reported in Scheme 1. 
The reactions, monitored by TLC on alumina, showed in 4 h the total disappearance of the 
starting nucleosides. In all cases, the desired products could be isolated in quantitative 
yields simply by removing the solvent under reduced pressure, thus not requiring further 
purification. [28,29] 
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Solvent reaction:  CH3CN for ToThyRu and ToThyCholRu  
CH2Cl2 for DoHuRu and HoThyRu 
Scheme 1. Synthesis of the ruthenium complexes ToThyRu, HoThyRu, DoHuRu and ToThyCholRu. 
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The obtained ruthenium complexes were characterized by NMR and ESI-MS. The 
1
H and 
13
C-NMR spectra showed broadened signals, due to the presence of the 
paramagnetic ruthenium(III) nucleus. In the 
1
H-NMR spectrum - registered in CDCl3 - of 
the salts, this also induced a dramatic upfield shift of the pyridine protons and of the 
methyl protons of the DMSO ligand, respectively here found at δ = - 2.0 ppm, and δ = -
12.00 ppm ca., as very broadened signals, which can be considered diagnostic of the 
effective complex formation. [30,31] The ESI-MS spectra were recorded in negative ions 
mode, showing m/z signals only for the expected molecular ions and thus confirming the 
identity of the target structures. The 
1
H-NMR and ESI-MS spectra for ToThyRu are 
reproduced in Figure 2. 
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a 
 
b 
 
Figure 2. a) ESI-MS (negative ions) spectrum of ToThyRu; b) Upfield expansion for the 1H NMR 
spectrum of ToThyRu (500 MHz, CDCl3) 
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2.2 Characterization of ToThyRu, HoThyRu, DoHuRu, and 
ToThyCholRu 
 
In analogy to what previously mentioned for NAMI-A, also the here synthesized Ru 
complexes, ToThyRu, HoThyRu, DoHuRu and ToThyCholRu, have showed limited stability 
when left in prolonged contact with aq. solutions. In fact, depending on the physico-
chemical conditions, a clear change in the properties of the Ru-complex is observed, with 
formation of insoluble green precipitates in a period going from few hours, in phosphate 
buffers, to few days in water (see Figure 3). [28, 29] 
 
 
 
 
 
 
 
 
a 
 
 
 
 
 
 
 
 
b 
 
Figure 3. a. ToThyCholRu in H2O (stable for 72 h); b. ToThyCholRu in a pseudo-physiological solution (stable 
for 4 h). 
 
The degradation process is imputable to the replacement of the ligands of the 
ruthenium complex by water molecules and/or hydroxide ions, well known for NAMI-A 
and related analogs. [32] Also in the present case Ru complexes undergo this process, as 
confirmed by the changes of the UV/Vis spectra with time. In Figure 4 the time evolution 
of the UV/Vis spectra for ToThyCholRu in H2O and pseudo-physiological conditions is 
reported.  
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Figure 4. Absorbance evolution with time of 0.1 mmolkg-1 ToThyCholRu solution in: (a) water (72 h), (b) 
pseudo-physiological conditions (4 h). Two isosbestic points are present at 274 and 358 nm, respectively. 
The dashed lines refer to the formation of dark particles in solution and the arrows indicate the direction 
of evolution with time. The inset represents the absorbance evolution with time of NAMI-A solution. [32]  
 
As expected, the degradation phenomena are more marked at alkaline pH. To 
sensibly reduce the aquation processes of the Ru complexes, as well as to increase the 
biocompatibility of the formulations and modulate the amount of Ruthenium carried, the 
synthesized amphiphilic molecules were let to co-aggregate with amounts of 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC). This commercially available phospholipid - 
as previously mentioned, widely represented in eukaryotic cell membranes - was here 
chosen as the stabilizing system for these Ru-complexes in view of its well ascertained 
biocompatibility. The resulting co-aggregate systems were then studied in pure water and 
in a buffer containing NaCl and K2HPO4 at physiological ionic strength (here cited as 
“pseudo-physiological conditions”). As a matter of fact, the presence of POPC increases 
the aggregates stability, since no precipitation due to poly-oxo species formation is 
observed. Nevertheless, in pseudo-physiological conditions the stability of the Ru-
complex aggregates in mixture with POPC is guaranteed for several days only if the Ru 
amount does not exceed 15% in molar fraction inside the aggregates (see Figure 5).  
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Figure 5. UV-VIS time evolution of the ToThyCholRu-POPC 15:85 sample at 0.3 mmolkg-1 total concentration 
in pseudo-physiological conditions over a period of 150 h. The arrows indicate the sense of the spectra 
evolution with time. 
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Figure 6 Example of the hydrodynamic radii distribution of the aggregates formed by Ru-complexes in:  
a) pure water; b) physiological ionic strength NaCl solution; c) pseudo-physiological conditions in POPC 
formulation (Ru-complex/POPC 15:85 molar ratio). For all cases, the concentration of the investigated 
samples was 0.1 mmol kg
-1
. 
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As pure compounds, Ru-containing amphiphilic complexes, namely ToThyRu, 
HoThyRu, DoHuRu and ToThyCholRu, were investigated by DLS and SANS in bidistilled 
water and at physiological ionic strength, i.e. NaCl 0.9% wt solution. The same systems in 
pseudo-physiological conditions, as previously hinted, could not be investigated in detail 
because of the fast hydrolysis and polymerization phenomena. 
The hydrodynamic radii distributions of ToThyRu, HoThyRu, DoHuRu and 
ToThyCholRu pure aggregates in water and NaCl solution are reported in Figures 6a and 
6b. From inspection of the Figures for the single-tailed molecules ToThyRu, HoThyRu, and 
ToThyCholRu, a bi-modal well-separated distribution of the hydrodynamic radii is 
observed. However, while for the ToThyRu system the smallest objects represent only a 
negligible percentage of the bi-modal distribution, the contrary is true for HoThyRu and 
ToThyCholRu. Furthermore, a perusal of Figure 6a shows that the dimensions of the 
biggest aggregates in ToThyRu solution qualitatively correspond to those of the smallest 
ones for the HoThyRu system. For ToThyCholRu the presence of two different aggregates 
is observed, with mean hydrodynamic radii of ~ 10 and ~ 30 nm, respectively. In the case 
of the double tailed DoHuRu aggregates, the mean value of its monomodal radius 
distribution is similar to the value shown by the biggest aggregates formed by ToThyRu 
and the smallest ones formed by HoThyRu. Similar results are observed in NaCl solution, 
except for ToThyCholRu, that shows a major population for the smallest aggregates (see 
Figure 6b).  
In pseudo-physiological conditions in POPC formulation (Ru complex/POPC 15:85 
molar ratio) all the complexes show a monomodal distribution of the aggregates that 
present a hydrodynamic radii distribution similar to pure POPC (Figure 6c). Analyzing also 
the SANS results we can deduce that the aggregation is essentially driven by POPC, as 
shown in Table 1.  
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Sample in pseudo-physiological conditions 
(0.1 mmol kg-1) 
Morphology τ/Å N 
 
dL/Å 
 
ToThyRu/POPC vesicles 4.5±0.5 12±1 6.5±0.3 
HoThyRu/POPC vesicles 4.4±0.3 25±1 5.4±0.1 
DoHuRu/POPC vesicles 4.2±0.7 10±1 6.7±0.4 
ToThyCholRu/POPC vesicles 4.5±0.7 1-2 78±7 
POPC vesicles 4.4±0.1 5±1 8.7±0.5 
Table 1. SANS results for the investigated systems. 
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2.3 In Vitro Bioactivity Study 
 
To gain an insight into their antiproliferative activity, the cytotoxicity profile of 
these novel nucleolipid-ruthenium complexes toward human cancer cells was analyzed in 
parallel with a ruthenium complex, that we named AziRu. This novel salt, designed as an 
analog of NAMI-A with one pyridine ligand replacing the imidazole residue – i.e., the same 
ruthenium-surrounding subsystem present in ToThyRu, HoThyRu, DoHuRu and 
ToThyCholRu -, was here prepared to evaluate, by direct comparison, the benefits due to 
the presence of the nucleolipids within the structure of the complexes.  
 
N
Ru
Cl Cl
Cl Cl
S O Na+
 
AziRu (NAMI-A-like ruthenium complex) 
 
Cell lines were exposed to AziRu for 72 h in a growth inhibition assay and the 
cytotoxicity was determined in terms of IC50 values. The detected cytotoxicity values were 
rather moderate and the IC50 values for AziRu were 900, 690, 515, 405 and 1500 µM in 
HeLa, CaCo-2, WiDr, MCF-7 and SH-SY5Y cells, respectively. First, under the same 
incubation conditions these results indicate a significant difference in ruthenium 
cytotoxicity exclusively depending on the cell line, suggesting a selective cell-dependent 
mechanism of action. [33] Moreover, in accordance to many published studies on 
ruthenium complexes, AziRu cytotoxicity was much lower than that of a well known 
reference drug (data not shown) based on transition metals as the antitumor cisplatin. 
[34] However, concerning NAMI-A, it should be considered that the concentration needed 
to reach in vitro cytotoxicity is much higher than the NAMI-A concentration that is 
capable to inhibit the formation of metastases, suggesting that the recognized 
antimetastatic activity of NAMI-A is probably not due exclusively to a reduction in cell 
viability. [35] 
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A complete and comprehensive study on the in vitro bioactivity was carried out on 
the ToThyRu/POPC, HoThyRu/POPC, DoHuRu/POPC and ToThyCholRu/POPC 
formulations. Focusing on the cells (MCF-7 and WiDr lines) more sensitive to the 
ruthenium treatment in our in vitro experimental model, we assessed the potential 
cytotoxic effect of ruthenium-containing liposomes, and interestingly we found that the 
studied complexes in POPC formulation were definitively more active than AziRu in both 
cell lines. A graphical representation of these results is reported in Figure 7 for the 
ToThyCholRu/POPC liposome. 
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Figure 7. Growth inhibition of MCF-7 (panel A)  and WiDr cells (panel B) treated for 72 h with AziRu (•)  and 
ToThy-CholRu/POPC 15:85 liposome (◊), evaluated by MTT assay and cell counting. Data are expressed as 
percentage of untreated cells and are reported as mean of three independent experiments ± SEM. 
 
The latter is a noteworthy finding in the design and biological evaluation of 
innovative supramolecular systems for the anticancer drugs vectorization. The calculated 
IC50 values reported in Table 2 for the real amount of ruthenium delivered to cells after 72 
h of incubation in cell culture media also suggested that complexes in POPC formulation 
were more effective than AziRu in inducing growth inhibition in MCF-7 and WiDr cell 
lines. In addition, the evaluation of the potentiating factor (PF) values demonstrated that 
ruthenium vectorization by this liposome potentiated the growth inhibition induced by 
AziRu, reaching values higher than 3 in cancer cells of different histogenesis (see Table 2). 
Particularly interesting are the results obtained on the MCF-7 cell lines for the 
formulations ToThyRu/POPC and HoThyRu/POPC with IC50 values of 9 and 15 µM, 
respectively, and high potentiating factors (45 and 27, respectively). Similar in vitro results 
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emerged from bioassays on other human cancer cell lines for all the complexes, albeit 
generally less sensitive to the action of the antiproliferative ruthenium. In Figure 8, as a 
representative example, the results obtained on other cell lines for the 
ToThyCholRu/POPC system are reported.  
 
 
Table 2. IC50 values (µM) of Azi-Ru (a NAMI-A-like Ru complex) and of ToThyRu/POPC, HoThyRu/POPC, 
DoHuRu/POPC and ToThyCholRu/POPC liposomes in the indicated cell lines following 72 h of incubation, 
and the corresponding potentiating factors (P.F.). (a) IC50 values are reported as the mean value ± SEM; (b) 
potentiating factor calculated as the ratio of IC50 values of the complexes in POPC formulation with respect 
to the IC50 of AziRu complex. MCF-7, human breast adenocarcinoma cells; WiDr, human epithelial colorectal 
adenocarcinoma cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Growth inhibition of CaCo-2, Hela and SH-SY5Y cells treated for 72 h with AziRu (•)  and ToThy-
CholRu/POPC 15:85 liposome (◊), evaluated by MTT assay and cell counting. Data are expressed as 
percentage of untreated cells and are reported as the mean of three independent experiments ± SEM. 
CaCo-2, human epithelial colorectal adenocarcinoma cells; HeLa, human cervical cancer cells; SH-SY5Y, 
human neuroblastoma cells. 
Cell Lines 
IC50
a ( P.F.b) 
AziRu ToThyRu/POPC HoThyRu/POPC DoHuRu/POPC ToThyCholRu/POPC 
MCF-7 405 ± 10 9±4 (45) 15±2 (27) 71 ± 6 (5.7) 70 ± 12 (5.7) 
WiDr 515 ± 15 75±4 (6.9) 40±5 (12.9) 99 ± 5 (5.2) 165 ± 10 (3.1) 
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Hence, consistently with the data previously described in Chapter 2 for the 
nucleolipid nanovectors, [36] different aggregate compositions differentially impacted 
cell viability. As demonstrated by cytotoxic activities higher than in the case of AziRu, the 
ruthenium-containing nucleolipidic liposomes stabilized with POPC seem to deliver the 
transition metal into the cells in a very effective way. Within this context, it is believed 
that free ruthenium complexes such as NAMI-A enter cells via a passive or facilitated 
passive transport molecular mechanism, albeit apparently with more difficulty than other 
antitumor drugs based on transition metals, such as cisplatin. [37] Together with other 
considerations, this outcome may account for the lower cytotoxicity of emerging 
ruthenium-based molecules assayed for antineoplastic activity, thus emphasizing the 
critical role of a proper vehiculation. The importance of the liposome stabilization 
imparted by the presence of the naturally occurring POPC is also supported by the fact 
that pure Ru complexes, even if per se organized in liposomial super-structures, resulted 
in a significantly lower cytotoxic effect. It can be therefore concluded that the absence of 
POPC within these novel liposomal formulations always reduces the effectiveness of the 
vehiculated anti-cancer drug.  
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3. Synthesis of a fluorescently-labelled nucleolipid 
Ruthenium(III) complex 
 
For a detailed investigation of the in vivo mechanism of the synthesized 
complexes, including the internalization process into cells and their metabolic fate, we 
have designed a novel nucleolipid, built using HoThy as the main scaffold and further 
functionalized with a fluorescent label. To this purpose we have selected the dansyl 
group. This is a fluorescent molecule widely used in biochemistry and chemistry to label 
organic compounds. It offers several advantages: dansyl is a residue with limited steric 
hindrance compared to other common fluorescent dyes; it is easy to install and 
chemically stable in a large variety of reaction conditions; moreover, it is very sensitive to 
the solvent polarity conditions, thus offering relevant information on the local 
environment in which it is found. [38] Fluorescently-labelled nucleolipid 9 thus consists 
of: 
- one pyridine-methyl arm at the N-3 position, as the “chemical handle” for the 
successive metal complexation; 
- a dansyl group attached via a sulphate linkage in position 2’; 
- one oleic acid residue in position 3’; 
- one hepta(ethylene glycol) chain in position 5’. 
 
Following the design we have adopted for ToThyRu, HoThyRu, DoHuRu and 
ToThyCholRu nanovectors, the latter residues have been attached through ester linkages, 
chemically stable but in principle easily reversible in vivo by esterases degradation (see 
Figure 9). 
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Figure 9. Fluorescently labelled Ruthenium(III) complex 9, here designed as an analog of HoThyRu. 
 
The synthesis of complex 9 was accomplished in 9 steps starting from uridine. The 
first step ensures the regioselective protection of the hydroxyl groups in positions 3’ and 
5’, so to successively allow the efficient insertion of the fluorescent label in the 2’-OH 
position. To this purpose we have selected the acid-labile 4-monomethoxytrityl (MMTr) 
protective group. Following the procedure described by Ogilvie et al. to obtain 
dimethoxytritylether derivatives of uridine, [39] we have treated this nucleoside with 2.8 
equivalents of MMTrCl and AgNO3 in the presence of pyridine, obtaining two 
regioisomers, 1a and 1b, with an overall yield of 91%, which were easily purified by silica 
gel column chromatography. In this procedure, regioisomer 1a was obtained in 19% yield 
while protected nucleoside 1b in 72% isolated yield (Scheme 2). The latter derivative has 
been exploited as the starting material in the design of novel nucleolipid - Ru(III)-
complexes, discussed in the following section; in parallel, 1a was used as the precursor of 
target derivative 9, the synthesis of which is here presented.  
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Scheme 2. Synthesis of MMTr-protected uridine derivatives 1a and 1b.  
Reaction conditions: Uridine, MMTrCl (2.8 equiv), AgNO3 (2.8 equiv), Py, THF, 12 h, r.t. 
 
Regioisomer 1a was then functionalized with a pyridine-methyl group in position N-
3 by reaction with 4-(bromomethyl)pyridine hydrobromide in the presence of K2CO3, in 
analogy with the synthetic scheme used for the preparation of ToThy, HoThy, DoHu and 
ToThyChol. Successively, the N-3 alkylated nucleoside 2 was reacted with dansyl chloride, 
to give dansyl-labelled derivative 3, with the dye inserted in 2’ position (Scheme 3). 
Ditritylated nucleoside 3 was deprotected by acidic treatment with TFA in the presence of 
TIS to obtain deprotected nucleoside 4. The successive reaction with a stoichiometric 
amount of TBDMSCl in the presence of imidazole allowed the selective protection of the 
position 5’. Subsequent esterification of 5 with oleic acid in the presence of DCC as the 
condensing agent led to nucleolipid 6. This was then deprotected at the 5’ position 
through a mild desilylation procedure, involving the use of Et3N∙3HF in THF, to obtain 
alcohol 7. This nucleolipid was then esterified by reaction of the 5’-OH group with a 
residue of BnO(CH2CH2O)6CH2COOH in the presence of DCC, used as the condensing 
agent, giving derivative 8. As a final step, desired ruthenium complex 9 was obtained by 
reaction of 8 with an equimolar amount of [RuCl4(DMSO)2]
-
Na
+
 for 1 h at 40 °C in CH2Cl2. 
As in the case of ToThyRu, HoThyRu, DoHuRu and ToThyCholRu, complex 9 was 
characterized by ESI-MS analysis in the negative mode, showing only two diagnostic 
peaks, corresponding to the expected m/z ions (respectively at 1487.78 [M
-
-DMSO] and 
1566.76 [M
-
]), thus fully confirming the identity and purity of the desired Ru-complex-
containing nucleolipid. 
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Scheme 3. Synthesis of ruthenium complex 9. a) 4-(bromomethyl)pyridine hydrobromide, K2CO3, DMF, 48 h, 
60 °C; b) Dansyl chloride, DMAP, TEA, CH2Cl2, 15 min, r.t.; c) TFA, TIS, 1 h, r.t.; d) TBDMSCl, imidazole, DMF, 
2 h, r.t.; e) Oleic acid, DCC, DMAP, CH2Cl2, 1 h, r.t.; f) Et3N∙3HF, THF, 12 h, r.t.; g) BnO(CH2CH2O)6CH2COOH, 
DCC, DMAP, CH2Cl2, 12 h, r.t.; h) [RuCl4(DMSO)2]
-
Na
+
, CH2Cl2, 1 h, 40 °C. 
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4. Synthesis of a second generation of nucleolipid 
Ruthenium(III) complexes 
 
To expand the repertoire of available nucleolipid ruthenium(III) complexes and 
thus define the best structural requirements to obtain efficient anticancer agents, we 
have also explored a novel design, based on a different decoration of the nucleosidic 
skeleton. In the first series of compounds we have prepared (ToThyRu, HoThyRu, DoHuRu 
and ToThyCholRu, discussed in section 2.1), remarkably the pyridine-methyl group, 
chosen as the privileged ligand for ruthenium, is anchored to the N-3 position of the 
nucleobase. In principle, in order to exploit the recognition abilities of the nucleobases, 
these should not be blocked by hindered groups. Therefore, on the basis of the promising 
results obtained for the first generation of ruthenium(III) complexes, we here propose a 
novel nucleolipid carrying the pyridine-methyl group on the sugar moiety, as a model for 
a second generation of metal-complexed nucleolipids. The synthesized molecule 21 
consists of: 
- one pyridine-methyl arm at the 3’ position, linked through an amide bond, as 
the ligand for the metal complexation; 
- one oleic acid residue in position 2’; 
- one hepta(ethylene glycol) chain in position 5’. 
 
A wide range of analogs of 21 can be easily accessible by varying the nature of the 
hydrophilic and lipophilic chains attached to the furanosic moiety (Figure 10). 
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Figure 10. Novel nucleolipid ruthenium(III) complex 21. 
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Key intermediate for the synthesis of this compound is the modified nucleoside 3′-
azido-3′-deoxy-1-β-D-xylofuranosyluracil 14 showed in Figure 11. This is a very simple 
building block, having three functional groups which can be easily differentiated: two 
hydroxyls, one primary and one secondary function, and one azido group, which can be 
considered as a masked amino group, being easily reduced to a primary amine. By 
exploiting a rational scheme of protecting groups to temporarily deactivate these 
functions, it is therefore possible to insert on each of them a specific decoration in a very 
selective and efficient manner. Nucleoside 14 was already known in the literature, but the 
previously described synthesis involved a large number of synthetic steps and low yields. 
[40] In this work we have adopted a new, optimized protocol, requiring only 
straightforward and high yielding steps. 
NH
O
ON
O
OH
HO
N3
14  
Figure 11. 3′-azido-3′-deoxy-1-β-D-xylofuranosyluracil 14. 
 
As a starting material we have selected nucleoside 1b, carrying one free hydroxyl 
group in the 3’ position. The key step for the conversion of the 3’-OH group into an azide 
involves the use of the Mitsunobu reaction which leads to inversion of configuration at C-
3’. [41] To this purpose, our first goal has been the development of a synthetic strategy 
for the efficient and easy protection of the nucleobase in N-3 position to prevent, under 
the Mitsunobu reaction conditions, the formation of the corresponding 2,3’-anhydro-
derivative (Figure 12). [42] 
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Figure 12. 2,3’-anhydro-derivative. 
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This target was accomplished by the use of the Boc, that was inserted as the N-3 
protective group by a simple synthetic manipulation developed in our research group (see 
Chapter 6). [43] 
Nucleoside 1b was first protected in 3’ position by insertion of an acetyl group; 
successively, nucleoside 10 was protected in N-3 position with a Boc group by reaction 
with Boc2O, TEA and DMAP in DCM obtaining nucleoside 11 in 80% isolated yield. The 3’-
acetyl group was then removed by treatment with catalytic K2CO3 in CH3OH/TEA 
obtaining nucleoside 12 in quantitative yield. The acetylation/deacetylation procedures 
required prolonged reaction times (compared to the classically reported procedures), 
probably as a consequence of the high steric hindrance of the 3’ position (Scheme 4). 
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Scheme 4. Synthesis of derivative 14. a) Ac2O, Py, 12 h, r.t.; b) Boc2O, TEA, DMAP, DCM, 1 h, r.t.; c) K2CO3, 
MeOH / Et3N (3:1), 24 h, r.t.; d) PPh3, DIAD, DPPA , THF, 24 h, r.t.; e) TFA, TIS/DCM (1:9), 1 h, r.t. 
 
The Mitsunobu reaction was carried out treating nucleoside 12 with PPh3, DIAD 
and DPPA, leading to the 3’-azido-3’-deoxyxylofuranosyl nucleoside 13 in 92% isolated 
yield; on this substrate the reaction with 10% TFA and TIS in DCM was carried out to 
achieve the fully deprotected nucleoside 14. Following this synthetic scheme, the desired 
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nucleoside 3′-azido-3′-deoxy-1-β-D-xylofuranosyluracil was obtained in 6 steps with 50% 
overall yields starting from uridine. 
The obtained nucleoside 14 was easily manipulated to obtain the desired complex 21. As 
the first step, we have protected the 5’ position with the TBDMS group and then 
esterified the 2’ position with oleic acid, using DCC as the condensing agent, thus 
obtaining derivative 16 (Scheme 5). 
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Scheme 5. Synthesis of nucleolipid 19. a) TBDMSCl, imidazole, DMF, 1 h, r.t.; b) oleic acid; DCC, DMAP, 
CH2Cl2, 2 h, r.t.; c) H2 1 atm, Pd/C 10% p.p., AcOEt, 24 h, r.t.; d) 2-(pyridin-4-yl)acetic acid hydrochloride; 
DCC, DMAP, CH2Cl2, 12 h, r.t.; e) Et3N∙HF, THF, 3 h, r.t.; f) BnO(CH2CH2O)6CH2COOH, DCC, DMAP, CH2Cl2, 2 h, 
r.t. 
  
The reduction of the azide group to amine was carried out by reaction with H2 (P= 
1 atm) in the presence of Pd/C for 24 h. The amino-nucleoside 17 was obtained in almost 
quantitative yields in a pure form, simply filtering off and washing the catalyst. Then, the 
amino group was reacted with a residue of 2-(pyridin-4-yl)acetic acid hydrochloride to 
obtain derivative 18. The subsequent reaction with Et3N∙3HF liberates the 5’-OH group in 
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nucleoside 19 that was then functionalized with a residue of benzyl-capped hexa(ethylene 
glycol) acetic acid, providing nucleolipid 20. The reaction of 20 with an equimolar amount 
of [RuCl4(DMSO)2]
-
Na
+
 for 1 h at 40 °C in CH2Cl2 led to complex 21 in quantitative yields, 
obtained in a pure form by TLC control and ESI-MS analysis, thus not requiring any further 
purification (Scheme 6). 
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 Scheme 6. Synthesis of Ru(III) complex 21. a) [RuCl4(DMSO)2]
-
Na
+
, CH2Cl2, 1 h, 40 °C. 
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5. Conclusions 
 
In this Chapter the synthesis and characterization of a novel family of 
Ruthenium(III) complexes based on amphiphilic nucleolipids, as potential anticancer 
drugs, has been described. The first four derivatives, ToThyRu, HoThyRu, DoHuRu and 
ToThyCholRu, were synthesized starting from the corresponding nucleolipid nanovectors 
already described in Chapter 2, by complexation with the easily accessible ruthenium salt 
[RuCl4(DMSO)2]
-
Na
+
. These novel amphiphilic complexes were characterized by ESI-MS 
data and then studied in their self-assembling properties in aqueous solutions and 
pseudo-physiological conditions. A detailed study of their aggregative behaviour has 
shown that the synthesized compounds form a wide variety of supramolecular 
aggregates. Aggregates formed by the pure Ru-containing complexes show a fast 
degradation kinetics that, depending on pH, is almost complete from few hours to some 
days. This behaviour is absolutely comparable to the one reported in the literature for 
NAMI-A and other Ru-complexes currently in clinical trials; as a matter of fact, the scarce 
stability in physiological conditions is mentioned as the major, crucial limit to possible 
future exploitations of all the known Ru-based candidates as marketable drugs. We 
therefore addressed this main issue by testing these complexes in formulation with 
natural, biocompatible phospholipids. First, very promising results have been obtained by 
mixing the here synthesized Ru-complexes with POPC. Particularly, we observed that, 
when the ruthenium complexes are lodged in POPC liposomes up to a 15% in moles, the 
degradation in physiological media is virtually null for several days and the formulation is 
stable for at least several weeks. 
It is worth mentioning that in vitro bioscreenings based on the evaluation of 
concentrations-effect curves reveal that complexes in POPC formulation are much more 
effective in inhibiting the growth of human cancer cells of different histogenesis with 
respect to the reference ruthenium-complex NAMI-A-like Azi-Ru. In particular, promising 
results were obtained with ToThyRu/POPC and HoThyRu/POPC formulations on MCF-7 
cancer cells. Therefore, this study opens new perspectives in the synthesis and 
characterization of highly biocompatible transition metal-based aggregates having 
potential applications as antineoplastic agents.  
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Successively, for a detailed investigation of the in vivo mechanism of action of the 
synthesized complexes, including studies on their internalization process into cells and 
their metabolic fate, we have designed nucleolipid-complex 9, built using HoThy as the 
main scaffold and further functionalized with the fluorescent dansyl group. On this novel 
Ru(III) nucleolipid-complex and its precursor 8 studies are actually in progress on their 
cytotoxic activity on a panel of cancer cells lines, and on the in vivo mechanism of action, 
carried out by taking advantage also of fluorescence microscopy techniques. 
As a further improvement, to expand the repertoire of available nucleolipid 
ruthenium(III) complexes and thus define the best structural requirements to obtain 
efficient anticancer agents, I have also explored a novel design, based on a different 
decoration of the nucleosidic skeleton. In particular, novel nucleolipid 21 carrying the 
pyridine-methyl group on the sugar moiety was synthesized, as a model compound for a 
second generation of metal-complexed nucleolipids. To this purpose, I selected 3′-azido-
3′-deoxy-1-β-D-xylofuranosyluracil as the key nucleosidic scaffold to obtain the target, 
highly functionalized nucleolipid. A novel synthetic procedure was developed and 
optimized to prepare this modified nucleoside, obtained in only six straightforward 
synthetic steps in 50% yield starting from Uridine. Successive synthetic manipulation of 
this modified nucleosidic building block, requiring seven, simple and efficient steps, 
afforded the model nucleolipid 21 in 20% overall yields. 
 
                                                                                                                                          Chapter 3 
75 
 
6. Experimental Section 
 
General synthetic methods. 
All the reagents were of the highest commercially available quality and were used 
as received. TLC analyses were carried out on silica gel plates from Merck (60, F254). 
Reaction products on TLC plates were visualized by UV light and then by treatment with a 
10 % Ce(SO4)2/H2SO4 aqueous solution. For column chromatography, silica gel from Merck 
(Kieselgel 40, 0.063-0.200 mm) was used. NMR spectra were recorded on Bruker WM-
400, Varian Gemini 200 and Varian Inova 500 spectrometers, as specified. All the chemical 
shifts are expressed in ppm with respect to the residual solvent signal. Peak assignments 
have been carried out on the basis of standard H-H COSY and HSQC experiments. The 
following abbreviations were used to explain the multiplicities: s = singlet; d = doublet; t = 
triplet; q = quartet; m = multiplet; b = broad; dd = double doublet. For the ESI MS 
analyses, a Waters Micromass ZQ instrument – equipped with an Electrospray source – 
was used in the positive and/or negative mode. MALDI TOF mass spectrometric analyses 
were performed on a PerSeptive Biosystems Voyager-De Pro MALDI mass spectrometer in 
the Linear mode using 3,4-dihydroxybenzoic acid as the matrix. 
 
 
General procedure for the synthesis of Nucleoside-Ru complexes ToThyRu, 
HoThyRu, DoHuRu and ToThyCholRu 
 
The selected nucleolipid (0.033 mmol) was dissolved in 1 mL of the appropriate dry 
solvent (CH3CN for ToThy; CH2Cl2 for HoThy, DoHu and ToThyChol) and then [trans-
RuCl4(DMSO)2]
-
 Na
+
 (0.033 mmol) was added. The reaction mixture was stirred at 40 °C 
and the solvent was then removed under reduced pressure. The reaction, monitored by 
TLC on alumina, showed in 4 h the total disappearance of the starting material to give the 
desired salt in almost quantitative yields. 
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• ToThyRu 
Red powder: Rf = 0.5 [CHCl3/CH3OH, 95:5 (v/v)].  
1H NMR (CDCl3, 500 MHz): significant signals at δ 7.39 (s, 1H, H-6); 6.37 (m, 1H, H-1'); 
5.40-5.37 (overlapped signals, 2H, H-9 and H-10 oleic acid); 5.30 (s, 2H, -CH2Py); 5.23 (m, 
1H, H-3'); 4.99 (s, 1H, -OCH2CO- TEG); 4.30 (broad signals, 2H, H2-5)'; 3.74 (m, 1H, H-4'); 
3.67-3.37 [overlapped signals, 15H, 3x(-O-CH2-CH2-O-) and CH3O- TEG ]; 2.34 (m, 2H, H-
2'); 2.07-1.93 (overlapped signals, 4H, CH2-8 and CH2-11 overlapped signals); 1.61-1.31 
[broad and overlapped signals, 27H, 12x(-CH2- oleic acid), CH3-Thy]; 0.89 (apparent triplet, 
3H, CH3-18 oleic acid); -2.05 (very broad signal, Py-Ru); -12.7 (very broad signal, CH3 
DMSO). 
13C NMR (CDCl3, 50 MHz): significant signals at δ 173.0 (C=O oleic acid); 169.5 (C=O TEG); 
160.9 (C-4); 154.4 (C-2); 133.5 (C-6); 129.8 and 129.5 (C-9 and C-10 oleic acid); 110.6 (C-
5); 84.6 (C-1'); 81.6 (C-4'); 73.7 (C-3'); 71.6, 70.9 and 70.3 (O-CH2-CH2-O- TEG); 68.6 (-
OCH2CO- TEG); 63.8 (C-5'); 58.8 (CH3O- TEG); 44.8 (-CH2Py); 33.8 (C-2'); 31.6, 29.6, 29.4, 
29.0, 28.8, 26.9, 24.4 and 22.4 (aliphatic carbons of oleic acid); 14.2 (CH3-18 oleic acid); 
12.4 (-CH3-Thy). 
ESI-MS (negative ion): calculated for C45H73Cl4N3O12RuS, 1123.27; m/z, found: 1124.24 
(M
-
). 
 
• HoThyRu 
Red powder: Rf = 0.4 [AcOEt/CH3OH, 1:1 (v/v)]. 
1H NMR (CDCl3, 500 MHz, 0.06 M): significant signals at δ 7.50-7.26 [broad and 
overlapped signals, 6H, H-6 and (5 x aromatic protons of Bn)]; 6.34 (broad signal, 1H, H-
1'); 5.38 and 5.34 (m, 2H, H-9 and H-10 oleic acid); 4.56 (s, 2H, -CH2-Ph); 4.47 (m, 2H, H2-
5'); 4.36-4.15 (broad and overlapped signals, 3H, H-4' and -OCH2CO-HEP); 3.80-3.51 
[broad and overlapped signals, 24H, 6x(-O-CH2-CH2-O-)]; 2.35-2.28 (overlapped signals, 
4H, H2-2' and CH2-2 oleic acid); 2.05-1.94 (broad signals, 4H, CH2-8 and CH2-11 oleic acid); 
1.58-1.31 [broad and overlapped signals, 27H, 12x(-CH2- oleic acid), CH3-Thy]; 0.89 (broad 
signal, 3H, CH3-18 oleic acid); -1.98 (very broad signal, Py-Ru); -13.0 (very broad signal, 6H, 
CH3 DMSO). 
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13C NMR (CDCl3, 50 MHz): significant signals at δ 173.0 (C=O oleic acid); 169.8 (C=O HEP); 
163.1 (C-4); 153.8 (C-2); 138.0 (C quaternary aromatic carbon of Bn); 133.6 (C-6); 129.7 
(C-9 and C-10 oleic acid); 128.1, 127.5 and 127.3 (aromatic carbons Bn); 110.7 (C-5); 83.6 
(C-1'); 82.0 (C-4'); 74.0 (C-3'); 73.1 (-CH2Ph); 71.0, 70.6 and 69.4 (O-CH2-CH2-O- HEP); 68.1 
(-OCH2CO- HEP); 64.3 (C-5'); 44.7 (-CH2Py); 37.1 (C-2'); 31.6, 29.4, 29.2, 29.0, 28.8, 26.9, 
24.4 and 22.3 (aliphatic carbons of oleic acid); 14.1 (CH3-18 oleic acid); 12.6 (-CH3-Thy). 
ESI-MS (negative ions): calculated for C57H89Cl4N3O15RuS, 1331.38; m/z, found: 1332.86 
(M
-
). 
 
• DoHuRu 
Red powder: Rf = 0.3 [AcOEt/CH3OH, 1:1 (v/v)]. 
1H NMR (CDCl3, 500 MHz): significant signals at δ 7.53 (d, J = 8.5 Hz, 1H, H-6); 7.36-7.26 
[overlapped signals, 5H, aromatic proton of Bn)]; 6.03 (d, J = 5.0 Hz, 1H, H-1'); 5.89 (d, J = 
8.0 Hz, 1H, H-5); 5.37 (overlapped signals, 2H, H-2' and H-3'); 5.34 [overlapped signals, 4H, 
2 x (H-9 and H-10 oleic acid)]; 5.00 (broad singlet, 2H,-CH2Py); 4.56 (s, 2H, -CH2-Ph); 4.23-
4.01 (broad and overlapped signals, 3H, H2-5', H-4', -OCH2CO- HEP); 3.74-3.63 [overlapped 
signals, 24H, 6x(-O-CH2-CH2-O-)]; 2.34 and 2.25 [overlapped signals, 4H, 2x(CH2)-2 oleic 
acid)]; 2.21 and 2.01 [overlapped signals, 8H, [2x(CH2-8) and 2x(CH2-11) oleic acid]; 1.56-
1.27 [overlapped signals, 48H, 2x(12 x -CH2-) oleic acid]; 0.89-0.87 [overlapped signals, 6H, 
2x(CH3)-18 oleic acid)]; -1.97 (very broad signal, Py-Ru); -12.9 (very broad signal, CH3 
DMSO). 
13C NMR (CDCl3, 50 MHz): significant signals at δ 171.5, 170.9 and 163.8 (C=O esters); 
157.7 (C-4); 147.8 (C-2); 140.7 (C-6); 138.9 (quaternary carbon of Bn); 130.0 (C-9 and C-10 
oleic acids); 128.0, 127.2 and 127.0 (aromatic carbons of Bn); 101.0 (C-5); 90.0 (C-1'); 80.9 
(C-4'); 73.2 and 70.5 (C-2' and C3'); 70.5 (-CH2Ph); 70.0 (O-CH2-CH2-O- HEP); 68.7 (-
OCH2CO- HEP); 63.8 (C-5'); 43.0 (-CH2Py); 33.8 [overlapped signals, 2x(-CH2)-2 oleic acid)]; 
31.6, 29.9, 29.6, 29.3, 29.0, 27.5, 25.3, 24.1 and 22.3 (aliphatic carbons of oleic acid); 13.0 
[2x( CH3-18 oleic acid)]. 
ESI-MS (negative ions): for C74H119Cl4N3O17RuS, calculated 1595.61; m/z, found: 1596.9 
(M
-
). 
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• ToThyCholRu 
red powder: Rf: 0.4 (CHCl3/CH3OH, 95:5, v/v). 
1H NMR (CDCl3, 500 MHz): δ significant signals at δ 9.00 (d, J = 6 Hz, 1H, H-6); 6.69 (bs, 1H, 
H-1’); 5.54 (bs, 1H, H-6 Chol), 5.41 (bs, 1H, H-3’); 5.08 (s, 2H, -CH2-Py); 4.25-4.00 
(overlapped signals, 7H, H-5’a and H-5’b, -CH2C=O TEG, CH2C=O and H-4’); 3.65-3.3.51 
(overlapped signals, 12H, 3x –OCH2-CH2O-); 3.40 (s, 3H, -OCH3); 3.23 (bs, 1H, H-3 Chol); 
2.38 (m, 2H, H-2’); 1.00 (s, 3H, CH3-19); 0.95 (d, J = 6.0 Hz, 3H, CH3-21 Chol); 0.86 
(coincident d’s, J = 4.5 Hz, 6H, CH3-26 and CH3-27 Chol); 0.72 (s, 3H, CH3-18 Chol), -1.87 
(bs, Py protons); -12.66 (bs, CH3 of DMSO). 
13C NMR (CDCl3, 125 MHz): δ significant signals δ 170.0 (C=O Chol ester); 169.3 (C=O TEG 
ester); 160.8 (C-4); 139.9 (C-5 Chol); 132.1 (C-6); 121.9 (C-6 Chol); 109.1 (C-5); 84.4 (C-1’); 
82.2 (C-4’); 81.4 (C-3 Chol); 74.3 (C-3’); 71.8, 70.8, 70.3 (carbons of TEG); 68.4 (-CH2C=O 
TEG); 65.1 (-CH2C=O Chol); 63.7 (C-5’); 59.1 (-OCH3); 49.8 (-CH2Py); 42.0 (C-2’); 22.5 and 
22.1 (C-27 and C-26 Chol); 19.0 (C-19 Chol); 18.4 (C-21 Chol); 14.2 (CH3-Thy); 11.6 (C-18 
Chol). 
ESI-MS (negative ions): for C56H87Cl4N3O13RuS
-
 calculated 1283.37; found m/z: 1285.18 
(M
-
); 1209.12 (M
-
-DMSO). 
 
• Synthesis of AziRu complex 
In analogy to the synthesis of 1, pyridine (3.0 μl, 0.037 mmol) was dissolved in 0.3 ml of 
dry acetonitrile and then [trans-RuCl4(DMSO)2]
–
 Na
+
 (15.6 mg, 0.037 mmol) was added. 
The reaction mixture was stirred at 50 °C for 2 h and the solvent was then removed in 
vacuo, giving the desired product AziRu, identified on the basis of its NMR and ESI-MS 
data (data not shown), in quantitative yields. 
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Synthesis of fluorescent Ruthenium complex 9. 
 
Synthesis of compounds 1a and 1b. 
Uridine (1.00 g, 4.09 mmol) was suspended in 120 mL of anhydrous THF. Pyridine (3.30 
mL, 40.9 mmol), AgNO3 (1.95 g, 11.5 mmol) and MMTrCl (3.54 g, 11.5 mmol) were 
sequentially added to the solution. The resulting mixture was stirred at room 
temperature for 12 h, then the suspension was filtered and dried under reduced 
pressure. The crude was dissolved in CH2Cl2 and then washed with a water solution of 
NaHCO3 5% p.p.; the collected organic phases were dried over anhydrous Na2SO4, 
concentrated under reduced pressure and purified on a silica gel column, eluted with n-
hexane/AcOEt (1:1, v/v + 1% TEA). Nucleoside 1a was obtained in 19% isolated yield (614 
mg, 0.778 mmol), while its regioisomer 1b in 72% yield (2.32 g, 2.95 mmol). 
1a: white solid; Rf = 0.6 [n-hexane/AcOEt, 4:6 v/v]. 
1b: white solid; Rf = 0.8 [n-hexane/AcOEt 4:6 v/v]. 
Regioisomer 1a: 
1H-NMR (C6D6, 200 MHz): δ 7.78-6.7 (29H, overlapped signals, H-6 and aromatic protons 
of MMTr); 6.45 (1H, d, J = 4.6 Hz, H-1’); 5.27 (1H, d, J = 8.6 Hz, H-5); 5.02 (1H, d, J = 7.2 Hz, 
H-3’); 4.60 (1H, dd, J = 4.4 and 4.6 Hz, H-2’); 4.14 (1H, broad singlet, H-4’); 3.52-3.11 (2H, 
m, H-5’a and H-5’b); 3.35 (6H, s, 2x OCH3). 
13C-NMR (C6D6, 50 MHz): δ 163.3 (C-4); 159.5, 145.2, 144.5, 135.8, 135.4, 131.4, 130.9, 
133.6 (aromatic carbons of MMTr); 151.4 (C-2); 140.2 (C-6); 102.7 (C-5); 90.2 (C-1’); 88.2 
and 87.7 (quaternary carbons of MMTr); 83.3 (C-4’); 75.2 (C-3’); 73.8 (C-2’); 63.2 (C-5’); 
54.8 (OCH3). 
ESI-MS (positive ions): for C49H44N2O8, calculated 788.8823; found m/z: 811.94 [M+Na
+
]; 
827.79 [M+K
+
]. 
Regioisomer 1b: 
1H NMR (C6D6, 200 MHz): δ 7.70 (1H, d, J = 8.2 Hz, H-6); 7.64-6.64 (28H, overlapped 
signals, aromatic protons of MMTr); 6.61 (1H, d, J = 7.2 Hz, H-1’); 5.22 (1H, d, J = 8.4 Hz, H-
5); 4.70 (1H, dd, J = 4.4 and 4.6 Hz, H-2’); 4.03 (1H, bs, H-3’); 3.33 (3H, s, OCH3); 3.29 (3H, 
s, OCH3); 3.13-2.92 (3H, overlapped signals, H-5’a, H-5’b and H-4’). 
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13C NMR (C6D6, 50 MHz): δ 163.3 (C-4); 159.7, 159.4, 149.5, 144.9, 144.3, 143.9, 135.9, 
135.2, 131.0, 130.6, 128.7, 128.5, 128.2, 128.0, 127.5, 123.6, 114.1, 113.6 (aromatic 
carbons of MMTr ); 151.8 (C-2); 140.8 (C-6); 103.2 (C-5); 88.0 and 87.8 (quaternary 
carbons of MMTr); 87.1 (C-1’); 84.7 (C-4’); 78.2 (C-3’); 71.3 (C-2’); 64.7 (C-5’); 54.9 (OCH3). 
ESI-MS (positive ions): for C49H44N2O8, calculated 788.8823; found m/z: 811.97 [M+Na
+
]; 
827.84 [M+K
+
]. 
 
Synthesis of compound 2. 
1a (600 mg, 0.760 mmol) was dissolved in 4 mL of anhydrous DMF. K2CO3 (420 mg, 3.04 
mmol) and 4-(bromomethyl)pyridine hydrobromide (384 mg, 0.152 mmol) were then 
added to the solution, which was stirred at 60 °C for 48 h. The solution was then 
concentrated under reduced pressure, diluted with CH2Cl2 and washed three times with 
H2O. The collected organic phases were dried over anhydrous Na2SO4, concentrated 
under reduced pressure and purified on a silica gel column, eluted with n-hexane/AcOEt 
(35:65, v/v + 1% TEA). Nucleoside 2 was obtained in 35% isolated yield (237 mg, 0.269 
mmol). 
2: white solid; Rf = 0.4 [n-hexane/AcOEt, 4:6 v/v]. 
1H-NMR (CDCl3, 200 MHz): δ 8.38 (2H, d, J = 5.8 Hz, 2x HαPy); 7.63-6.51 (31H, overlapped 
signals, H-6, 2x HβPy and aromatic protons of MMTr); 6.41 (1H, d, J = 4.8 Hz, H-1’); 5.28 
(1H, d, J = 8.0 Hz, H-5); 4.72 (2H, m, CH2Py); 4.54 (1H, dd, J = 4.6 and 4.4 Hz, H-3’); 4.04 
(1H, broad singlet, H-4’); 3.90 (1H, m, H-2’); 3.49-3.07 (2H, m, H-5’a and H-5’b); 3.26 and 
3.21 (6H, s, 2x OCH3). 
13C-NMR (CDCl3, 50 MHz): δ 161.9 (C-4); 159.8, 146.1, 144.5, 135.8, 135.3, 131.2, 130.9, 
129.0, 128.5, 128.1 128.0 127.5, 113.6 (aromatic carbons of MMTr); 151.3 (C-2); 150.0 
(CαPy); 145.1 (CγPy); 139.0 (C-6); 123.7 (CβPy); 101.6 (C-5); 91.4 (C-1’); 88.0 and 87.7 
(quaternary carbons of MMTr); 83.3 (C-4’); 74.8 (C-3’); 74.0 (C-2’); 63.8 (C-5’); 54.8 
(OCH3); 43.0 (CH2Py). 
ESI-MS (positive ions): for C55H49N3O8, calculated 879.9929; found m/z: 881.73 [M+H
+
]. 
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Synthesis of compound 3. 
2 (104 mg, 0.118 mmol) was dissolved in anhydrous CH2Cl2 (1.0 mL). TEA (66 µL, 0.472 
mmol), DMAP (1.0 mg, 0.0060 mmol) and dansyl chloride (41 mg, 0.153 mmol) were then 
added to the solution. The reaction mixture was stirred at room temperature for 15 min, 
then the solvent was removed under reduced pressure and the residue purified on a silica 
gel column, eluted with n-hexane/AcOEt (7:3, v/v + 1% TEA). The product 3 was obtained 
in 87% isolated yield (114 mg, 0.103 mmol). 
3: yellow solid; Rf= 0.4 [n-hexane/AcOEt 3:7 v/v] 
1H-NMR (CDCl3, 500 MHz): δ 8.47 (2H, d, J = 5.5 Hz, 2x HαPy); 7.86 (2H, d, J = 6.0 Hz, 2x 
HβPy); 7.54-6.69 (35H, overlapped signals of Dansyl group, MMTr and H-6); 6.54 (1H, d, J= 
9.0 Hz, H-1’); 5.38 (1H, d, J = 8.0 Hz, H-5); 5.22-4.97 (3H, overlapped signals, CH2Py and H-
2’); 4.41 (1H, m, H-3’); 4.23 (1H, d, J= 5.0 Hz, H-4’); 3.81-3.71 (8H, overlapped signals, 
2xOCH3, H-5’a and H-5’b); 3.00 (6H, s, N(CH3)2). 
13C-NMR (CDCl3, 50 MHz): δ 161.0 (C-4); 158.6, 150.2, 143.8, 143.0, 135.9, 134.4, 131.7, 
131.4, 130.4, 130.2, 129.8, 129.3, 128.4, 127.9, 127.1, 119.4, 115.6, 113.2 (aromatic 
carbons of MMTr and Dansyl group); 151.6 (C-2); 150.0 (CαPy); 145.7 (CγPy); 136.8 (C-6); 
123.1 (CβPy); 101.7 (C-5); 88.2 and 87.3 (quaternary carbons of MMTr); 83.8 (C-1’); 83.1 
(C-4’); 77.9 (C-2’); 73.0 (C-3’); 62.8 (C-5’); 55.0 (OCH3); 45.2 [N(CH3)2]; 42.9 (CH2Py). 
ESI-MS (positive ions): for C67H60N4O10S, calculated 1113.2791; found m/z: 1113.06 
[M+H
+
]; 1135.05 [M+Na
+
]; 1151.99 [M+K
+
]. 
 
Synthesis of compound 4. 
3 (108 mg, 0.097 mmol), dissolved in anhydrous CH2Cl2 (0.90 mL), was treated with 50 µL 
of TFA and 50 µL of TIS. The reaction mixture was stirred at room temperature for 1 h, 
then the solvent was removed under reduced pressure and the residue purified on a silica 
gel column, eluted with AcOEt/CH3OH (8:2, v/v). Product 4 was obtained in quantitative 
yields (55 mg, 0.097 mmol).  
4: yellow solid; Rf= 0.3 [AcOEt/CH3OH, 95:5 v/v]. 
1H-NMR (CD3OD, 200 MHz): δ 8.60 (2H, d, J = 8.6 Hz, 2x Hα Py); 8.27-7.23 (9H, overlapped 
signals, protons of Dansyl group, H-6 and, 2x Hβ Py); 6.14 (1H, d, J = 7.8 Hz, H-1’); 5.21 (1H, 
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d, J = 8.2 Hz, H-5); 5.0 (2H, m, CH2Py); 4.76 (1H, dd, J = 4.6 Hz and 4.8 Hz, H-2’); 4.38 (1H, 
d, J = 4.6 Hz, H-3’); 4.03 (1H, bs, H-4’); 3.63 (2H, m, H-5’a and H-5’b); 2.87 (6H, s, N(CH3)2). 
13C-NMR (CD3OD, 50 MHz): δ 161.0 (C-4); 156.5, 133.4, 132.6, 131.2, 130.7, 129.8, 126.3, 
120.1, 116.8 (aromatic carbons of Dansyl group); 153.1 (C-2); 151.9 (Cα Py); 144.5 (Cγ Py); 
139.6 (C-6); 124.3 (Cβ Py); 102.6 (C-5); 88.1 (C-1’); 86.2 (C-4’); 81.1 (C-2’); 71.6 (C-3’); 62.6 
(C-5’); 45.7 [N(CH3)2]; 44.6 (CH2Py). 
ESI-MS (positive ions): for C27H28N4O8S, calculated 568.5982; found m/z: 568.86 [M+H
+
]; 
590.78 [M+Na
+
]; 606.68 [M+K
+
]. 
 
Synthesis of compound 5. 
4 (51 mg, 0.093 mmol), dissolved in anhydrous DMF (0.5 mL), was reacted with 
TMBDMSCl (17 mg, 0.112 mmol) and imidazole (13 mg, 0.186 mmol). The solution was 
stirred for 2 h at room temperature; then the solvent was removed under reduced 
pressure and the residue purified on a silica gel column, eluted with AcOEt/CH3OH (95:5, 
v/v). Compound 5 was obtained in 69% isolated yield (55 mg, 0.064 mmol). 
5: yellow solid; Rf = 0.6 [AcOEt/CH3OH, 95:5 v/v]. 
1H-NMR (CDCl3, 200 MHz): δ 8.56 (1H, d, J = 9.0 Hz, H-6); 8.45 (2H, d, J = 6.0 Hz, 2x HαPy); 
8.16-7.13 (8H, overlapped signals, protons of Dansyl group, 2x HβPy); 6.21 (1H, d, J = 6.0 
Hz, H-1’); 5.19 (1H, d, J = 8.0 Hz, H-5); 4.82-4.65 (2H, m, CH2Py); 4.55 (1H, m, H-2’); 4.37 
(1H, m, H-3’); 4.13 (1H, bs, H-4’); 3.73 (2H, m, H-5’a and H-5’b); 2.84 (6H, s, N(CH3)2); 0.84 
(SiC(CH3)3); 0.02 and -0.02 (Si(CH3)2). 
13C-NMR (CDCl3, 100 MHz): δ 161.0 (C-4), 150.2, 132.4, 131.0, 129.9, 129.7, 129.4, 128.9 
(aromatic carbons of Dansyl group); 151.9 (C-2); 149.2 (Cα Py); 145.6 (Cγ Py); 136.9 (C-6); 
123.5 (Cβ Py); 101.8 (C-5); 85.3 (C-1’); 84.6 (C-4’); 85.3 (C-2’); 70.5 (C-3’); 63.4 (C-5’); 45.2 
[N(CH3)2]; 43.1 (CH2Py); 25.9 (SiC(CH3)3); 18.3 (SiC(CH3)3) -5.6 (Si(CH3)2). 
ESI-MS (positive ions): for C33H42N4O8SSi, calculated 682.8591; found m/z: 682.84 [M+H
+
]; 
704.79 [M+Na
+
]. 
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Synthesis of compound 6. 
5 (40 mg, 0.059 mmol), dissolved in anhydrous CH2Cl2 (1.0 mL), was treated with oleic 
acid (24 µL, 0.077 mmol), DMAP (3.6 mg, 0.030 mmol) and DCC (24 mg, 0.12 mmol). The 
solution was stirred for 1 h at room temperature; then the solvent was removed under 
reduced pressure and the residue purified on a silica gel column, eluted with n-
hexane/AcOEt (2:8, v/v). Nucleolipid 6 was obtained in almost quantitative yields (56 mg, 
0.059 mmol). 
6: yellow solid; Rf = 0.8 [AcOEt]. 
1H-NMR (CDCl3, 200 MHz): δ 8.60 (1H, d, J = 8.4 Hz, H-6); 8.47 (2H, d, J = 5.8 Hz, 2x HαPy); 
8.18-7.11 (8H, overlapped signals, protons of Dansyl group, 2x HβPy); 6.22 (1H, d, J = 7.2 
Hz, H-1’); 5.35-5.24 (4H, overlapped signals, H-5, H-3’, H-9 and H-10 oleic acid); 4.87 (2H, 
m, CH2Py); 4.78 (1H, dd, J = 5.6 and 5.4 Hz, H-2’); 4.09 (1H, bs, H-4’); 3.78 (2H, m, H-5’a and 
H-5’b); 2.87 (6H, s, N(CH3)2); 2.42 (2H, t, J = 7.4 and 7.4 Hz, CH2C=O); 2.00-1.25 (20H, 
overlapped signals, aliphatic protons of oleic acid); 0.92-0.83 (12H, overlapped signals, 
SiC(CH3)3 and CH3 oleic acid); 0.09 and 0.04 (Si(CH3)2). 
13C-NMR (CDCl3, 100 MHz): δ 169.3 (C=O); 161.0 (C-4), 149.6, 139.5, 136.3, 132.1, 130.6, 
130.1, 129.7, 129.6, 129.5, 128.5, 122.6, 118.8, 115.3, 109.4 (aromatic carbons of Dansyl 
group); 151.7 (C-2); 150.1 (CαPy); 144.7 (CγPy); 136.3 (C-6); 123.1 (CβPy); 102.0 (C-5); 84.7 
(C-1’); 83.8 (C-4’); 76.3 (C-2’); 70.8 (C-3’); 62.8 (C-5’); 45.1 [N(CH3)2]; 43.0 (CH2Py); 34.7, 
33.7, 32.5, 31.7, 30.7, 29.4, 29.1, 28.9, 28.8, 27.0, 26.2, 25.4, 24.7, 24.0, 22.4 (aliphatic 
carbons of oleic acid); 25.7 (SiC(CH3)3); 18.2 (SiC(CH3)3); 14.5 (CH3 oleic acid); -5.8 and -5.8 
(Si(CH3)2). 
ESI-MS (positive ions): for C51H74N4O9SSi, calculated 947.3052; found m/z: 947.12 [M+H
+
]; 
969.08 [M+Na
+
]; 985.14 [M+K
+
]. 
 
Synthesis of compound 7. 
6 (50 mg, 0.053 mmol), dissolved in anhydrous THF (1.0 mL), was reacted with Et3N∙3HF 
(34 µL, 0.212 mmol). The solution was stirred for 12 h at room temperature; then the 
solvent was removed under reduced pressure and the residue purified on a silica gel 
column, eluted with n-hexane/AcOEt (2:8, v/v). Nucleolipid 7 was obtained in 68% 
isolated yield (30 mg, 0.036 mmol). 
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7: yellow solid; Rf = 0.6 [n-hexane/acetone, 1:1 v/v]. 
1H-NMR (CDCl3, 200 MHz): δ 8.60 (1H, d, J = 8.6 Hz, H-6); 8.52 (2H, bs, 2x HαPy); 8.18-7.13 
(8H, overlapped signals, protons of Dansyl group, 2xHβPy); 5.93 (1H, d, J = 6.8 Hz, H-1’); 
5.43-5.33 (4H, overlapped signals, H-5, H-3’, H-9 and H-10 oleic acid); 5.18 (1H, dd, J = 7.0 
and 5.6 Hz, H-2’); 4.81 (2H, m, CH2Py); 4.10 (1H, bs, H-4’); 3.77 (2H, bs, H-5’a and H-5’b); 
2.89 (6H, s, N(CH3)2); 2.27 (2H, t, J = 7.4 and 7.4 Hz, CH2C=O); 2.0-1.27 (20H, overlapped 
signals, aliphatic protons of oleic acid); 0.89 (3H, m, CH3 oleic acid). 
13C-NMR (CDCl3, 50 MHz): δ 172.6 (C=O); 161.3 (C-4), 150.4, 133.8, 132.3, 131.0, 130.0, 
129.7, 128.8, 123.0, 118.8, 115.5 (aromatic carbons of Dansyl group); 152.0 (C-2); 149.0 
(CαPy); 146.0 (CγPy); 138.8 (C-6); 123.7 (CβPy); 102.4 (C-5); 88.6 (C-1’); 84.3 (C-4’); 76.5 (C-
2’); 71.0 (C-3’); 61.7 (C-5’); 45.3 [N(CH3)2]; 43.1 (CH2Py); 33.9, 31.9, 29.7, 29.5, 29.3, 29.1, 
27.2, 25.6, 24.9, 24.7, 22.7 (aliphatic carbons of oleic acid); 14.1 (CH3 oleic acid). 
ESI-MS (positive ions): for C45H60N4O9S, calculated 833.0443; found m/z: 833.08 [M+H
+
]; 
855.07 [M+Na
+
]; 870.98 [M+K
+
]. 
 
Synthesis of compound 8. 
7 (28 mg, 0.034 mmol), dissolved in anhydrous CH2Cl2 (0.8 mL), was reacted with 
BnO(CH2CH2O)6CH2COOH (19 mg, 0.044 mmol), DMAP (2.0 mg, 0.017 mmol) and DCC (14 
mg, 0.068 mol). The solution was stirred for 12 h at room temperature; then the solvent 
was removed under reduced pressure and the residue purified on a silica gel column, 
eluted with n-hexane/acetone (1:1, v/v). The product 8 was obtained in almost 
quantitative yields (42 mg, 0.034 mmol). 
8: yellow solid; Rf = 0.4 [n-hexane/acetone, 1:1 v/v]. 
1H-NMR (CDCl3, 200 MHz): δ 8.54 (1H, d, J = 8.4 Hz, H-6); 8.48 (2H, d, J = 4.8 Hz, 2x HαPy); 
8.11-6.92 (13H, overlapped signals, protons of Dansyl group, 2x HβPy and protons of Bn); 
5.80 (1H, d, J = 5.4 Hz, H-1’); 5.50 (1H, d, J = 8.2 Hz, H-5); 5.30 (2H, m, H-10 and H-9 oleic 
acid); 5.17 (1H, dd, J = 6.2 and 4.0 Hz, H-3’); 5.08 (1H, dd, J = 5.6 and 5.8 Hz, H-2’); 4.82 
(2H, m, CH2Py); 4.26-4.12 (5H, overlapped signals, H-4’, CH2C=O, H-5’a and H-5’b); 4.50 
(2H, s, CH2Bn); 3.69-3.58 (24H, overlapped signals, OCH2CH2O), 2.83 (6H, s, N(CH3)2); 2.14-
1.27 (22H, overlapped signals, aliphatic protons of oleic acid); 0.82 (3H, m, CH3 oleic acid). 
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13C-NMR (CDCl3, 50 MHz): δ 172.6 and 169.4 (2xC=O); 161.3 (C-4), 150.1, 138.5, 132.4, 
130.7, 130.5, 130.0, 129.8, 129.6, 129.6, 128.9, 128.3, 127.7, 127.5, 122.9, 118.7, 115.5 
(aromatic carbons of Dansyl group and Bn); 152.1 (C-2); 149.1 (CαPy); 145.8 (CγPy); 138.2 
(C-6); 123.5 (CβPy); 102.4 (C-5); 89.3 (C-1’); 80.1 (C-4’); 76.7 (C-2’); 73.1 (CH2Bn); 71.0 (C-
3’);  70.5, 69.6, 69.4 (OCH2CH2O); 63.1 (C-5’); 45.3 [N(CH3)2]; 43.2 (CH2Py); 33.9, 33.5, 32.6, 
31.8, 30.6, 29.7, 29.6, 29.4, 29.2, 29.0, 28.9, 27.1, 26.2, 25.6, 24.9, 22.6 (aliphatic carbons 
of oleic acid); 14.0 (CH3 oleic acid). 
ESI-MS (positive ions): for C66H92N4O17S, calculated 1245.5183; found m/z: 1245.31 
[M+H
+
]; 1267.18 [M+Na
+
]. 
 
Synthesis of Ru complex 9. 
Nucleolipid 8 (31 mg, 0.025 mmol), dissolved in 0.8 mL of anhydrous DCM, was treated 
with [RuCl4(DMSO)2]
-
Na
+
 (10.6 mg, 0.025 mmol) and the resulting solution was taken 
under stirring at 40 °C for 1 h. TLC monitoring on alumina showed in 1 h the total 
disappearance of the starting material; the reaction mixture was therefore taken to 
dryness, giving the desired product 9 in quantitative yields, obtained in a pure form, not 
requiring further purification (40 mg, 0.025 mmol). 
1H-NMR (CDCl3, 500 MHz): significant signals at δ 7.36-7.26 (aromatic proton of Bn and 
Dansyl group); 5.38-3.75 (very broad signals: protons of ribose, H-5 and polyether); 2.04-
0.90 (overlapped signals, protons of oleic acid); -1.85 (very broad signal, protons of Py); -
12.49 (very broad signal, 2x CH3 DMSO). 
13C-NMR (CDCl3, 50 MHz): significant signals at δ 129.2; 128.9; 127.7; 127.0; 71.2; 48.3; 
33.3; 28.9; 28.6; 28.4; 26.4; 24.8; 24.2; 13.3. 
ESI-MS (negative ions): for C68H98N4O18RuS2, calculated -1566.5337; found m/z: -1487.78 
[M
-
-DMSO]; 1566.76 [M
-
]. 
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Synthesis of Ruthenium complex 21 
 
Synthesis of compound 10. 
1b (870 mg, 1.10 mmol) was dissolved in Py (3.0 mL) and Ac2O (1.5 mL). The solution was 
stirred at room temperature for 12 h, then the reaction was quenched with 2 mL of 
MeOH. The crude was washed with DCM/H2O; the collected organic phase was dried over 
anhydrous Na2SO4, concentrated under reduced pressure to give compound 10 in 98% 
isolated yield (898 mg, 1.08 mmol). 
10: white solid, Rf = 0.4 [n-hexane/AcOEt, 1:1 v/v]. 
1H-NMR (CDCl3, 500 MHz): δ 7.60 (1H, d, J = 8.5 Hz, H-6); 7.48-6.71 (28H, overlapped 
signals, aromatic protons of MMTr); 6.55 (1H, d, J = 7.5 Hz, H-1’); 5.12 (1H, d, J = 8.5 Hz, H-
5); 4.48 (1H, dd, J = 8.0 Hz, H-2’); 3.83 (2H, bs, H-3’ and H-4’); 3.79 (3H, s, OCH3); 3.78 (3H, 
s, OCH3); 3.20 (2H, ABX system, J = 11.0 and 1.5 Hz, H-5’a and H-5’b); 1.99 (3H, s, CH3C=O). 
13C-NMR (CDCl3, 50 MHz): δ 169. 7 (C=O); 163.6 (C-4); 159.7, 159.4, 149.5, 144.9, 144.4, 
144.3, 143.9, 135.9, 135.1, 131.1, 130.6, 129.3, 128.8, 128.5, 128.2, 128.0, 127.5, 125.7, 
123.8, 113.9, 113.7 (aromatic carbons of MMTr); 151.6 (C-2); 140.3 (C-6); 103.2 (C-5); 
87.9 and 87.7 (quaternary carbons of MMTr); 86.8 (C-1’); 84.4 (C-4’); 75.9 (C-3’); 72.8 (C-
2’); 64.2 (C-5’); 54.9 (OCH3); 20.5 (CH3C=O). 
ESI-MS (positive ions): for C51H46N2O9, calculated 830.32; found m/z: 854.10 [M+Na
+
]; 
870.09 [M+K
+
]. 
 
Synthesis of compound 11. 
10 (889 mg, 1.07 mmol), dissolved in 6 mL of anhydrous CH2Cl2, was treated with TEA 
(448 μL, 3.21 mmol), Boc2O (467 mg, 2.14 mmol) and DMAP (65 mg, 0.535 mmol). The 
solution was stirred at room temperature for 1 h, then the solvent was removed under 
reduced pressure and the crude was purified on a silica gel column, eluted with n-
hexane/AcOEt (6:4, v/v + a few drops of TEA). The desired product 11 was obtained in 
80% isolated yield (793 mg, 0.856 mmol). 
11: white solid, Rf = 0.7 [n-hexane/AcOEt 1:1 v/v] 
1H-NMR (CDCl3, 500 MHz): δ 7.57 (1H, d, J = 8.5 Hz, H-6); 7.50-6.72 (28H, overlapped 
signals, aromatic proton of MMTr); 6.52 (1H, d, J = 8.0 Hz, H-1’); 5.06 (1H, d, J = 8.0 Hz, H-
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5); 4.42 (1H, dd, J = 6.0 and 5.5 Hz, H-2’); 3.80 (2H, bs, H-3’ and H-4’); 3.79 (3H, s, OCH3); 
3.77 (3H, s, OCH3); 3.19 (2H, ABX system, J = 9.5 and 2 Hz, H-5’a and H-5’b); 2.00 (3H, s, 
CH3C=O); 1.60 (9H, s, 3x CH3 Boc). 
13C-NMR (CDCl3, 50 MHz): δ 169. 9 (C=O); 160.2 (C-4); 159.1, 158.7, 143.9, 143.6, 143.5, 
143.0, 134.5, 134.4, 130.4, 130.1, 128.2, 128.1, 128.0, 127.9, 127.8, 127.3, 113.4, 113.2 
(aromatic carbons of MMTr); 148.9 (C-2); 147.6 (C=O Boc); 139.5 (C-6); 102.1 (C-5); 87.6 
(C-1’); 87.0 (quaternary carbon of MMTr); 86.6 (C(CH3)3 Boc); 84.3 (C-4’); 75.6 (C-2’); 72.5 
(C-3’); 63.7 (C-5’); 55.2 (OCH3); 27.3 (C(CH3)3 Boc); 20.5 (CH3C=O). 
ESI-MS (positive ions): for C56H54N2O11, calculated 930.37; found m/z: 954.11 [M+Na
+
]; 
970.30 [M+K
+
].  
 
Synthesis of compound 12. 
11 (965 mg, 1.036 mmol) was dissolved in 3 mL of MeOH and 1 mL of TEA. K2CO3 (29 mg, 
0.207 mmol) was added and the resulting solution was stirred at room temperature for 
12 h. Then the solvent was removed under reduced pressure and the crude was washed 
with DCM/H2O; the collected organic phase was dried over anhydrous Na2SO4, 
concentrated under reduced pressure to give the compound 12 in almost quantitative 
yields (921 mg, 1.035 mmol). 
12: white solid, Rf = 0.7 [n-hexane/AcOEt, 1:1 v/v]. 
1H-NMR (CDCl3, 200 MHz): δ 7.79 (1H, d, J = 8.2 Hz, H-6); 7.60-6.62 (28H, overlapped 
signals, aromatic protons of MMTr); 6.00 (1H, d, J = 5.4 Hz, H-1’); 5.11 (1H, d, J = 8.2 Hz, H-
5); 4.50 (1H, m, H-2’); 4.10 (1H, bs, H-3’); 3.81 (6H, overlapped singlets, 2x OCH3); 3.03 
(3H, m, H-4’, H-5’a and H-5’b); 1.65 (9H, s, 3x CH3 Boc). 
13C-NMR (CDCl3, 50 MHz): δ 160.3 (C-4); 159.2, 158.7, 143.9, 143.4, 143.3, 143.0, 134.3, 
134.1, 130.3, 130.1, 128.2, 128.0, 127.8, 127.4, 127.3, 113.7, 113.1 (aromatic carbons of 
MMTr); 149.0 (C-2); 147.6 (C=O Boc); 140.0 (C-6); 102.0 (C-5); 87.6 (C-1’); 86.6 
(quaternary carbons of MMTr and C(CH3)3 Boc); 84.6 (C-4’); 78.0 (C-2’); 70.7 (C-3’); 64.2 
(C-5’); 55.1 (OCH3); 27.3 (C(CH3)3 Boc). 
ESI-MS (positive ions): for C54H52N2O10, calculated 888.36; found m/z: 911.2 [M+Na
+
]; 
927.3 [M+K
+
].  
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Synthesis of compound 13. 
12 (464 mg, 0.520 mmol), dissolved in 5 mL of anhydrous THF, was reacted with PPh3 (410 
mmg, 1.56 mmol) and DIAD (307 μL, 1.56 mmol). The resulting solution was stirred at 
room temperature for 5 minutes, then DPPA (336 μL, 1.560 mmol) was added and the 
reaction mixture stirred overnight at room temperature. The solvent was then removed 
under reduced pressure and the crude was purified on a silica gel column, eluted with n-
hexane/AcOEt (75:25, v/v + TEA). The desired product 13 was obtained in 92% isolated 
yield (440 mg, 0.481 mmol). 
13: white solid, Rf = 0.7 [n-hexane/AcOEt, 3:2 v/v]. 
1H-NMR (CDCl3, 500 MHz): δ 7.48 (1H, d, J = 8.0 Hz, H-6); 7.34-6.81 (28H, overlapped 
signals, aromatic protons of MMTr); 6.4 (1H, bs, H-1’); 5.61 (1H, d, J = 8.0 Hz, H-5); 4.10 
(1H, m, H-2’); 3.94 (1H, bs, H-4’); 3.79 (6H, overlapped singlets, 2x OCH3); 3.52 (1H, m, H-
5’a); 3.07 (1H, m, H-5’b), 2.63 (1H, d, J = 3.0Hz, H-3’);1.64 (9H, s, 3x CH3 Boc). 
13C-NMR (CDCl3, 50 MHz): δ 159.8 (C-4); 159.2, 158.6, 143.9, 143.6, 143.2, 134.7, 134.5, 
130.4, 130.1, 127.9, 127.7, 127.4, 126.9, 113.5, 112.9 (aromatic carbons of MMTr); 148.3 
(C-2); 147.4 (C=O Boc); 140.0 (C-6); 102.6 (C-5); 90.5 (C-1’); 88.7 (C-4’); 86.8 and 86.6 
(quaternary carbons of MMTr); 83.4 (C(CH3)3 Boc); 78.9 (C-2’); 66.6 (C-3’); 60.9 (C-5’); 54.9 
(OCH3); 27.3 (C(CH3)3 Boc). 
ESI-MS (positive ions): for C54H51N5O9, calculated 913.37; found m/z: 814.90 [M-Boc+H
+
]. 
FT-IR: 2112.9 (N3 stretching). 
 
Synthesis of compound 14. 
13 (440 mg, 0.481 mmol), dissolved in 2.7 mL of anhydrous CH2Cl2, was reacted with 0.15 
mL of TFA and 0.15 mL of TIS. The resulting solution was stirred at room temperature for 
1 h, then the solvent was removed under reduced pressure and the crude was purified on 
a silica gel column, eluted with n-hexane/AcOEt (1:4, v/v). The desired product 14 was 
obtained in 97% isolated yield (126 mg, 0.468 mmol). 
14: white solid, Rf= 0.1 [n-hexane/AcOEt 3:7 v/v] 
1H-NMR (CD3OD, 500 MHz): δ 7.86 (1H, d, J = 8.0 Hz, H-6); 5.79 (1H, d, J = 3.0 Hz, H-1’); 
5.71 (1H, d, J = 8.0 Hz, H-5); 4.37 (1H, m, H-4’); 4.35 (1H, dd, J = 3.5 and 3.0 Hz, H-2’); 4.18 
(1H, dd, J = 4.0 and 3.0, H-3’); 3.85 (1H, d, J = 4.5 Hz, H-5’a and H-5’b). 
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13C-NMR (CD3OD, 125 MHz): 166.8 (C-4); 152.9 (C-2); 142,8 (C-6); 102.9 (C-5); 92.2 (C-1’); 
82.9 (C-4’); 80.3 (C-2’); 68.3 (C-3’); 61.7 (C-5’). 
ESI-MS (positive ions): for C9H11N5O5, calculated 269.08; found m/z: 270.0 [M+H
+
]; 292.0 
[M+Na
+
]. 
 
Synthesis of compound 15. 
14 (197 mg, 0.732 mmol), dissolved in 1 mL of anhydrous DMF, was reacted with 
imidazole (119 mg, 1.76 mmol) and TBDMSCl (132 mg, 0.878 mmol). The solution was 
stirred at room temperature for 1 h, then the solvent was removed under reduced 
pressure and the crude was purified on a silica gel column, eluted with n-hexane/AcOEt 
(1:1, v/v). The desired product 15 was obtained in 80% isolated yield (131 mg, 0.586 
mmol). 
15: oil, Rf = 0.5 [n-hexane/AcOEt, 1:1 v/v]. 
1H-NMR (CDCl3, 200 MHz): δ 7.73 (1H, d, J = 8.4 Hz, H-6); 5.79 (1H, d, J = 1.4 Hz, H-1’); 
5.71 (1H, d, J = 8.0 Hz, H-5); 4.45 (overlapped signals, H-2’ and H-4’); 4.20 (1H, m, H-3’); 
3.93 (2H, d, J = 5.2 Hz, H-5’a and H-5’b), 0.921 (9H, s, SiC(CH3)3), 0.12 (6H, s, Si(CH3)2). 
13C-NMR (CDCl3, 50 MHz): 164.0 (C-4); 151.2 (C-2); 140.3 (C-6); 101.8 (C-5); 91.8 (C-1’); 
81.7 (C-4’); 79.4 (C-2’); 65.9 (C-3’); 61.0 (C-5’); 25.8 (SiC(CH3)3); 18.2 (SiC(CH3)3); -5.5 and -
5.6 (Si(CH3)2). 
ESI-MS (positive ions): for C15H25N5O5Si, calculated 383.4750; found m/z: 384.14 [M+H
+
]; 
406.06 [M+Na
+
]; 422.00 [M+K
+
]. 
 
Synthesis of compound 16. 
15 (100 mg, 0.261 mmol), dissolved in 2 mL of anhydrous DCM, was reacted with DMAP 
(16 mg, 0.131 mmol), oleic acid (88 mg, 0.316 mmol) and DCC (81 mg, 0.392 mmol). The 
solution was stirred at room temperature for 2 h, then the solvent was removed under 
reduced pressure and the crude was purified on a silica gel column, eluted with n-
hexane/AcOEt (7:3, v/v). The desired product 16 was obtained in 74% isolated yield (125 
mg, 0.193 mmol). 
16: oil, Rf = 0.7 [n-hexane/AcOEt, 1:1 v/v]. 
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1H-NMR (CDCl3, 200 MHz): δ 7.70 (1H, d, J = 8.2 Hz, H-6); 6.05 (1H, d, J = 3.8 Hz, H-1’); 
5.76 (1H, dd, J = 1.4 and 8.2 Hz, H-5); 5.33 (2H, m, H-9 and H-10 oleic acid); 4.4 (1H, t, J = 
3.2 and 3.2 Hz, H-2’); 4.22 (2H, m, H-3’ and H-4’); 3.91 (2H, d, J = 4.8 Hz, H-5’a and H-5’b), 
2.5 (2H, dd, J = 6.8 and 7.8 Hz, 2x H-2 oleic acid); 2.02 (4H, m, 2x H-8 and 2x H-11 oleic 
acid); 1.63 (2H, m, H-3 oleic acid), 1.28 (20H, overlapped signals of oleic acid); 0.92 (9H, s, 
SiC(CH3)3), 0.87 (3H, t, J = 6.6 Hz, CH3 oleic acid); 0.12 (6H, s, Si(CH3)2). 
13C-NMR (CDCl3, 50 MHz): δ 172.4 (C=O), 163.1 (C-4); 150.3 (C-2); 139.8 (C-6); 130.0 and 
129.6 (C-9 and C-10 oleic acid); 102.9 (C-5); 87.2 (C-1’); 80.2 (C-4’); 79.5 (C-2’); 64.6 (C-3’); 
61.0 (C-5’); 33.8, 31.8, 29.7, 29.6, 29.4, 29.2, 29.0, 28.9, 27.1, 24.6, 22.6 (aliphatic carbons 
of oleic acid); 25.8 (SiC(CH3)3); 18.2 (SiC(CH3)3); 14.0 (-CH3 oleic acid); -5.5 and -5.7 
(Si(CH3)2). 
ESI-MS (positive ions): for C33H57N5O6Si, calculated 647.9211; found m/z: 648.12 [M+H
+
]; 
670.01 [M+Na
+
]; 686.07 [M+K
+
]. 
 
Synthesis of compound 17. 
16 (31 mg, 0.048 mmol) was dissolved in anhydrous AcOEt (0.7 mL) and then Pd/C 10% 
p.p. (10 mg, 0.0.01 mmol) was added. The solution was stirred at room temperature for 
12 h under pressure of H2 (1 atm), then the solvent was removed under reduced pressure 
and the crude was filtered on a short column of silica gel, eluted with AcOEt. The desired 
product 17 was obtained in almost quantitative yields (30 mg, 0.048 mmol). 
17: oil, Rf = 0.2 [n-hexane/AcOEt, 3:2 v/v]. 
1H-NMR (CDCl3, 200 MHz): δ 8.04 (1H, d, J = 8.4 Hz, H-6); 6.03 (1H, d, J= 4.8 Hz, H-1’); 5.72 
(1H, d, J = 8.4 Hz, H-5); 5.35 (2H, m, H-9 and H-10 oleic acid);  5.0 (1H, t, J = 5.2 and 5.2 Hz, 
H-2’); 4.20 (2H, m, H-4’); 3.93 (2H, m, H-5’a and H-5’b), 3.68 (1H, dd, J = 6.4 and 5.8 Hz, H-
3’); 2.36 (2H, t, J = 7.4 Hz, 2x H-2 oleic acid); 2.02 (4H, m, 2x H-8 and 2x H-11 oleic acid); 
1.58 (2H, m, H-3 oleic acid), 1.27 (20H, overlapped signals oleic acid); 0.93 (12H, 
overlapped signals, CH3 oleic acid and SiC(CH3)3), 0.14 (6H, s, Si(CH3)2). 
13C-NMR (CDCl3, 50 MHz): δ 173.2 (C=O), 162.7 (C-4); 150.2 (C-2); 140.8 (C-6); 130.0 and 
129.6 (C-9 and C-10 oleic acid); 102.4 (C-5); 86.2 (C-1’); 81.5 (C-4’); 80.2 (C-2’); 61.9 (C-5’); 
56.6 (C-3’); 33.9, 31.8, 29.6, 29.4, 29.2, 29.0, 27.1, 24.6, 22.5 (aliphatic carbons of oleic 
acid); 25.8 (SiC(CH3)3); 18.0 (SiC(CH3)3); 14.0 (-CH3 oleic acid); -5.7 (Si(CH3)2). 
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ESI-MS (positive ions): for C33H59N3O6Si, calculated 621.9236; found m/z: 622.15 [M+H
+
]; 
644.07 [M+Na
+
]; 660.13 [M+K
+
]. 
 
Synthesis of compound 18. 
Nucleolipid 17 (48 mg, 0.077 mmol), dissolved in 1 mL of anhydrous DCM, was treated 
with DMAP (28 mg, 0.231 mmol), 2-(pyridin-4-yl)acetic acid hydrochloride (20 mg, 0.116 
mmol) and DCC (40 mg, 0.193 mmol). The solution was stirred at room temperature for 
12 h, then the solvent was removed under reduced pressure and the crude was purified 
on a silica gel column, eluted with n-hexane/AcOEt (2:8, v/v). The desired product 18 was 
obtained in 99% isolated yield (56 mg, 0.076 mmol). 
1H-NMR (CD3OD, 200 MHz): δ 8.47 (2H, d, J = 4.4 Hz, 2x HαPy); 7.82 (1H, d, J = 8.0 Hz, H-
6); 7.39 (2H, d, J = 5.8 Hz, 2x HβPy); 5.81 (1H, d, J = 5.4 Hz, H-1’); 5.70 (1H, d, J = 8.2 Hz, H-
5); 5.35 (2H, m, H-9 and H-10 oleic acid); 4.72 (1H, dd, J = 6.2 and 7.2 Hz, H-2’); 4.35 (1H, 
m, H-3’); 3.93 (5H, overlapped signals, H-5’a and H-5’b, H-4’, CH2Py), 2.36 (2H, dd, J = 7.4 
and 7.0 Hz, 2x H-2 oleic acid); 2.02 (4H, m, 2x H-8 and 2x H-11 oleic acid); 1.60 (2H, m, H-3 
oleic acid), 1.29 (20H, overlapped signals oleic acid); 0.90 (12H, overlapped signals, CH3 
oleic acid and SiC(CH3)3), 0.07 (6H, s, Si(CH3)2). 
13C-NMR (CD3OD, 50 MHz): δ 174.7 (C=O oleyl), 171.8 (C=O amide); 165.8 (C-4); 152.2 (C-
2); 150.2 (CαPy); 146.8 (CγPy); 143.2 (C-6); 130.9 (CβPy); 126.2 (C-9 and C-10 oleic acid); 
103.2 (C-5); 89.9 (C-1’); 80.6 (C-4’); 79.4 (C-2’); 63.2 (C-5’); 55.7 (C-3’); 42.8 (CH2Py); 34.7, 
34.6, 33.0, 30.8, 30.6, 30.4, 30.3, 30.2, 30.1, 28.1, 26.7, 26.0, 25.7, 23.7, 19.2 (aliphatic 
carbons of oleic acid); 26.5 (SiC(CH3)3); 18.0 (SiC(CH3)3); 14.5 (-CH3 oleic acid); -5.2 and -
5.3 (Si(CH3)2). 
ESI-MS (positive ions): for C40H64N4O7Si, calculated 741.0443; found m/z: 741.19 [M+H
+
]; 
763.17 [M+Na
+
]; 768.02 [M+K
+
]. 
 
Synthesis of compound 19. 
Nucleolipid 18 (56 mg, 0.076 mmol), dissolved in 1 mL of anhydrous THF, was treated 
with 50 µL of Et3N∙3xHF (0.30 mmol). The solution was stirred at room temperature for 3 
h, then the solvent was removed under reduced pressure and the crude was purified on a 
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silica gel column, eluted with AcOEt/CH3OH (95:5, v/v). The desired product 19 was 
obtained in 86% isolated yield (41 mg, 0.065 mmol). 
1H-NMR (CDCl3, 200 MHz): δ 8.55 (2H, d, J = 4.4 Hz, 2x HαPy); 7.68 (1H, d, J = 8.0 Hz, H-6); 
7.29 (2H, d, J = 6.2 Hz, 2x HβPy); 5.71 (1H, d, J = 7.8 Hz, H-5); 5.45-5.24 (5H, overlapped 
signals, H-1’, CH2Py, H-9 and H-10 oleic acid); 4.75 (1H, bs, H-2’); 4.23 (1H, bs, H-3’); 3.64 
(3H, bs, H-5’a and H-5’b, H-4’); 2.34 (2H, t, J = 7.4 and 7.4 Hz, CH2C=O); 1.99-1.27 (26H, 
overlapped signals oleic acid); 0.89 (3H, m, CH3 oleic acid). 
13C-NMR (CDCl3, 50 MHz): δ 173.4 (C=O oleyl), 170.3 (C=O amide); 163.1 (C-4); 150.3 (C-
2); 149.7 (CαPy); 144.0 (CγPy); 143.3 (C-6); 130.1 (CβPy); 129.6 (C-9 and C-10 oleic acid); 
103.2 (C-5); 93.5 (C-1’); 79.5 (C-4’); 78.6 (C-2’); 60.2 (C-5’); 54.9 (C-3’); 42.8 (CH2Py); 33.8, 
31.9, 29.7, 29.3, 29.1, 27.2, 24.6, 22.7 (aliphatic carbons of oleic acid); 14.1 (-CH3 oleic 
acid). 
ESI-MS (positive ions): for C34H50N4O7, calculated 626.3679; found m/z: 627.38 [M+H
+
]. 
 
Synthesis of compound 20. 
19 (17 mg, 0.027 mmol), dissolved in 0.7 mL of anhydrous DCM, was reacted with DMAP 
(2.0 mg, 0.013), BnO(CH2CH2O)6CH2COOH (15 mg, 0.035 mmol) and DCC (8.0 mg, 0.040 
mmol). The solution was stirred at room temperature for 2 h, then the solvent was 
removed under reduced pressure and the crude was purified on a silica gel column, 
eluted with n-hexane/acetone (2:3, v/v). The desired product 20 was obtained in 70% 
isolated yield (20 mg, 0.019 mmol). 
1H-NMR (CDCl3, 500 MHz): δ 8.65 (2H, bs, 2x HαPy); 7.37-7.25 (7H, overlapped signals, 
aromatic proton of Bn, H-6, 2x HβPy); 5.75 (1H, d, J = 8.0 Hz, H-5); 5.30-5.27 (5H, 
overlapped signals, H-1’, CH2Py, H-9 and H-10 oleic acid); 4.76 (1H, bs, H-2’); 4.55 (2H, s, 
CH2Bn); 4.39 (1H, bs, H-3’); 4.18-4.30 (5H, bs, H-5’a and H-5’b, H-4’, CH2C=O); 3.77-3.63 
(24H, OCH2CH2O); 2.33 (2H, dd, J = 8.0 and 7.0 Hz, CH2C=O); 1.93-1.08 (26H, overlapped 
signals oleic acid); 0.87 (3H, dd, J = 6.0 and 7.0 Hz, CH3 oleic acid). 
13C-NMR (CDCl3, 125 MHz): δ 173.2, 172.3 and 169.6 (C=O ester, C=O amide), 162.5 (C-4); 
156.7 (CαPy); 150.0 (C-2); 142.8 (CγPy); 138.1 (quaternary carbon of Bn); 128.3, 127.6, 
127.5 (CβPy, C-9 and C-10 oleic acid); 103.2 (C-5); 93.3 (C-1’); 80.9 (C-4’); 79.6 (C-2’); 73.1 
(CH2Bn); 70.4, 70.3 (OCH2CH2O); 69.3 (CH2C=O); 61.9 (C-5’); 54.7 (C-3’); 49.0 (CH2Py); 33.8, 
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29.6, 29.3, 29.2, 29.1, 29.0, 25.5, 24.8, 24.5, 22.6 (aliphatic carbons of oleic acid); 14.0 (-
CH3 oleic acid). 
ESI-MS (positive ions): for C55H82N4O15, calculated 1039.2574; found m/z: 1041.27 [M+H
+
]; 
1063.20 [M+Na
+
]; 1079.24 [M+K
+
]. 
 
Synthesis of compound 21. 
Nucleolipid 20 (18 mg, 0.017 mmol), dissolved in 0.4 mL of anhydrous DCM, was treated 
with [RuCl4(DMSO)2]
-
Na
+
 (7.0 mg, 0.017 mmol) and the resulting solution was taken under 
stirring at 40 °C for 2 h. TLC monitoring on alumina showed in 4 h the total disappearance 
of the starting material; the reaction mixture was therefore taken to dryness, giving the 
desired product 21 in quantitative yields, obtained in a pure form, not requiring further 
purification (23 mg, 0.017 mmol). 
1H NMR (CDCl3, 500 MHz): significant signals at δ 7.55-7.30 (protons of Bn and H-6); 4.96-
3.86 (very broad signals: protons of ribose, H-5 and polyether); 2.7-0.9 (overlapped 
signals, protons of oleic acid); -1.98 (protons of Py); -9.59 (2x CH3 DMSO). 
13C NMR (CDCl3, 125 MHz): significant signals at δ 128.2, 127.9, 127.4 (carbons of Bn, C-9 
and C-10 oleic acid); 49.3 (CH2Py); 33.9, 31.3, 29.1, 28.8, 25.0, 24.7, 22.1 (aliphatic 
carbons of oleic acid); 13.5 (-CH3 oleic acid). 
ESI-MS (negative ions): for C57H88N4O16RuS, calculated -1360.2728; found m/z: -1284.37 
[M
-
-DMSO]; -1359.89 [M
-
]. 
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Chapter 4. 
 
Design and Synthesis of a Novel Cationic 
Aminoacylnucleolipid as a Model Compound for Highly 
Functionalized Nucleolipids 
 
 
1. Catanionic vesicles: structure, properties and applications  
 
Catanionic amphiphiles are generally bicatenar systems that result from mixing 
oppositely charged surfactants in water (Figure 1). [1] 
 
 
Figure 1. A bicatenary catanionic amphiphile. 
 
When discussing the preparation methods of catanionic amphiphiles, it is 
necessary to distinguish between catanionic mixtures and catanionic surfactants (pure ion 
pairs). [2] In the latter category, the inorganic counterions associated with the 
amphiphiles are eliminated, whereas in catanionic mixtures, counterions remain in 
solution. For use in vectorization, the presence of residual salts is to be avoided, as some 
salts may be toxic. 
Catanionic surfactants can spontaneously form vesicles in water. [3,4] However, it 
should be noted that the catanionic surfactants usually precipitate when the two 
oppositely charged amphiphiles are mixed in equimolar quantities. [3] In fact, the 
electrostatic interaction between charges leads to a shrinking of the polar head and 
therefore a decrease in the hydrophilicity of the system. The weakened solvation sphere 
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makes more difficult the solubilization. Thus catanionic vesicles are generally formed with 
an excess of either positive or negative charge. In 1997, Menger and coworkers [5] 
proposed the first example of a water-soluble catanionic surfactant based on a glycosidic 
amphiphile (Figure 2). 
 
 
Figure 2. Structure of the first sugar-derived catanionic surfactant described in the literature. 
 
If not for sporadic examples, catanionic vesicles have not been explored in 
vectorization. [4] A new concept has been developed that involves the direct association 
of a potentially ionizable drug with a surfactant that gives rise to a catanionic active 
entity. [6,7] Catanionic vesicles, such as membranes, creating a compartmentalization 
that allows the trapping of molecules or macromolecules, are therefore used as 
nanoreactors or as agents of transport and release ("delivery vehicles") of drugs, DNA and 
receptors in various biomedical non-invasive experiments. As multicharged systems, the 
strong electrostatic interactions that are established between the cell membrane and the 
outer surface of the vesicle can induce fusion processes, creating an efficient transport 
system. [1] One of the great benefits that makes catanionic vesicles ideal candidates for 
drug delivery is that, unlike liposomes, the preparation of which requires the use of an 
organic solvent and specific preliminary manipulations, catanionic vesicles are 
spontaneously formed in water, thus avoiding the use of organic solvents or other, 
potentially toxic, products. As reported by M. Blanzat, I. Rico-Lattes and coworkers, only 
one study, carried out in their laboratories, is undergoing industrial development. This 
research involves the cutaneous delivery of an anti-inflammatory drug by direct 
association with a sugar-derived amphiphile forming a catanionic surfactant (Figure 3). 
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Figure 3. Structure of a catanionic surfactant from the association of an anti-inflammatory drug and a sugar-
derived surfactant. 
 
The catanionic assembly, which spontaneously forms vesicles, ensures an 
increased anti-inflammatory activity of the active principle together with a controlled and 
prolonged release through the skin. It also protects the drug from harmful irradiation 
effects. [8,9] In consideration of the intrinsic anionic nature of the Ru(III) complexes we 
have studied as potential anticancer agents (here described in Chapter 3), it has been 
considered the possibility to use these systems in mixture with cationic nucleolipids, so to 
obtain peculiar catanionic vesicles, for an optimized cell delivery and prolonged in vivo 
half-life. In this frame, the design and synthesis of a novel model cationic nucleolipid has 
therefore been undertaken and is here described. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                Chapter 4 
100 
 
2. Cationic nucleolipids: design of a novel cationic 
aminoacylnucleolipid 
 
Nucleolipid-based liposomes may typically be exploited as drug-carriers, being 
able to transport both hydrophilic compounds, encapsulated in the aqueous 
compartment, and lipophilic species, inserted within the lipid layers. Liposomes are 
generally able to incorporate drugs in high concentration, protecting them against 
extracellular enzymatic degradation and allowing efficient delivery within cells by 
endocytosis. 
A recent work by Yang et al. [10] showed very interesting examples of cationic 
nucleolipids obtained from uridine linking one arginine residue at the 5’ position and two 
fatty acid chains at the 2’ and 3’ OH attached through carbamate linkages, chemically 
stable but easily degradable in vivo (Figure 4). 
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Figure 4. Cationic nucleolipids synthesized by Yang et al. [10] 
 
These derivatives, exhibiting poor cytotoxicity, were able to self-aggregate into 
stable liposomes and thus efficiently vehiculate siRNA in vitroErrore. Il segnalibro non è 
definito..  
Inspired by these systems, we reasoned that a synthetic platform for a more 
general and versatile design allowing a large variety of diverse cationic nucleolipids would 
be desirable. Therefore we searched for structural modifications of the original 
nucleoside backbone allowing a higher degree of functionalization than it is generally 
allowed starting from a natural ribo- or deoxyribonucleoside. More specifically, our idea 
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was to select as the starting material a nucleoside equipped with at least three easily 
differentiable functional groups, so to attach at each of them – using very simple, efficient 
and selective procedures and by inserting chemical bonds of different lability in 
physiological conditions - a different residue, endowed with a specific property. 
Considering that the nucleobases have to be kept unchanged, since in principle it is 
desirable to maintain unaltered their recognition abilities, all the required modifications 
must be introduced at the level of the sugar moiety. An ideal starting scaffold - satisfying 
these requirements - is the modified nucleoside 3-amino-3-deoxy-1-β-D-
xylofuranosyluracil, easily obtained in 6 steps and 50% overall yields starting from uridine 
following the protocol previously described in Chapter 3, that we have exploited in 
parallel also for the synthesis of a novel nucleolipid-Ru(III) complex. In three, 
straightforward steps, this amino-nucleoside can be easily transformed into the derivative 
5-O-tert-butyldimethylsilyl-3-amino-3-deoxy-2-oleyl-1-β-D-xylofuranosyluracil, the 
synthesis of which has been previously described in Chapter 3. 
 
NH
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OH
HO
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O  
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Figure 5.   a. 3-amino-3-deoxy-1-β-D-xylofuranosyluracil;      
 b. 5-O-TBDMS-3-amino-3-deoxy-2-oleyl-1-β-D-xylofuranosyluracil. 
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In order to obtain a suitable model compound for a novel class of cationic 
nucleolipids, we have here exploited this nucleoside analog to build aminoacylnucleolipid 
5, decorated with the following groups:  
 
I. a hydrophilic, polyether chain attached at the 5’ position; 
II. a lipophilic fatty acid chain at the 2’ position, ensuring the desired 
amphiphilicity to the final compound – and intrinsically the ability to 
generate large aggregates in aqueous conditions; 
III. a proline residue at the 3’ position, ionized in physiological conditions and 
therefore conferring the desired positive charge. 
 
The synthesized molecule 5 is reported in Figure 6. Compared with the previously 
described cationic nucleolipids reported by Yang et al. and depicted in Figure 4, this 
design offers in principle one additional functional group for diversification. In the here 
synthesized compound, this diversification site was exploited to insert a hydrophilic, 
polyether chain, so to obtain an amphiphile with a better balanced 
lipophilicity/hydrophilicity ratio in its backbone, and expectedly endowed with better 
nanostructuring performances in aqueous media with respect with known literature 
examples. 
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Figure 6. Cationic aminoacylnucleolipid 5. 
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3. Synthesis of cationic aminoacylnucleolipid 
 
The synthetic scheme adopted for the synthesis of aminoacylnucleolipid 5 is based 
on the use, as the starting material, of the nucleoside 5’-O-TBDMS-3’-amino-3’-deoxy-2’-
oleyl-1-β-D-xylofuranosyluracil, obtained following the procedures described in Chapter 
3.  
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Scheme 1. a.  Boc-Pro, DCC, DMAP, DCM, 12 h, r.t.;  b. Et3N∙3HF, THF, 12 h, r.t.;  c. BnO(CH2CH2O)6CH2COOH, 
DCC, DMAP, DCM, 2 h, r.t.;  d. TFA, 10% TIS, DCM, 1 h, r.t.; e. NH4
+
Cl
-
/H2O, lyophilizations. 
 
As shown in Scheme 1, the first step involves the condensation of a residue of N-
Boc Proline with the amino group at the 3’ position of nucleoside 1, realized by classical 
DCC activation, giving aminoacylnucleolipid 2. The desired amide was then deprotected at 
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the 5’ position by treatment with Et3N∙3HF in THF to give nucleoside 3 in almost 
quantitative yields. At this stage a hydrophilic residue of BnO(CH2CH2O)6CH2COOH was 
attached at the 5’ position through an ester linkage, thus obtaining nucleoside 4. The final 
step requires a simple manipulation by a mild acidic treatment (10% TFA in DCM) 
ensuring the clean Boc removal, accomplished in almost quantitative yield to give 
aminonucleolipid 5 as a trifluoroacetate salt. To obtain the aminoacylnucleolipid in a 
better biocompatible form we have then replaced the trifluoroacetate counterion with a 
chloride anion: this was realized by treatment of 5 with an equimolar amount of NH4
+
Cl
-
 
and subsequent repeated lyophilizations from water. The absence of CF3COO
-
 was 
confirmed by 
13
C-NMR analysis, which in concentrated samples after extremely long 
acquisition times (>24 h) did not show the diagnostic signals of the carbons of 
trifluoroacetate, even in traces.  
Detailed studies on the biocompatibility and ability to generate stable self-
aggregates in aqueous solution are currently in progress in collaboration with specialized 
laboratories. 
Moreover, the aminoacylnucleolipid 5 will be studied in formulation with anionic 
derivatives. Particularly, our current interests are focused on the investigation of 
catanionic vesicles formed by amphiphilic nucleolipids Ru(III) complexes (anionic 
derivatives) described in Chapter 3, in mixture with the here described cationic 
nucleolipid 5 with the final aim to generate more stable formulations for the ruthenium-
containing nucleolipids for in vivo experiments. 
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4. Conclusions 
 
A novel cationic aminoacylnucleolipid is here described. This prolyl-nucleolipid 
based on Uridine was obtained by exploiting a straightforward, high yielding and versatile 
synthetic protocol, starting from the easily accessible 5’-O-TBDMS-3’-amino-3’-deoxy-2’-
oleyl-1-β-D-xylofuranosyluracil key intermediate. Target nucleoside 5 has been designed 
as a model compound, synthesized as the first member of a more general class of highly 
functionalized nucleolipids carrying positive charges, in principle allowing a large variety 
of different, related analogs with a high degree of molecular diversity. 
Studies on a detailed physico-chemical characterization of this nucleolipid are 
currently in progress in the laboratories of proff. Luigi Paduano and Gerardino D’Errico of 
the Dept. of Chemistry “Paolo Corradini” of “Federico II” University of Naples, carried out 
by using a combined approach, including DLS, surface tension and conductibility 
measurements in aqueous solution. Moreover, tests on the cytotoxicity activity on 
various human cells lines and bacteria are also underway in collaboration with specialized 
laboratories (more in detail: with the research group of prof. Alfredo Colonna, of the 
Dept. of Pharmacology of “Federico II” University of Naples, as far as the general 
cytotoxicity analyses and the biocompatibility studies are concerned, and with Dr. Monica 
Benincasa of the Dept. of Life Sciences of University of Trieste, as far as the antimicrobial 
and antifungal tests are concerned).  
Successively, the ability of the here synthesized cationic nucleolipid 5 to generate 
catanionic vesicles when mixed in formulation with the ruthenium(III)-containing 
nucleolipids, showed in Chapter 3, will be investigated in detail with the final goal to 
increase the biostability and also enhance the bioactivity of the Ru(III) complexes.  
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5. Experimental section 
 
General Methods. 
All the reagents were of the highest commercially available quality and were used as 
received. TLC analyses were carried out on silica gel plates from Merck (60, F254). 
Reaction products on TLC plates were visualized by UV light and then by treatment with a 
10 % Ce(SO4)2/H2SO4 aq. solution. For column chromatography, silica gel from Merck 
(Kieselgel 40, 0.063-0.200 mm) was used. NMR spectra were recorded on Varian XR 200 
and Varian Inova 500 spectrometers, as specified. All the chemical shifts are expressed in 
ppm with respect to the residual solvent signal. Peak assignments have been carried out 
on the basis of standard 
1
H-
1
H COSY and HSQC experiments. The following abbreviations 
were used to explain the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; m = 
multiplet; b = broad; dd = double doublet. For the ESI MS analyses, a Waters Micromass 
ZQ instrument – equipped with an Electrospray source. 
 
Synthesis of compound 2. 
Nucleolipid 1 (28 mg, 0.045 mmol), dissolved in anhydrous CH2Cl2 (0.50 mL), was reacted 
with DMAP (3.0 mg, 0.025 mmol), Boc-Proline (13 mg, 0.060 mmol) and DCC (14 mg, 
0.068 mmol). The resulting solution was stirred at room temperature for 12 h, then the 
solvent was removed under reduced pressure and the crude was purified on a silica gel 
column, eluted with n-hexane/AcOEt (7:3, v/v). The desired product 2 was obtained in 
98% isolated yield (36 mg, 0.044 mmol). 
2: oil, Rf = 0.5 [n-hexane/AcOEt (1:1, v/v)]. 
1
H NMR (DMSO-d6, 500 MHz): δ 11.41 (1H, bs, NH-3); 7.96 (1H, d, J = 7.0 Hz, NH-3’); 7.75 
(1H, m, H-6); 5.83 (1H, d, J = 6.0 Hz, H-1’); 5.74 (1H, bs, H-5); 5.56 (1H, d, J = 8.0 Hz, Hα 
Proline); 5.31 (2H, m, H-9 and H-10 oleic acid); 5.24 (1H, bs, H-2’); 4.62 (1H, m, H-3’); 4.27 
(1H, bs, H-4’); 3.70 (2H, m, H-5’a and H-5’b); 3.30 (2H, overlapped signals, 2x Hβ Proline); 
2.27 (2H, bs, CH2C=O oleic acid); 1.97 (4H, d, J = 6.0 Hz, 2x H-8 and 2x H-11 oleic acid); 
1.76 (2H, m, Hγ Proline); 1.48 – 1.24 (33H, overlapped signals, aliphatic protons of oleic 
acid, Boc and 2x Hδ Proline); 0.85 (12H, overlapped signals, CH3 oleic acid and SiC(CH3)3), 
0.07 and 0.05 (6H, s’s, Si(CH3)2). 
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13
C NMR (DMSO-d6, 125 MHz): δ 172.3 (C=O), 162.9 (C-4); 156.5 (C=O Proline); 153.1 
(C=O Boc); 150.4 (C-2); 140.6 (C-6); 129.5 (C-9 and C-10 oleic acid); 102.1 (C-5); 85.8 (C-
1’); 78.6 (C-2’ and C-4’); 77.3 (Cα Proline); 62.3 (C-5’); 60.0 (C-3’), 53.1 (Cδ Proline); 47.5 (Cγ 
Proline); 33.3 (Cβ Proline); 31.2, 29.1, 28.8, 28.6, 28.2, 28.0, 26.6, 25.3, 24.4, 24.2, 22.1 
(aliphatic carbons of oleic acid and Boc -C(CH3)3); 25.8 (SiC(CH3)3); 17.8 (SiC(CH3)3); 14.0 (-
CH3 oleic acid); -5.5 (Si(CH3)2). 
ESI-MS (positive ions): for C43H74N4O9Si, calcd. 818.5225; found m/z: 820.41 [M+H
+
]; 
842.13 [M+Na
+
]; 858.25 [M+K
+
]. 
 
Synthesis of compound 3. 
Nucleolipid 2 (60 mg, 0.073 mmol), dissolved in anhydrous THF (1.0 mL), was treated with 
Et3N⋅3HF (35 μL, 0.22 mmol). The solution was stirred at room temperature for 12 h, then 
the solvent was removed under reduced pressure and the crude was purified on a silica 
gel column, eluted with n-hexane/AcOEt (1:4, v/v). The desired product 3 was obtained in 
93% isolated yield (48 mg, 0.068 mmol). 
3: oil, Rf= 0.2 [n-hexane/AcOEt (3:7, v/v)]. 
1
H NMR (DMSO-d6, 500 MHz): δ 11.34 (1H, bs, NH-3); 8.06 (1H, bs, NH-3’); 7.99 (1H, d, J = 
8.0 Hz, H-6); 5.89 (1H, bs, H-1’); 5.73 (1H, d, J = 7.5 Hz, H-5); 5.56 (1H, d, J = 8.0 Hz, Hα 
Proline); 5.32 (3H, m, H-2’, H-9 and H-10 oleic acid); 5.17 (1H, m, OH-5’); 4.74 (1H, m, H-
3’); 4.24 (1H, bs, H-4’); 3.57 (2H, m, H-5’a and H-5’b); 3.29 (2H, overlapped signals, 2x Hβ 
Proline); 2.27 (2H, bs, CH2C=O oleic acid); 1.97 (4H, d, J = 5.5 Hz, 2x H-8 and 2x H-11 oleic 
acid); 1.73 (2H, m, Hγ Proline); 1.52 – 1.24 (33H, overlapped signals, aliphatic protons of 
oleic acid, Boc and 2x Hδ Proline); 0.85 (3H, t, J = 6.5 and 7.0 Hz, CH3 oleic acid). 
13
C NMR (DMSO-d6, 125 MHz): δ 172.7 (C=O); 163.1 (C-4); 156.8 (C=O Proline); 153.4 
(C=O Boc); 150.6 (C-2); 140.9 (C-6); 129.8 (C-9 and C-10 oleic acid); 102.4 (C-5); 85.2 (C-
1’); 78.9 (C-4’); 78.5 (C-2’); 77.2 (Cα Proline); 60.5 (C-5’); 60.0 (C-3’); 52.9 (Cδ Proline); 47.7 
(Cγ Proline); 33.5 (Cβ Proline); 31.5, 29.2, 29.0, 28.9, 28.7, 28.6, 28.4, 28.2, 26.8, 25.5, 
24.6, 24.4, 22.3 (aliphatic carbons of oleic acid and Boc -C(CH3)3); 14.2 (-CH3 oleic acid).  
ESI-MS (positive ions): for C37H60N4O9, calcd. 704.4360; found m/z: 705.98 [M+H
+
]; 728.03 
[M+Na
+
]; 743.97 [M+K
+
]. 
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Synthesis of compound 4. 
Nucleolipid 3 (45 mg, 0.064 mmol), dissolved in anhydrous CH2Cl2 (1.0 mL), was treated 
with DMAP (4.0 mg, 0.032 mmol), BnOCH2CH2(OCH2CH2)5OCH2COOH (36 mg, 0.083 
mmol) and DCC (20 mg, 0.096 mmol), added in the order. The solution was stirred at 
room temperature for 2 h, then the solvent was removed under reduced pressure and 
the crude was purified on a silica gel column, eluted with n-hexane/acetone (1:1, v/v). 
The desired product 4 was obtained in 84% isolated yield (60 mg, 0.054 mmol). 
4: oil, Rf = 0.4 [n-hexane/acetone (1:1, v/v)]. 
1
H NMR (DMSO-d6, 500 MHz): δ 11.40 (1H, bs, NH-3); 8.23 (1H, bs, NH-3’); 7.70 (1H, d, J = 
7.5 Hz, H-6); 7.34 – 7.27 (5H, m, aromatic protons of Bn); 5.87 (1H, d, J = 5.5, H-1’); 5.78 
(1H, bs, H-5); 5.32 (3H, d, J = 8.0 Hz, Hα Proline, H-9 and H-10 oleic acid); 5.42 (1H, dd, J = 
6.5 and 6.0 Hz, H-2’); 5.33 (2H, m, CH2Bn); 4.70 (1H, m, H-3’); 4.48 (3H, bs, H-4’ and 
CH2C=O); 4.10 (2H, m, H-5’a and H-5’b); 3.50 (24H, overlapped signals, -OCH2CH2O-); 3.30 
(2H, overlapped signals, 2x Hβ Proline); 2.27 (2H, m, CH2C=O oleic acid); 1.97 (4H, d, J = 5.5 
Hz, 2x H-8 and 2x H-11 oleic acid); 1.72 (2H, m, Hγ Proline); 1.52 – 1.00 (33H, overlapped 
signals, aliphatic CH2 protons of oleic acid, Boc and 2x Hδ Proline); 0.85 (3H, t, J = 6.5 and 
7.0 Hz, CH3 oleic acid). 
13
C NMR (CD3OD, 50 MHz): δ 172.1 and 170.7 (2x C=O), 166.1 (C-4); 156.8 (C=O Proline); 
152.7 (C=O Boc); 146.6 (C-2); 140.2 (C-6); 139.8 (quaternary carbon of Bn group); 131.4, 
131.3, 129.9, 129.4, 129.2 (C-9 and C-10 oleic acid and aromatic CH carbons of Bn); 103.9 
(C-5); 82.5 (C-1’); 81.8 (C-4’), 79.0 (C-2’); 74.6 (OCH2C=O); 72.4 (Cα Proline); 72.0, 71.6, 
71.1 (overlapped signals, OCH2CH2O); 69.8 (-OCH2Bn); 63.8 (C-5’); 63.2 (C-3’), 56.3 (Cδ 
Proline); 33.5 (Cβ Proline); 31.5, 29.2, 29.0, 28.9, 28.7, 28.6, 28.4, 28.2, 26.8, 25.5, 24.2 
(aliphatic CH2 carbons of oleic acid and Boc-C(CH3)3); 15.0 (-CH3 oleic acid). Cγ Proline is 
buried under the solvent signal. 
ESI-MS (positive ions): for C58H92N4O17, calcd. 1116.6457; found m/z: 1118.88 [M+H
+
]; 
1140.66 [M+Na
+
]; 1156.65 [M+K
+
]. 
 
Synthesis of compound 5. 
Nucleolipid 4 (54 mg, 0.048 mmol), dissolved in anhydrous DCM (0.85 mL), was reacted 
with TFA (0.15 mL). The reaction was stirred at room temperature for 1 h, then the 
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solvent was removed under reduced pressure and the crude was coevaporated with 2-
propanol (1.0 mL for 3 times). The desired final compound was thus obtained in almost 
quantitative yields in the form of trifluoroacetate salt (55 mg, 0.048 mmol).  
Successive treatment with one equivalent (2.6 mg, 0.048 mmol) of ammonium chloride, 
followed by repeated lyophilizations from water, gave target compound 5 in the form of 
chloride salt. 
5: white powder, Rf = 0.2 [n-hexane/acetone (1:4, v/v)]. 
1
H NMR (DMSO-d6, 500 MHz): δ 11.40 (1H, bs, NH-3); 8.81 (1H, d, J = 8.0 Hz, NH-3’); 7.70 
(1H, d, J = 8.0 Hz, H-6); 7.34 – 7.26 (5H, complex signals, aromatic protons of Bn); 5.89 
(1H, d, J = 6.0, H-1’); 5.78 (1H, d, J = 7.5 Hz, H-5); 5.30 (3H, m, H-2’, H-9 and H-10 oleic 
acid); 4.72 (1H, m, H-3’); 4.84 (3H, bs, H-4’ and OCH2C=O); 4.15 (3H, overlapped signals, 
Hα proline, H-5’a and H-5’b); 3.51 (24H, overlapped signals, OCH2CH2O); 3.34 (2H, m, 
CH2C=O oleic acid); 2.30 (2H, m, 2 x Hβ proline); 1.96 (4H, m, 2x H-8 and 2x H-11 oleic 
acid); 1.50 (2H, overlapped signals, Hγ proline and CH2CH2C=O); 1.26 – 1.00 (24H, 
overlapped signals, aliphatic CH2 protons of oleic acid and 2x Hδ proline); 0.83 (3H, m, CH3 
oleic acid). 
13
C NMR (CD3OD, 50 MHz): δ 172.5 and 170.5 (2x C=O); 166.2 (C-4); 160.3 (C=O Proline); 
152.6 (C-2); 144.3 (C-6); 139.9 (quaternary carbon of Bn); 131.4 131.3, 130.0, 129.5, 129.3 
(C-9 and C-10 oleic acid and aromatic CH carbons of Bn); 104.1 (C-5); 91.2 (C-1’); 80.3 (C-
4’); 78.0 (C-2’); 74.5 (Cα Proline); 72.2, 71.7, 70.9 (-OCH2CH2O-); 69.8 (-OCH2Bn); 69.5 
(OCH2CO); 64.3 (C-3’); 61.7 (C-5’), 56.8 (Cδ Proline); 48.0 (Cγ Proline); 35.2 (Cβ Proline); 
33.5, 32.3, 31.3, 31.1, 30.8, 28.6, 27.5, 27.2, 27.0, 26.5, 26.2, 25.5, 24.2 (aliphatic CH2 
carbons of oleic acid); 15.0 (-CH3 oleic acid). 
ESI-MS (positive ions): for C53H84N4O15, calcd. 1016.5933; found m/z: 1018.57 [M+H
+
]; 
1040.56 [M+Na
+
]; 1056.44 [M+K
+
]. 
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Chapter 5. 
 
Design, Synthesis and Characterization of Novel 
Guanosine-based Amphiphiles 
 
 
1. Introduction: Guanosine and G-assembly 
 
Guanosine is a special nucleoside: it can expand the Watson-Crick interactions 
capability having a higher number of acceptor/donor H-bonding sites. In particular, 
guanine moieties may give rise to the Hoogsteen interactions involving positions 6 and 7 
as acceptors (A), and 1 and 2 as donors (D) (Figure 1).  
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Figure 1. Hoogsteen’s interaction sites of Guanosine. 
 
Guanosine can self-assemble in various supramolecular architectures. The most 
relevant is the G-quartet, a cyclic planar array of four guanosines, each of which gives and 
receives two hydrogen bonds. These aggregates are stabilized by the coordination of a 
metal ion (generally, sodium or potassium) with the carbonyl group in position 6 (Figure 
2). At high concentrations, the G-quartet can form G-quadruplex structures by overlaying 
several plans of G-quartets in a cylindrical or helical symmetry (Figure 3). [1]   
                                                                                                                             
 
 
In the absence of cations guanosine
form another supramolecular architecture: the G
sheet-like bidimensional assemblies involving 
position 3 (Figure 4). [2,3]
 
Figure 2. G-quartet arrangement. 
Figure 3. G-quadruplex formation. 
 
s, when derivatized with 
-ribbon. The G-ribbon
another donor site on the nucleobase: the 
 
Figure 4. G-ribbon structure. 
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lipophilic groups, can 
s are organized in 
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In Figure 5 some examples of lipophilic guanosines described in the literature are 
reported. These molecules are able to self-organize in G-quartet or G-ribbon-based 
architectures in relation to the presence or absence of metal cations. Milestones in this 
research field are the works of G. P. Spada [1b,3-5], J. T. Davis [1,6-8] and K. Araki [9-11], 
who have studied several compounds obtained from guanosine by inserting various 
lipophilic chains on the ribose moiety. 
NH
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NH2N
O
OO
O
NH
N
N
O
NH2N
O
OO
OSi
O
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N
O
NH2N
O
O
O
O
O  
Figure 5. Examples of lipophilic guanosine derivatives reported in the literature [1b]. 
 
It is to be mentioned that all the synthetic schemes so far proposed for their 
preparation are not general in their scope, not allowing an easy access to highly 
functionalized derivatives; particularly it is not possible to obtain compounds carrying a 
large diversity of functionalizations on the sugar motif. 
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2. Design of a library of amphiphilic guanosine derivatives 
 
This part of my research has been focused on the design, synthesis and 
characterization of a mini-library of amphiphilic, sugar-modified guanosine derivatives.  
If several amphiphilic nucleolipids based on adenosine, cytosine, uridine or 
thymidine are described in the literature, 
very few examples are known concerning 
guanosine [12-16] and almost completely 
unexplored are the potential applications 
of guanosine-based amphiphiles in 
biomedical applications and/or as self-
assembling materials. Still, guanosine-
based amphiphiles in principle are extremely intriguing compounds, filling the gap 
between the hydrophilic guanosine or guanosine phosphate derivatives and related G-
quadruplex systems, on one side, and the known lipophilic guanosine analogs, on the 
other. In this scenario, it was urgent to preliminary provide a general synthetic scheme 
allowing for a high diversification of the ribose functionalizations in the guanosine 
backbone. 
A variety of synthetic strategies have been proposed to prepare nucleolipids. In 
most cases, the design is based on the chemical modification of the sugar functions, thus 
minimally perturbing the nucleobase moieties, and keeping unaltered their critical 
recognition sites. Ester functions are typically considered as ideal chemical connections 
for nucleosidic ribose derivatizations, offering several advantages: these linkages can be 
obtained through straightforward and high yielding condensations, not requiring prior 
modifications of the nucleoside moieties, and, remarkably, are rapidly cleaved by cell 
esterases, liberating the “free” nucleosides within the cells once the transport function 
through lipid bilayers is achieved. [17] 
The general design here presented for the preparation of amphiphilic guanosine-
derivatives is based on the insertion of a saturated fatty acid residue – i.e., myristic acid – 
as the lipophilic chain. In the synthesized compounds, here named G1-G8 (Figure 6), this 
group was attached at the ribose secondary hydroxyls, to give bi-tailed compounds G1-
G5, or at the 5’-OH end, to give mono-tailed derivative G7. [18] Higher molecular diversity 
NH
N
N
O
NH2N
O
OO
O
O
R2
O
R1
R3
R3= Polar Group
 
- Polyethers
- Aminoacids
- Charged groups
- Carbohydrates
R1, R2= lipophilic groups: fatty acids
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was introduced at the level of the hydrophilic groups, chosen among polyethers 
(introduced in G1, G6, G7 and G8), charged functional groups (in G3), or natural α-
aminoacids (in G2 and G4) and carbohydrates (in G5). Aiming at a simple, versatile and 
finely tunable synthetic scheme, the library of sugar-modified amphiphilic analogs was 
prepared starting from a unique key intermediate (3, Figure 6), exhaustively protected on 
the nucleobase, [19] and exhibiting three ribosidic OH groups available for condensations 
with various appendages. 
In the series G1-G5, following the Grinstaff and Berthélémy’s approach, [12] the 
ribose secondary OH functions have been exploited to insert fatty acid residues, while the 
5’-OH is derivatized with different hydrophilic groups, introduced to balance the 
hydrophobic contribution of the lipid chains. G7 was designed as the G1 analog having 
the same lipophilic and hydrophilic tails but with inverted ratio, while G6 is decorated 
uniquely with polyether groups. Finally, the G8 derivative was designed as a G7 analog; it 
was obtained by insertion - in position 5’ - of 5-doxyl-stearic acid, bearing the stable doxyl 
spin label group, for applications in studies of interactions with cell membranes, 
monitored by ESR experiments. 
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Figure 6. Library of the here studied compounds G1-G8. [18] 
 
 
In this manner, the series of compounds G1, G7, G6 was generated, with 
respectively 2, 1 or 0 myristic acid tails, and in turn 1, 2 or 3 triethylene glycol groups. 
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3. Synthesis of compounds G1-G8 
 
The synthetic access to the target sugar-modified guanosine analogs was thus 
realized starting from compound 3, obtained in three straightforward steps from 
guanosine (Scheme 1). [18] The Boc group, though seldom used for nucleobase 
protection in nucleoside chemistry, [20] was here selected to protect the guanine moiety 
in consideration of the easy installation procedure, its lipophilic character, facilitating 
guanosine manipulations in organic solvents, and, above all, the convenient removal 
conditions. As a matter of fact, Boc deprotection can be achieved by mild acidic 
treatments (dilute TFA solutions in anhydrous organic solvents), fully compatible with the 
ester linkages, and eventually originates only volatile side products, thus not requiring 
column chromatography to give the pure, deprotected compounds. In order to obtain 3, 
guanosine was first regioselectively protected [21] by treatment with acetic anhydride in 
CH3CN and TEA; tri-O-acetylated derivative 1 was then reacted with an excess of di-tert-
butyl dicarbonate (Boc2O) in CH3CN in the presence of TEA and DMAP, giving fully 
protected nucleoside 2. Interestingly, this compound, obtained in acceptable yields (57%) 
compared to previously reported procedures, [20] showed a tert-butyl group linked to the 
O-6 position. This, in analogy with a previous report on guanine protection, [19] may be 
ascribed to spontaneous loss of CO2, promoted by DMAP, from the original N-1 Boc 
carbamate, undergoing an internal transposition to the O
6
-tert-butyl ether (Scheme 1). 
Differently from the above cited case, we could not isolate the tris-Boc protected 
intermediate and only compound 2 was recovered after column chromatography. This 
derivative was then exhaustively deacetylated by treatment with methanolic ammonia, 
giving target compound 3, obtained in 56% overall yields for three steps.  
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Scheme 1. I) Synthesis of intermediate 3. Reaction conditions: a) Boc2O, TEA, DMAP, CH3CN, r.t., 72 h, 57%; 
b) NH3, CH3OH, 12 h, r.t., quant. II) Rationalization of the formation of the O
6
-tert-butyl derivative. 
 
The synthesis of compounds G1-G5 was accomplished in two simple manipulations 
starting from derivative 6, in turn obtained in three steps from key intermediate 3 
(Scheme 2). Reaction of 3 with TBDPSCl and imidazole in DMF provided 5’-protected 
nucleoside 4, which was then condensed with myristic acid in the presence of DCC, 
cleanly giving 2’,3’-di-O-myristoyl derivative 5. TBDPS group removal was achieved by 
treatment of 5 with the complex Et3N∙3HF in THF, leading to target compound 6 in 70% 
overall yield from 3. G1 was then obtained in almost quantitative yields in two steps, 
involving first the coupling of 5’-OH deprotected nucleoside 6 with 
monomethoxy(triethylene glycol) acetic acid, prepared as described in Chapter 2, [17] 
using DCC as the condensing agent, followed by an acidic treatment with 10% TFA in 
CH2Cl2 for 2 h at r.t., to achieve full nucleobase deprotection. 
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Scheme 2. Synthesis of G1-G4. Reaction conditions: a) TBDPSCl, imidazole, DMF, r.t., 2 h, 92%; b) 
CH3(CH2)12COOH, DCC, DMAP, 12 h, r.t., 95%; c) Et3N∙3HF, THF, 48 h, r.t., 80%; d) coupling with: for 7a 
CH3O(CH2CH2O)3CH2COOH; for 7b Fmoc-Glu(OtBu)OH; for 7d Fmoc-Ser(OTrt)OH in CH2Cl2, DCC, 1.5 h, r.t.; 
for 7c SO3 x Et3N, DMF, 45 min, r.t., 70%; e) i. Only for 7b and 7d: Fmoc removal with 10% piperidine in 
DMF, 20-40 min, r.t., ii. 10% TFA in CH2Cl2, 2 h, r.t., quant. 
 
Hybrid nucleosides G2 and G4 were obtained using a similar procedure, based on the 
coupling of derivative 6 with commercially available Fmoc-protected α-amino acids - 
respectively, Fmoc-Glu(OtBu)-OH and Fmoc-Ser(OTrt)-OH -, also in these cases mediated 
by DCC activation. The choice of Fmoc in lieu of Boc-protection could allow, in principle, 
the possibility of further derivatization of the final compounds, as, for instance, peptide 
elongation or attachment of special reported groups. For both compounds, Fmoc 
removal, cleanly achieved by reaction with 10% piperidine in DMF, was followed by 
treatment with 10% TFA in CH2Cl2 for 2 h at r.t., ensuring an effective one-pot 
deprotection of the guanine and of the side-chains of glutamic acid and serine residues, 
respectively masked as tert-butyl ester and trityl ether. 
Compound G3 was prepared reacting 6 with the commercially available complex 
SO3∙Et3N in DMF, followed by final TFA deprotection, carried out as above described, thus 
leading to the desired 5’-O-sulfate derivative in 70% yields for the two steps. 
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Preparation of glyco-nucleolipid hybrid G5 – incorporating a disaccharide residue, 
here chosen to confer a higher hydrophilic character to the final derivative compared to 
the series G1-G4 - required prior synthetic elaboration of the disaccharide building block. 
To this purpose, α,α’-D-trehalose was selected on the basis of its favourable properties: it 
is an easily available, symmetrical, non-reducing disaccharide, not undergoing 
mutarotation. The latter issue is of the utmost relevance from a synthetic point of view, 
considering that the overall strategy to obtain the here described guanosine-containing 
nucleolipids is based on a final acidic treatment. The succinic group was here chosen as 
the linker providing the covalent attachment of the trehalose residue to the 5’-OH end of 
the guanosine scaffold. This was introduced on one primary hydroxyl of the disaccharide, 
previously subjected to the following derivatizations, depicted in Scheme 3: i) mono-
silylation of the starting disaccharide, carried out with TBDPSCl and imidazole in DMF at  
0 °C, giving 8 in 86 % yield; ii) exhaustive Boc protection of the remaining seven hydroxyls, 
by treatment with Boc2O in CH3CN, in the presence of TEA and DMAP, leading to 9 in 58 % 
yield; iii) removal of the tert-butyldiphenylsilyl protecting group by reaction with Et3N∙3HF 
in THF, providing 10 with 80 % yield; iv) reaction with succinic anhydride and cat. DMAP in 
THF, allowing the target succinylated trehalose derivative 11 in 78 % yield. This building 
block was finally used for the DCC-promoted coupling with nucleoside 6, yielding target 
12 in 86 % yield. As in the case of G1-G4, target compound G5 was then obtained upon 
TFA treatment of 12, quantitatively allowing in a single step the complete sugar and 
nucleobase deprotection. 
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Scheme 3. Synthesis of G5. Reaction conditions: a) TBDPSCl, imidazole, DMF, 50 min, 0 °C, 86%; b) Boc2O, 
TEA, DMAP, CH3CN, 48 h, r.t., 58%; c) Et3N x 3HF, THF, 72 h, r.t., 80%; d) succinic anhydride, DMAP, THF, 24 
h, 78%; e) coupling with 6, DCC, CH2Cl2, 3 h, r.t., 86%; f) 10% TFA in CH2Cl2, 3 h, r.t., quant. 
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Derivative G6 was obtained in two steps starting from 3, involving first exhaustive 
derivatization with monomethoxy(triethylene glycol) acetic acid, [17] in the presence of 
DCC, followed by TFA treatment of 13 for the nucleobase Boc removal, as depicted in 
Scheme 4. 
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Scheme 4. Synthesis of G6. Reaction conditions: a) CH3O(CH2CH2O)3CH2COOH, DCC, DMAP, CH2Cl2, 48 h, r.t., 
42%; b) 10% TFA in CH2Cl2, 3 h, r.t., quant. 
Finally, derivative G7 was prepared from nucleoside 4, upon esterification of both 
secondary hydroxyls with monomethoxy(triethylene glycol) acetic acid, [17] leading to 
compound 14 which was successively desilylated, coupled with myristic acid at the 5’-OH 
group and successively deprotected on the guanine moiety (Scheme 5). 
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Scheme 5. Synthesis of G7. Reaction conditions: a) CH3O(CH2CH2)3CH2COOH, DCC, DMAP, CH2Cl2 1 h, r.t., 
80%; b) Et3N∙3HF, THF, 18 h, r.t., 56%; c) CH3(CH2)12COOH, DCC, DMAP, CH2Cl2, 2 h, r.t., quant.; d) TFA 10% 
in CH2Cl2, 2.5 h, r.t., quant. 
Guanosine derivative G8, bearing a spin label group on the lipophilic residue in 
position 5’, was obtained starting from intermediate 15. This was coupled with 5-doxyl-
stearic acid to give intermediate 17, that was then deprotected on the nucleobase as 
previously described (Scheme 6). 
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Scheme 6. Synthesis of G8. Reaction conditions: a) 5-Doxyl-stearic acid, DCC, DMAP, CH2Cl2, 3 h, r.t., quant.; 
b) 10% TFA in CH2Cl2, quant. 
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All the intermediate products here synthesized were purified by silica gel column 
chromatography and then fully characterized by 
1
H and 
13
C-NMR spectroscopy, as well as 
by ESI mass spectrometry. Final compounds G1-G8, obtained from the corresponding 
nucleobase-protected precursors by a simple treatment with 10% TFA in CH2Cl2 followed 
by repeated coevaporations from isopropanol till complete disappearance of excess TFA, 
were identified on the basis of their NMR and ESI-MS spectra. 
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4. Characterization of G1-G7 
 
4.1 Study of the gelling abilities 
 
Preliminary structural investigations have been attempted on G1-G7 by means of 
NMR spectroscopy. [18] In all cases, NMR analysis showed for all the here prepared 
nucleosides dissolved in CDCl3 dramatically broadened and very badly resolved signals in 
the 
1
H and 
13
C NMR spectra. In addition, a typical concentration-dependent response was 
obtained, which precluded the possibility to gain useful structural information. With time, 
the signals broadening was more and more marked, particularly in the imino protons 
region of 
1
H NMR spectra, suggesting the presence of growing superstructures subjected 
to dynamic equilibria. Upon changing the solvent from CDCl3 to the less structuring 
CD3OD and/or varying the temperature in the range 288-328 °K, only minor benefits - in 
terms of resolution and line sharpness - could be observed. These results suggested for 
these compounds a strong tendency to form highly aggregated systems.  
As a first step to determine the properties of the newly synthesized amphiphilic 
derivatives, we have then investigated their solubility and gelling abilities, and the related 
data are summarized in Table 1.  
Strong tendency to aggregation – attributable to the well-known ability of 
guanine-based systems to realize a tight network of intermolecular hydrogen bonds - has 
been confirmed for all the synthesized samples, and their capacity as organogelators 
evaluated by the inversion method. [22] In all cases, analysis of these systems at 
concentrations lower than 20 mM did not indicate any tendency to form stable gels, and 
higher concentrations were therefore tested. 
G1 and G2 – examined in the range 3-7 % w/w (corresponding to ca. 25-70 mM) 
gave stable gels in polar solvents, as methanol, ethanol and CH3CN (pictures of the gels 
obtained from G1 and G2 are shown in Figure 2). In comparable concentration conditions 
(5% w/w), lipophilic guanosine derivatives based on 2’,3’-O-isopropylidenguanosine, 
carrying different n-alkylsilyl ethers at the 5’-position, synthesized by Araki and 
coworkers, [9] were found to gelate from n-decane, cyclohexane and n-hexane. Thus the 
here presented molecules offer new examples of low molecular weight organogelators, 
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which may profitably complement both the known lipophilic guanosines, and the 
hydrophilic, naturally occurring guanosine mono- and polyphosphates, covering a 
completely different polarity range of solvents, intermediate between highly apolar 
solvents and water. Analyzing the obtained results from a qualitative point of view, 
comparison of the systems G1-G7-G6 indicates that two long aliphatic chains are essential 
for gelation; on the other hand, the presence of charged (as in G3) or markedly 
hydrophilic groups (as in G5) seems to negatively affect the formation of stable gels. G4 is 
apparently a unique case, being essentially insoluble in all the most commonly used 
organic solvents, with the only exception of DMSO. 
 
Table 1. Solubility properties of derivatives G1-G7 in selected solvents 
Solvent 
G1 
26 mM 
 
G1 
57 mM 
 
G2 
57 mM 
 
G2 
67 mM 
 
G3 
57mM 
G5 
57 mM 
G6 
57 mM 
G7 
57 mM 
CH3OH G
[a]
 
3% 
G 
6% 
S G
[a]
 
7% 
S S S S 
Ethanol S S G
[a]
 
6% 
S S I S S 
CH3CN S G S S I I S I 
n-hexane S S P P P S P S 
Acetone S S S S P S S S 
Cyclohexane P P P P P S P P 
CHCl3 S S S S P S S S 
THF S S S S P P S S 
Dioxane S S S S P S S S 
H2O P P P P P P P P 
Propanol S S S S P P S S 
iso-propanol S S S S P P S S 
CH2Cl2 S S S S P S S S 
AcOEt S S S S P S S P 
[a] rapid gelification was achieved leaving the compound at +4 °C.; G = gel; S = homogeneous solution; I = 
insoluble. 
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Figure 7. a) Gel of G1 6 wt% in CH3CN; b) Gel of G2 6 wt% in EtOH. 
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4.2 CD studies 
 
In order to get useful information on the conformational behaviour in organic 
solvents of the synthesized amphiphilic compounds, CD spectra were registered in the 
non structuring solvent CHCl3. [18] For G4, only soluble in DMSO and therefore not 
directly comparable with the other systems under investigation, CD data were not 
acquired. 
To preliminarily assess the ability of the here investigated systems to form G-
tetrads, qualitative potassium picrate tests were carried out, following the procedure 
described for lipophilic guanosine derivatives. [23] In all cases, these colorimetric tests 
confirmed for the here investigated compounds, dissolved in CHCl3, the ability to extract 
K
+
 ions from aqueous solutions containing the yellow salt potassium picrate (Pic
-
K
+
), and 
transfer them in the organic phase. The yellow colour of the organic phases after this 
treatment was therefore indicative of G-tetrads formation by the guanosine derivatives: 
these attract from aqueous solutions K
+
 ions, in turn transporting with them, to ensure 
electroneutrality, also picrate anions, otherwise highly insoluble in organic solvents. As 
reported in Figure 8, in sample 1 there is a control aqueous solution of Pic
-
K
+
 - markedly 
coloured in yellow - in contact with CHCl3. In sample 2 there is a chloroform solution of a 
guanosine derivative (G1) which is left in contact with the aqueous Pic
-
K
+
 solution: here 
the transfer of the yellow colour from the aqueous to the chloroform phase is observed 
as a consequence of the transfer of Pic
-
K
+
. This qualitative test - indicative of G-tetrads 
formation by the guanosine derivatives – was positive for all the compounds here 
investigated, in the series G1 – G7. 
 
Figure 8. Test of potassium picrate on guanosine derivative G1 here synthesized, showing its capability to 
extract potassium ions from the aqueous solution and transfer them into the CHCl3 solution. 
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Then, compounds G1-G3 and G5-G7 were analyzed by CD spectroscopy in dilute 
CHCl3 solutions, before and after the addition of potassium picrate. 2’,3’,5’-tri-O-
acetylguanosine was also studied in parallel as a reference compound, having sugar 
modifications conferring high solubility in CHCl3, but no relevant contribution to the self-
assembling capability of the nucleoside; it can be therefore assumed – at least on a first 
basis - that its overall structuring process is only guided by the guanosine moiety and not 
influenced by the sugar decorations. This nucleoside, found to be positive to the 
potassium picrate test, showed a CD spectrum having a single negative band at 259 nm, 
very close to the maximum exhibited in the absorbance spectrum, registered in the same 
solvent (262 nm). This correspondence between the CD and UV spectra (see Figures 9 and 
10) would point to a random distribution of the G-tetrads generated by this nucleoside in 
solution, not producing ordered three-dimensional structures, with characteristic 
orientations of the chiral centres. 
 
  
Figure 9. CD spectra of 2’,3’,5’-tri-O-acetyl guanosine 
(2.7 mM solution in CHCl3). Green curve: 2’,3’,5’-tri-O-
acetyl guanosine before treatment with potassium 
picrate; blue curve: 2’,3’,5’-tri-O-acetyl guanosine 
after treatment with potassium picrate. Negative 
band at λ = 262 nm. 
Figure 10. UV spectrum of 2’,3’,5’-tri-O-acetyl 
guanosine (0.12 mM solution in CHCl3). Maximum 
absorption at λ = 259 nm. 
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Of the investigated amphiphilic derivatives, only G3 and G5 showed CD spectra 
reflecting – apart from the sign – the UV-vis ones, in analogy with 2’,3’,5’-tri-O-
acetylguanosine (see Figures 11 and 12).  
 
  
Figure 11. CD spectra of compound G3 (2.7 mM 
solution in CHCl3). Green curve: G3 solution before 
treatment with potassium picrate; blue curve: G3 
solution after treatment with potassium picrate. 
Figure 12. CD spectra of compound G5 (2.7 mM 
solution in CHCl3). Green curve: G5 solution 
before treatment with potassium picrate; blue 
curve: G5 solution after treatment with 
potassium picrate. Negative bands at λ = 265, 
289 nm. 
 
On the contrary, G1, G2, G6 and G7 – all having UV-vis profiles very similar to the 
reference compound (data not shown) - exhibited distinctive CD spectra with two intense 
bands of opposite sign, diagnostic of regular G-tetrads stacking organized in well defined 
octameric complexes, with C4 or D4 symmetry (Figures 13-16). Following the 
rationalization introduced by A. Randazzo and G. P. Spada, [24] the position of the 
opposite sign bands in the CD spectra of guanosine-based systems can provide 
information on the G-tetrads stacking not only in G-rich oligonucleotides –  i.e. in systems 
where the stacked guanines within each strand are covalently linked by the sugar-
phosphate oligonucleotide backbone – but also in non-covalently linked guanosine 
monomers. So the presence of a negative band centered at ca. 240 nm and a positive 
band at 260 nm is diagnostic of G-tetrads organized in homopolar stacking (also referred 
to as “H-to-T”, with H and T representing the “head” and the “tail” surfaces of a G-tetrad, 
[25] respectively, here facing each other). A blue-shift of 20-30 nm of both bands is 
diagnostic of heteropolar, “H-to-H” or “T-to-T”, stackings.   
Inspection of the spectra allows us to conclude that G6 exhibits homopolar G-
tetrad stacking, while G1, G2 and G7 tend to generate octamers containing only “H-to-H” 
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or “T-to-T” G-tetrads stacking. Interestingly,  G1,  G6 and  G7 showed spectra diagnostic 
of structuring of the G-tetrads even before addition of K
+
 cations. Since their G-tetrad-
forming ability has been previously proved by positive potassium picrate tests, these 
results can be explained only assuming that these systems display an extraordinary 
avidity for K
+
, which could be extracted from the traces present in solvents, glassware, 
etc. and thus incorporated into stable complexes even before direct contact with 
potassium solutions. To confirm this hypothesis, the guanosine analogs  G1, G6  and  G7, 
after the potassium picrate addition, were treated with an excess of the cryptand 
4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane, sequestering K
+
 ions, and 
analyzed at CD, showing only residual CD signals. 
 
  
Figure 13. CD spectra of compound G1 at 2.7 mM 
CHCl3; green curve, before addition of potassium 
picrate, λmax = 256, 283 nm; blue curve, after 
addition of potassium picrate, λmax = 262, 285 nm. 
Figure 14. CD spectra of compound G2 at 2.7 mM 
CHCl3; green curve, before addition of potassium 
picrate; blue curve, after addition of potassium 
picrate, λmax = 257, 293 nm 
 
 
 
 
Figure 15. CD spectra of compound G6 at 2.7 mM 
CHCl3; green curve, before addition of potassium 
picrate; blue curve, after addition of potassium 
picrate; λmax = 249, 265 nm. 
Figure 16. CD spectra of compound G7 at 2.7 mM 
CHCl3; green curve, before addition of potassium 
picrate; blue curve, after addition of potassium 
picrate; λmax = 264, 295 nm. 
 
CD melting experiments were carried out on G1, G2, G6 and G7 to get information on 
the thermal stability of the stacked G-tetrad systems. For all these compounds, under the 
studied conditions, a significant, non-linear decrease of the CD signal intensity on 
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increasing the temperature was observed, even if not in the form of well defined S-
shaped curves, referring to a single transition with a clearly identified melting 
temperature. This would be expected in the case of a single, columnar G-quadruplex 
structure, involving all the G-tetrads stacked in a high hierarchical order. In all cases, 
curves ascribable to the superimposition of multiple transitions were registered, 
indicating the coexistence in solution of non homogeneous dissociating systems, probably 
containing a variable number of stacked G-tetrads, however essentially stable at room 
temperature (Figures 17 and 18). 
  
Figure 17. CD-monitored melting denaturation curves of compound G1 (on the left, λ= 285 nm) and G2 (on 
the right, λ= 293 nm), scan rate = 0.5 °C/min; temperature range: 10 – 60 °C. 
  
Figure 18. CD-monitored melting denaturation curves of compound G6 (on the left, λ= 265 nm) and G7 (on 
the right, λ= 295 nm), scan rate = 0.5 °C/min; temperature range: 10 – 60 °C 
 
Taken together, these results show that in guanosine-based self-assembly of 
compounds G1-G3 and G5-G7 in CHCl3, a non-negligible role is played by the sugar 
functionalization. When the ribose decorations are not able to elicit intermolecular 
interactions, as is the case of 2’,3’,5’-tri-O-acetylguanosine, no specific three-dimensional 
structuring is observed. For G1, G2, G6 and G7 CD spectra showed the presence of regular 
G-tetrads stacking. However, CD-monitored thermal denaturation curves do not support 
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the existence of single, well defined G-quadruplex complexes. Interestingly, of these four 
nucleosides, only G6 - exclusively carrying polyether chains on the ribose moiety - is able 
to give homopolar stacking. On the contrary, the asymmetrically substituted guanosine 
derivatives, carrying both lipophilic and hydrophilic groups, tend to form heteropolar G-
tetrads stacking. This different behaviour can be explained in terms of relevant 
contributions to the overall self-assembly given by alkyl and polyether chains, which, 
contributing to self-assembly in solution, may favour a peculiar three-dimensional 
arrangement of the stacked G-tetrads. Following this interpretation, G3 and G5 do not 
show a regular G-tetrads stacking in CHCl3 solution, probably because of steric hindrance 
of the substituents, in G5, and presence of net negative charges, in G3, which prevent the 
formation of ordered aggregates. 
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4.3 Ionophoric activity 
 
The group of J. T. Davis has recently demonstrated that potassium promoted self-
assembly of lipophilic guanosine derivatives may contribute to stabilize ion channels 
active in phospholipid membranes. [6-8] 
In consideration of the amphiphilic backbone of the here synthesized derivatives, 
we therefore investigated the ionophoric activity of compounds G1-G7 using HPTS 
experiments, standard base-pulse assays which directly report H
+
/OH
-
 transport and 
indirectly cation/anion transport. These studies were carried out in collaboration with the 
research group of prof. Paolo Tecilla (Department of Chemical Sciences, University of 
Trieste). [18] 
For these experiments, liposomes (100 nm diameter) containing the pH-sensitive 
dye HPTS (8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt) were prepared in a pH 
7.0 HEPES buffer containing 100 mM NaCl (or MCl and NaX in the experiments for cation 
and anion selectivity, respectively) and, once the ionophore was added, the external pH 
was suddenly brought to 7.6 by addition of NaOH (or MOH in experiments for cation 
selectivity) and the fluorescence emission of the dye recorded. The emission maximum 
for HPTS is about 510 nm in both the acidic and conjugate base forms. However, the 
excitation wavelength of the acidic form (403 nm) is significantly different from that of 
the conjugate base form (460 nm) so that the acid/base ratio is directly reflected in the 
emission intensity modulation produced by alternating excitation at the two wavelengths. 
[24] In essence, the modulated emission signal, obtained cycling the excitation 
wavelength and recording the emission at 510 nm, reports the effective pH within the 
liposome. The increase of HPTS fluorescence emission indicates basification of the 
liposome inner water pools which may be correlated to the H
+
/OH
-
 transport and to the 
associated cation/anion symport or antiport. [26] The results obtained with compounds 
G1-G7 are reported in Figure 19. Amphotericin B (AmB), a naturally occurring ionophore, 
was a positive control in these experiments. 
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Figure 19. Normalized fluorescence change in HPTS emission (FI, λex 403 and 460 nm, λem 510 nm) as a 
function of time after addition of the base (50 µL of 0.5 M NaOH) to 95:5 EYPC/EYPG LUVs (100 nm 
diameter) loaded with HPTS (0.1 mM HPTS, 0.17 mM total lipid concentration, 25 mM HEPES, 100 mM NaCl, 
pH 7.0, total volume 3 mL, 25 °C), in the presence of 2% G1-G7 derivatives and Amphotericin B (AmB, 1%). 
The concentration of the ionophores is given in percent with respect to the total concentration of lipids. 
The control trace has been recorded in the absence of ionophore. EYPC = egg yolk phosphatidylcholine; 
EYPG egg yolk phosphatidylglycerol. 
 
Amphiphilic guanosine derivatives G1-G4 are mostly inactive, while an increasing 
ability to discharge the pH gradient is observed with compounds G7, G6 and G5. The most 
active derivative is G5 followed by G6, both characterized by a large hydrophilic portion, 
the disaccharide residue in G5 and three monomethoxy(triethylene glycol) chains in G6. 
The relationship activity/hydrophilicty is further confirmed by the trend observed with 
G1, G6 and G7 which differ for the number of monomethoxy(triethylene glycol) residues: 
on increasing the number of polar chains the activity increases. A similar behaviour was 
previously observed in somehow structurally related CyPLOS derivatives studied in my 
research group. [27] Also in that case the activity was strongly dependent on the number 
of polar ethylene glycol chains appended to a rigid macrocyclic scaffold and the activity 
was ascribed to a destabilization of the phospholipid bilayer caused by the insertion of 
the polar chains. The ionophoric activity of compounds G1-G7 is not influenced by the 
presence of K
+
 ion. Experiments performed in the conditions of Figure 19 but using KCl 
instead of NaCl and KOH instead of NaOH, and therefore in the presence of a high 
concentration of potassium ion as the only externally added cation, show kinetic profiles 
for the pH discharge which are practically superimposable to those obtained in the 
presence of Na
+
 ion (Figure 20).  
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Figure 20. Ionophoric activity of G1-G7 in the presence of Na
+
 and K
+
. Comparison between the activity of 
compounds G1-G7 (2%) measured in buffer containing Na
+
 (red curve) or K
+
 (green curve). The experimental 
conditions are the same ones reported in Figure 19. 
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This suggests that in the phospholipid membranes the potassium ion is not able to 
promote the assembly of the guanosine derivatives as, on the contrary, is observed in 
more concentrated chloroform solutions. The low tendency of simple guanosine 
derivatives to form G-quartets in phospholipid membranes was not really unexpected and 
parallels the findings reported by the group of J. T. Davis. Stable G-quartets were indeed 
reported only in systems in which the guanosine moieties are covalently linked to a 
proper scaffold [6] or inserted in derivatives in which self-assembly is mainly driven by the 
formation of hydrogen bonds between bis-urea [7] or bis-carbamate subunits.
 
[8] 
Apparently the sole interaction between potassium ion and guanosine is not strong 
enough to promote the self-assembling process in membranes, possibly due to the 
localization of the guanosine moieties close to the surface of the bilayer where water may 
compete efficiently with the formation of the G-tetrads.  
In order to better characterize the ionophoric activity of the amphiphilic guanosine 
derivatives we investigated the influence on the transport process of the nature of the 
cation or anion present in solution in the case of G5, which is the most active derivative. 
The HPTS assay, here used, may indeed give indirect information on the cation and/or 
anion selectivity of the transport process. The transmembrane discharge of the externally 
built on pH gradient, which is signalled by HPTS fluorescence emission increase, may 
derive by H
+
 efflux from the liposome inner water pool or by OH
-
 influx from the bulk 
water to the inner water pool of the liposome. In any case, this ion traffic has to be 
counterbalanced and this occurs through four overall processes: H
+
/Na
+
 antiport, OH
–
/Cl
–
 
antiport, H
+
/Cl
–
 symport and Na
+
/OH
–
 symport. Therefore, from the comparison of kinetic 
experiments performed in the presence of different cations and anions it is possible to 
gain indirect evidence on their effect on the transport process. The results obtained for 
the cation and anion selectivity experiments using as representative examples the group I 
alkali metals and the halogen anions are reported in Figure 21a and 21b, respectively. 
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Figure 21. a) Cation selectivities for ionophore G5 (3 % concentration), using the HPTS assay (100 mM 
MCl, pH 7.0, base pulse by addition of 50 µL of 0.5 M MOH; b) anion selectivities for ionophore G5 (2 % 
concentration), using the HPTS assay (100 mM NaX, pH 7.0, base pulse by addition of 50 µL of 0.5 M 
NaOH). The kinetics are corrected for the spontaneous permeation of the different anions. 
 
 
Inspection of Figure 21 shows that the rate of transport little depends on the 
cation present while it is strongly influenced by the anions and increases on going from 
fluoride to iodine, following the lyotropic sequence. This suggests that the transport 
process is governed by the translocation of the anion and in particular limited by its 
dehydration cost. 
Taken together, the obtained results indicate that the amphiphilic guanosines G1-
G7 partition in the membrane probably positioning the guanine moiety and the sugar ring 
close to the surface of the liposome and the appended chains dipped in the membrane. 
When the ribose decorations have a balanced amphiphilic character, as in the case of G5 
and G6, they destabilize the membrane thus allowing the transit of small ions in a non 
selective process mainly governed by the dehydration cost of the anions. The ionophore 
acts in a monomeric form even in the presence of potassium ion which, under the studied 
conditions, is apparently unable to promote the aggregation of the guanosine derivatives. 
The ionophore is too short to span the membrane and the ionophoric activity is probably 
related to the formation of a disordered zone in the membrane characterized by a higher 
permeability. Ions are therefore able to cross this disordered zone in a process which is 
intrinsically little selective and strongly correlated to the lipophilicity of the anions. 
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4.4 In vitro screening of their antiproliferative activity 
 
Antiviral [28] and anti-cancer [29] activity has been discovered in several G-rich 
oligonucleotides, and associated to the peculiar ability of these molecules to self-
assemble in G-quartet-based superstructures, in vivo recognized by specific proteins. On 
the other hand, biological activities are searched in modified nucleosides since almost 
half a century, and, currently, large biomedical interest is also associated to 
nanoaggregated systems. [30] Since novel guanosine derivatives G1-G7 seem to combine 
both the ability to form G-tetrads and to generate large nanoaggregates, in vitro 
experiments have been carried out on a panel of cancer and non-cancer cell lines in order 
to investigate their bioactivity in a preliminary screening.  
To this aim, cell lines were treated for 48 h with G1-G7 at various concentrations 
in a growth inhibition assay and the cytotoxicity was determined in terms of IC50 (Table 2). 
[18] 
The antiproliferative activity of these novel molecules was investigated in 
collaboration with the research group of Dr. Carlo Irace (Department of Experimental 
Pharmacology, Naples). 
The results showed for G1-G5 a moderate to weak selective cytotoxicity against 
both human MCF-7 breast adenocarcinoma and WiDr epithelial colorectal 
adenocarcinoma cells. In particular, G3 and G5 proved to be the most active compounds, 
exhibiting a significant antiproliferative profile against MCF-7 cells, with IC50 values of 22 
and 17 µM, respectively. IC50 values within the micromolar range are generally consistent 
with the ability to interfere with cell viability and/or proliferation. Interestingly, in 
contrast to several anti-proliferative drugs, these compounds did not show in vitro 
unspecific cytotoxicity toward tumor and non-tumor cell lines. This might suggest 
potential specific interactions with the biological targets. Detailed structure-activity 
relationship studies will be carried out in the frame of an extensive investigation aimed at 
the development of nucleolipids with selective antineoplastic activity.
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Table 2.  Cytotoxicity profile of compounds G1-G6 against cancer and non-cancer cell lines, IC50 (µM) 
[a]
. 
Cell line 
[b]
 G1 G2 G3 G4 G5 G6 G7 
HeLa 
WiDr 
MCF-7 
C6 
3T3-L1 
> 10
3
 
82 ± 6 
185 ± 12 
> 10
3 
> 10
3
 
198 ± 4 
90 ± 6 
96 ± 5 
245 ± 4 
> 10
3
 
445 ± 6 
135 ± 10 
22 ± 4  
616 ± 5 
750 ± 4 
130 ± 5 
130 ± 11 
46 ± 7 
152 ± 8 
> 10
3
 
436 ± 9 
136 ± 10 
17 ± 5  
302 ± 5 
> 10
3
 
> 10
3
 
> 10
3
 
> 10
3
 
880 ± 14 
> 10
3
 
> 10
3
 
1550 ± 15 
> 10
3
 
860 ± 18 
> 10
3
 
[a]  IC50 values are expressed as mean  ± SEM (n = 24) of three independent experiments. Bold values show 
IC50 < 100 µM.  [b] HeLa, human cervical cancer cells; MCF-7, human breast adenocarcinoma cells; WiDr, 
human epithelial colorectal adenocarcinoma cells; C6, rat glioma cells; 3T3-L1, murine embryonic 
fibroblasts (no cancer cells). 
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5. Conclusions 
 
In this study, a general and versatile synthetic strategy has been developed to 
obtain a library of amphiphilic, sugar-modified analogs of guanosine, generated by very 
simple and high yielding manipulations starting from a unique precursor, fully protected 
on the nucleobase. Large molecular diversity is ensured by insertion of different 
hydrophilic groups, as aminoacids, carbohydrates, oligoethers, and lipophilic residues, as 
fatty acid chains. In all cases, these appendages were attached to the ribose moiety 
through ester linkages, obtained under mild and very effective coupling conditions and, in 
principle, easily cleaved inside cells by esterases.  
Qualitative potassium picrate tests confirmed for all the synthesized compounds 
the ability to extract potassium ions from aq. solutions into CHCl3, and, thus, to form G-
tetrads. CD analysis on dilute CHCl3 solutions of these derivatives showed for G1, G2, G6 
and G7 CD spectra distinctive of different G-tetrad self-assemblies: for G6, the CD 
spectrum was diagnostic of homopolar stacking of the G-quartets, while for the other 
three compounds the CD bands supported for G-quartets heteropolar stacking. Two 
derivatives, G1 and G2, showed peculiar gelling abilities in polar solvents, as methanol, 
ethanol and acetonitrile, thus complementing lipophilic guanosine derivatives, known to 
form stable organogels in highly apolar solvents. When analyzed in their ion transport 
abilities, the activity was strongly correlated to the presence of a large hydrophilic portion 
in the molecule, with G5 shown to be the most active compound. An interesting 
antiproliferative activity was found for G3 and G5 when tested on MCF-7 cancer cells, 
with IC50 values in the 20 µM range, while no cytotoxicity emerged on normal, control 
cells. Taken together, these data show that guanosine-based amphiphiles display a variety 
of peculiar properties, largely and finely tunable as a function of the nature and number 
of the ribose substituents, which render this class of compounds of great interest for both 
their biological/biomedical potential and innovative applications related to the 
development of novel self-assembling materials. 
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6. Experimental section 
 
General Methods 
All the reagents were of the highest commercially available quality and were used 
as received. TLC analyses were carried out on silica gel plates from Merck (60, F254). 
Reaction products on TLC plates were visualized by UV light and then by treatment with a 
10 % Ce(SO4)2/H2SO4 aqueous solution. For column chromatography, silica gel from Merck 
(Kieselgel 40, 0.063-0.200 mm) was used. NMR spectra were recorded on Bruker WM-
400, Varian Gemini 200 and Varian Inova 500 spectrometers, as specified. All the chemical 
shifts are expressed in ppm with respect to the residual solvent signal. Peak assignments 
have been carried out on the basis of standard 
1
H-
1
H COSY and HSQC experiments. The 
following abbreviations were used to explain the multiplicities: s = singlet; d = doublet; t = 
triplet; q = quartet; m = multiplet; b = broad; dd = double doublet. For the ESI MS 
analyses, a Waters Micromass ZQ instrument – equipped with an Electrospray source – 
was used in the positive and/or negative mode. MALDI TOF mass spectrometric analyses 
were performed on a PerSeptive Biosystems Voyager-De Pro MALDI mass spectrometer in 
the Linear mode using 3,4-dihydroxybenzoic acid as the matrix. 
 
Synthesis of compound 2.  
Nucleoside 1 (986 mg, 2.41 mmol) was dissolved in anhydrous CH3CN (20 mL), then TEA 
(3.00 mL, 21.7 mmol), DMAP (147 mg, 1.20 mmol) and Boc2O (4.21 g, 19.3 mmol) were 
sequentially added. The mixture was stirred at room temperature for 72 h, then the 
solvent was removed under reduced pressure and the residue purified on a silica gel 
column (eluent: n-hexane/acetone 65:35, v/v). The desired product 2 was obtained in 
57% isolated yield (909 mg, 1.37 mmol). 
2: oil, Rf = 0.5 [acetone/n-hexane, 2:3 (v/v)].  
1
H NMR (CDCl3, 200 MHz): δ 8.09 [s, 1H, H-8]; 6.19 [d, J = 5.2 Hz, 1H, H-1’]; 5.79 [dd, J = 
5.4 and 4.4 Hz, 1H, H-2’]; 5.56 [dd, J = 4.4 and 4.8 Hz, 1H, H-3’]; 4.46 - 4.36 [overlapped 
signals, 3H, H-4’, H-5’a and H-5’b]; 2.13 [s, 6H, 2x CH3CO]; 2.06 [s, 3H, CH3CO]; 1.71 [s, 9H, 
C(CH3)3]; 1.41 [s, 18H, 2x OCOC(CH3)3].  
13
C NMR (CDCl3, 50 MHz): δ 170.2, 169.4 and 169.0 [3x CH3CO]; 161.1 [C-6]; 151.9 and 
151.4 [C-2, C-4]; 150.6 [2x OCOC(CH3)3]; 140.3 [C-8]; 121.4 [C-5]; 86.2 [C-1’]; 84.3 
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[OC(CH3)3]; 82.9 [C-4’]; 80.3 [2x OCOC(CH3)3]; 73.4 [C-2’]; 70.7 [C-3’]; 63.2 [C-5’]; 28.3 
[C(CH3)3]; 27.8 [2x OCOC(CH3)3]; 20.7, 20.5 and 20.3 [3x CH3CO].  
ESI-MS (positive ions): calcd. for C30H43N5O12 = 665.2908; found m/z 666.1 [M + H
+
]; 688.1 
[M + Na
+
]; 704.1 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C30H43N5O12Na: 688.2806; found 
m/z 688.2819 (M+Na
+
). 
 
Synthesis of compound 3.  
Nucleoside 2 (909 mg, 1.37 mmol) was dissolved in CH3OH (8.0 mL) and 2.0 mL of a 29.1 
% NH4OH aq. solution were added. The solution was stirred at room temperature for 12 
h, then the solvent was removed at reduced pressure and the residue washed three times 
with CH2Cl2/H2O. The collected organic phases were dried over anhydrous Na2SO4. The 
desired product 3 was obtained in almost quantitative yields. 
3: oil, Rf = 0.3 [CHCl3/CH3OH, 95:5 (v/v)].  
1
H NMR (CDCl3, 200 MHz): δ 8.10 [s, 1H, H-8]; 5.87 [d, J = 6.0 Hz, 1H, H-1’]; 4.78 [dd, J = 
5.6 and 5.6 Hz, 1H, H-2’]; 4.41 [broad signal, 1H, H-3’]; 4.22 [broad signal, 1H, H-4’]; 3.77 
[m, 2H, H-5’a and H-5’b]; 1.66 [s, 9H, C(CH3)3]; 1.39 [s, 18H, 2x OCOC(CH3)3].  
13
C NMR (CDCl3, 50 MHz): δ 161.1 [C-6]; 151.1 [C-2]; 150.8 [C-4]; 150.6 [2x OCOC(CH3)3]; 
142.8 [C-8]; 121.8 [C-5]; 91.0 [C-1’]; 87.2 [C-4’]; 84.5 [C(CH3)3]; 83.5 [2x OCOC(CH3)3]; 74.3 
[C-2’]; 71.6 [C-3’]; 62.6 [C-5’]; 28.2 [C(CH3)3]; 27.8 [2x OCOC(CH3)3].  
ESI-MS (positive ions): calcd. for C24H37N5O9 = 539.2591; found m/z 561.76 [M+Na
+
], 
577.76 [M+K
+
]. HRMS (MALDI-TOF): calcd. for C24H37N5O9Na = 562.2489; found m/z 
562.2452 [M+Na
+
]. 
 
Synthesis of compound 4.  
Nucleoside 3 (400 mg, 0.742 mmol) was dissolved in anhydrous DMF (3.0 mL), then 
TBDPSCl (227 µL, 0.890 mmol) and imidazole (116 mg, 1.70 mmol) were added. The 
solution was stirred for 2 h and then taken to dryness under reduced pressure. The crude 
was washed three times with CH2Cl2/H2O, the collected organic phases were dried over 
anhydrous Na2SO4, concentrated under reduced pressure and purified on a silica gel 
column (eluent: n-hexane/AcOEt 55:45, v/v). The desired product 4 was obtained in 92% 
isolated yield (530 mg, 0.682 mmol). 
4: oil, Rf = 0.3 [AcOEt/n-hexane, 1:1 (v/v)].  
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1
H NMR (CDCl3, 500 MHz): δ 8.11 [s, 1H, H-8]; 7.59 – 7.31 [m, 10H, aromatic proton]; 5.93 
[d, J = 6.0 Hz, 1H, H-1’]; 4.56 [dd, J = 5.5 and 6.0 Hz, 1H, H-2’]; 4.46 [m, 1H, H-3’]; 4.36 [m, 
1H, H-4’]; 3.82 [m, 2H, H-5’a and H-5’b]; 1.71 [s, 9H, C(CH3)3]; 1.47 [s, 18H, 2x OCOC(CH3)3]; 
0.93 [s, 9H, SiC(CH3)3].  
13
C NMR (CDCl3, 100 MHz): δ 160.9 [C-6]; 150.7 [C-2, C-4]; 150.6 [2x OCOC(CH3)3]; 139.9 
[C-8]; 135.4, 132.4, 130.7, 129.8, 128.7, 127.7 [aromatic carbons]; 120.8 [C-5]; 90.6 [C-1’]; 
87.0 [C-4’]; 84.0 [C(CH3)3]; 83.4 [2x OCOC(CH3)3]; 72.1 [C-2’]; 68.0 [C-3’]; 63.9 [C-5’]; 28.2 
[C(CH3)3]; 27.8 [2x OCOC(CH3)3]; 26.6 [SiC(CH3)3]; 19.0 [SiC(CH3)3].  
ESI-MS (positive ions): calcd. for C40H55N5O9Si = 777.3769; found m/z: 778.04 [M + H
+
]; 
799.90 [M + Na
+
]; 815.87 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C40H55N5O9SiNa = 
800.3667; found m/z: 800.3691 [M + Na
+
]. 
 
Synthesis of compound 5.  
4 (467 mg, 0.600 mmol) was dissolved in anhydrous CH2Cl2 (5.0 mL), then myristic acid 
(411 mg, 1.80 mmol), DCC (372 mg, 1.80 mmol) and DMAP (109 mg, 0.900 mmol) were 
sequentially added. The solution was stirred for 12 h at room temperature, then the 
solvent was removed at reduced pressure and the residue purified on a silica gel column 
(eluent: n-hexane/AcOEt 4:1, v/v). The desired compound was obtained in 95% isolated 
yield (680 mg, 0.570 mmol). 
5: oil, Rf = 0.3 [AcOEt/n-hexane,1:4 (v/v)].  
1
H NMR (CDCl3, 500 MHz): δ 8.18 [s, 1H, H-8]; 7.70 - 7.36 [overlapped signals, 10H, 
aromatic protons]; 6.35 [d, J = 6.5 Hz, 1H, H-1’]; 5.72 - 5.67 [overlapped signals, 2H, H-2’ 
and H-3’]; 4.22 [broad signal, 1H, H-4’]; 3.91 [m, 2H, H-5’a and H-5’b]; 2.35 [dd, J = 8.0 and 
7.5 Hz, 2H, -CH2CO]; 2.24 [m, 2H, -CH2CO]; 1.72 [s, 9H, C(CH3)3]; 1.63 [m, 4H, -CH2CH2CO]; 
1.40 [s, 18H, 2x OCOC(CH3)3]; 1.30 - 1.24 [overlapped signals, 40H, -CH2]; 0.88 [overlapped 
triplets, J = 7.0 and 6.5 Hz, 6H, 2x CH3].  
13
C NMR (CDCl3, 100 MHz): relevant signals at δ 172.1, 171.4 [2x COOCH2-]; 150.6 [2x 
OCOC(CH3)3]; 142.0 [C-8]; 135.2, 132.1, 130.4, 129.0, 128.6, 127.4 [aromatic carbons]; 
90.3 [C-1’]; 88.2 [C-4’]; 85.9 [C(CH3)3]; 80.5 [2x OCOC(CH3)3]; 72.8 [C-2’]; 69.1 [C-3’]; 64.0 
[C-5’]; 34.2, 33.9 [2x CH2COO myristic acid]; 31.8, 29.9, 29.7, 29.6, 29.5, 29.2, 28.8, 28.0, 
27.5 [22x -CH2, C(CH3)3, 2x OCOC(CH3)3]; 26.5 [SiC(CH3)3]; 22.5 [CH3]; 19.0 [SiC(CH3)3].  
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ESI-MS (positive ions): calcd. for C68H107N5O11Si = 1197.7736; found m/z = 1198.6 [M + 
H
+
]; 1222.1 [M + Na
+
]. HRMS (MALDI-TOF): calcd. for C68H107N5O11SiNa = 1220.7634; 
found m/z: 1220.7700 [M + Na
+
]. 
 
Synthesis of compound 6.  
To a solution of 5 (673 mg, 0.561 mmol), dissolved in 3.0 mL of anhydrous THF, Et3N∙3HF 
(1.83 mL, 11.2 mmol) was added under stirring at room temperature. After 48 h, the 
mixture was dried under reduced pressure, redissolved in CH2Cl2, transferred into a 
separatory funnel and then washed three times with H2O/CH2Cl2. The collected organic 
phases were dried over anhydrous Na2SO4, concentrated under reduced pressure and 
purified on a silica gel column (eluent: n-hexane/AcOEt 7:3, v/v). The desired product 6 
was obtained in 80% isolated yield (432 mg, 0.450 mmol). 
6: oil, Rf = 0.7 [AcOEt/n-hexane, 3:7 (v/v)].  
1
H NMR (CDCl3, 500 MHz): δ 7.93 [s, 1H, H-8]; 5.99 [overlapped signals, 2H, H-1’ and H-2’]; 
5.65 [m, 1H, H-3’]; 4.29 [broad signal, 1H, H-4’]; 3.85 [m, 2H, H-5’a and H-5’b]; 2.37 [t, J = 
7.5 and 7.5 Hz, 2H, -CH2CO]; 2.20 [t, J = 7.5 and 7.5 Hz, 2H, -CH2CO]; 1.71 [s, 9H, C(CH3)3]; 
1.65 [m, 4H, -CH2CH2CO]; 1.42 [s, 18H, 2x OCOC(CH3)3]; 1.25 - 1.22 [overlapped signals, 
40H, -CH2]; 0.87 [overlapped triplets, J = 5.5 and 6.5 Hz, 6H, 2x CH3].  
13
C NMR (CDCl3, 125 MHz): δ 172.3, 171.3 [2x COOCH2-]; 161.4 [C-6]; 151.0 [C-2, C-4]; 
150.3 [2x OCOC(CH3)3]; 141.9 [C-8]; 122.5 [C-5]; 88.2 [C-1’]; 86.2 [C-4’]; 84.5 [C(CH3)3]; 
83.1 [2x OCOC(CH3)3]; 72.4 [C-2’]; 72.3 [C-3’]: 62.4 [C-5’]; 34.0, 33.5 [2x CH2COO myristic 
acid]; 31.8, 29.5, 29.4, 29.3, 29.2, 29.0, 28.9, 28.2, 27.7 [22x -CH2, C(CH3)3, 2x 
OCOC(CH3)3]; 22.5 [CH3].  
ESI-MS (positive ions): calcd. for C52H89N5O11 = 959.6559; found m/z = 959.92 [M + H
+
]. 
HRMS (MALDI-TOF): calcd. for C52H89N5O11Na = 982.6456; found m/z: 982.6483 [M + Na
+
]. 
 
Synthesis of compound 7a.  
6 (216 mg, 0.225 mmol) was dissolved in 2.5 mL of anhydrous CH2Cl2. To the solution DCC 
(93 mg, 0.45 mmol), DMAP (5.0 mg, 0.04 mmol) and CH3O(CH2CH2O)3CH2COOH 
[19]
 (75 
mg, 0.34 mmol) were added and the resulting solution was stirred for 1.5 h at room 
temperature. The crude was concentrated under reduced pressure and purified on a silica 
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gel column (eluent: n-hexane/acetone 65:35, v/v). The desired product 7a was obtained 
in 97% isolated yield (254 mg, 0.218 mmol). 
7a: oil, Rf = 0.5 [acetone/n-hexane, 35:65 (v/v)].  
1
H NMR (CDCl3, 200 MHz): δ 8.17 [s, 1H, H-8]; 6.19 [d, J =5.6 Hz, 1H, H-1’]; 5.82 [t, J = 5.6 
and 5.6 Hz, 1H, H-2’]; 5.56 [m, 1H, H-3’]; 4.42 [overlapped signals, 3H, H-4’, H-5’a and H-
5’b]; 4.23 [s, 2H, -OCH2CO-]; 3.72 - 3.40 [overlapped signals, 12H, 3x -OCH2CH2O-]; 3.35 [s, 
3H, CH3O-]; 2.37-2.20 [overlapped signals, 4H, 2x COCH2-]; 1.69 - 1.22 [overlapped signals, 
71H, C(CH3)3, 2x OCOC(CH3)3, -CH2-]; 0.85 [overlapped triplets, J = 5.4 and 6.8 Hz, 6H, 2x 
CH3].  
13
C NMR (CDCl3, 50 MHz): δ 172.2, 171.8 [2x -CH2COO myristoyl residue]; 169.7 [-
OCH2COO-]; 161.0 [C-6]; 152.1 [C-2]; 151.3 [C-4]; 150.6 [2x OCOC(CH3)3]; 140.7 [C-8]; 
121.2 [C-5]; 85.8 [C-1’]; 84.1 [C-4’]; 82.9 [2x OCOC(CH3)3]; 80.5 [C(CH3)3]; 72.9 [C-2’]; 71.8 
[C-3’]; 70.9, 70.7, 70.6, 70.5 [3x -OCH2CH2O-]; 68.6 [-OCH2COO-]; 63.6 [C-5’]; 58.9 [CH3O-]; 
33.9, 33.8 [2x -CH2COO myristoyl residue]; 31.8, 29.6, 29.4, 29.3, 29.2, 29.2, 29.1, 29.0, 
28.2, 27.8 [22x -CH2, C(CH3)3, 2x OCOC(CH3)3]; 22.6 [2x CH3].  
ESI-MS (positive ions): calcd. for C61H105N5O16 = 1163.7556; found m/z = 1164.50 [M + H
+
]; 
1186.47 [M + Na
+
]; 1202.49 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C61H105N5O16Na = 
1186.7454; found m/z: 1186.7479 [M + Na
+
]. 
 
Synthesis of compound G1.  
7a (254 mg, 0.218 mmol), dissolved in 2.0 mL of anhydrous CH2Cl2, was reacted with 0.25 
mL TFA. The solution was stirred at room temperature for 2 h, then the solvent was 
removed under reduced pressure and the residue was coevaporated three times with i-
PrOH. The desired product G1 was thus obtained in quantitative yield as a pure 
compound (198 mg, 0.218 mmol). 
G1: oil, Rf = 0.3 [acetone/n-hexane, 8:2 (v/v)].  
1
H NMR (CD3OD, 10.8 mM, 500 MHz): δ 7.92 [s, 1H, H-8]; 6.06 [d, J = 5.5 Hz, 1H, H-1’]; 
5.87 [t, J = 5.5 and 6.0 Hz, 1H, H-2’]; 5.69 [t, J = 5.5 and 5.5 Hz, 1H, H-3’]; 4.55 - 4.40 
[overlapped signals, 3H, H-4’, H-5’a and H-5’b]; 4.23 [m, 2H, -OCH2CO-]; 3.74 – 3.68, 3.65 – 
3.63, 3.54 – 3.51 [m’s, 4H each, 3x -OCH2CH2O-]; 3.59 [s, 3H, CH3O-]; 2.44 - 2.32 
[overlapped signals, 4H, 2x OOCCH2-]; 1.69 - 1.54 [overlapped signals, 4H, 2x OOCCH2CH2-
]; 1.43 - 1.22 [overlapped signals, 40H, 20x -CH2-]; 0.86 [overlapped triplets, J = 5.5 and 
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6.5 Hz, 6H, 2x CH3]. 
13
C NMR (CD3OD, 10.8 mM, 100 MHz): δ 174.4, 174.2 [2x -CH2COO 
myristoyl residue]; 171.9 [-OCH2COO-]; 160.9 [C-6]; 157.1 [C-2]; 152.4 [C-4]; 138.3 [C-8]; 
118.7 [C-5]; 89.0 [C-1’]; 82.8 [C-4’]; 75.1 [C-2’]; 73.4 [C-3’]; 72.3, 71.9, 71.5 [3x -
OCH2CH2O-]; 70.0 [-OCH2COO-]; 64.8 [C-5’]; 58.2 [CH3O-]; 35.2, 33.6 [2x -CH2COO 
myristoyl residue]; 31.9, 31.3, 31.0, 30.7, 27.3, 27.0, 26.9, 26.5, 24.2 [22x -CH2]; 14.9 [2x 
CH3]. ESI-MS (positive ions): calcd. for C47H81N5O12 = 907.5882; found m/z = 908.57 [M + 
H
+
]. HRMS (MALDI-TOF): calcd. for C47H81N5O12Na = 931.1621; found m/z: 931.1666 [M + 
Na
+
]. 
 
Synthesis of compound 7b.  
6 (184 mg, 0.192 mmol) was dissolved in 2.0 mL of anhydrous CH2Cl2. To the solution, DCC 
(59 mg, 0.29 mmol), DMAP (1.2 mg, 0.0096 mmol) and Fmoc-Glu(OtBu)OH (106 mg, 0.250 
mmol) were added. The mixture was stirred for 3 h at room temperature, then the 
solvent was removed under reduced pressure and the residue was purified on a silica gel 
column (eluent: n-hexane/AcOEt 4:1, v/v). The desired product 7b was obtained in 93% 
isolated yield (244 mg, 0.178 mmol). 
7b: oil, Rf = 0.4 [acetone/n-hexane, 2:3 (v/v)].  
1
H NMR (CDCl3, 200 MHz): δ 8.12 [s, 1H, H-8]; 7.73 - 7.21 [overlapped signals, 8H, Fmoc 
aromatic protons]; 6.10 [d, J = 4.8 Hz, 1H, H-1’]; 5.77 [dd, J = 5.2 and 5.8 Hz, 1H, H-2’]; 
5.61 [dd, J = 4.2 and 5.0 Hz, 1H, H-3’]; 4.54 - 4.27 [overlapped signals, 7H, H-4’, H-5’a and 
H-5’b, H-α Glu, CH2 Fmoc, CH Fmoc]; 2.35 - 2.20 [overlapped signals, 8H, 2x CH2CO 
myristoyl residue, CH2-β and CH2-γ Glu]; 1.67 [s, 9H, C(CH3)3]; 1.39 [s, 27H, 3x 
OCOC(CH3)3]; 1.22 [s, 44H, 22x CH2 myristoyl residues]; 0.87 [overlapped signals, J = 5.4 
and 6.4 Hz, 6H, 2x CH3].  
13
C NMR (CDCl3, 50 MHz): δ 171.9, 171.8, 171.7, 171.5 [COO myristoyl and Glu residues]; 
160.9 [C-6]; 155.9 [CO Fmoc]; 151.8, 151.1 [C-2 and C-4]; 150.5 [2x OCOC(CH3)3]; 143.5, 
127.5, 126.9, 125.0, 119.7 [Fmoc aromatic carbons]; 141.1 [C-8]; 121.1 [C-5]; 83.9 [C-1’]; 
82.7 [C-4’]; 80.7, 80.2 [2x OCOC(CH3)3 and C(CH3)3]; 73.1 [C-2’]; 70.3 [C-3’]; 67.0 [CH2 
Fmoc]; 64.2 [C-5’]; 53.6 [C-α Glu]; 46.9 [CH Fmoc]; 33.6, 33.5, 31.7, 29.5, 29.3, 29.2, 29.0, 
28.1, 27.9, 27.7, 24.6, 24.5, 22.5 [2x CH2CO myristoyl residues, CH2-β and CH2-γ Glu, 22x 
CH2 myristoyl residues, C(CH3)3, 2x OCOC(CH3)3]; 13.9 [2x CH3].  
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ESI-MS (positive ions): calcd. for C76H114N6O16 = 1366.8291; found m/z = 1311.02 [M - t-Bu 
+ H
+
]; 1333.13 [M - t-Bu + Na
+
]; 1368.24 [M+H
+
]. HRMS (MALDI-TOF): calcd. for 
C76H114N6O16Na = 1389.8189; found m/z: 1389.8203 [M + Na
+
]. 
 
Synthesis of compound G2.  
7b (64 mg, 0.060 mmol), dissolved in anhydrous DMF (0.45 mL), was reacted with 
piperidine (50 µL). The solution was stirred at room temperature for 20 min and then the 
solvent was removed under reduced pressure. The residue was purified on a silica gel 
column (eluent: n-hexane/AcOEt 1:1, v/v). Then the product was dissolved in 0.90 mL of 
anhydrous CH2Cl2 and 0.10 mL of TFA. The solution was stirred at room temperature for 2 
h, then the solvent was removed under reduced pressure and the residue coevaporated 
three times with i-PrOH without further purification. The desired product G2 was 
obtained in 80% overall yield for the two steps (40 mg, 0.048 mmol). 
G2: amorphous solid, Rf = 0.1 [CHCl3/CH3OH, 9:1 (v/v)]. 
 
1
H NMR (CD3OD, 500 MHz): δ 7.90 [s, 1H, H-8]; 6.08 [d, J = 5.5 Hz, 1H, H-1’]; 6.00 
[apparent triplet, J = 5.5 Hz, 1H, H-2’]; 5.68 [apparent triplet, J = 5.0 Hz, 1H, H-3’]; 4.60 [m, 
2H, H-5’a and H-5’b]; 4.47 [broad signal, 1H, H-4’]; 4.19 [t, J = 6.5 Hz, 1H, H-α Glu]; 2.52 [m, 
2H, CH2-γ Glu]; 2.44 - 2.34 [m, 4H, 2x CH2CO myristoyl residues]; 2.27 - 2.14 [m, 2H, CH2-β 
Glu]; 1.65 – 1.54 [m, 4H, 2x CH2CH2CO myristoyl residues]: 1-40 - 1.28 [overlapped signals, 
40H, 20x CH2]; 0.90 [overlapped triplets, J = 6.0 and 7.0 Hz, 6H, 2x CH3].  
13
C NMR (CD3OD, 100 MHz): δ 174.5, 174.2, 170.8 [COO myristoyl and Glu residues]; 
163.2 [C-6]; 159.7 [C-2]; 156.1 [C-4]; 138.7 [C-8]; 118.3 [C-5]; 86.3 [C-1’]; 81.7 [C-4’]; 74.5 
[C-2’]; 72.1 [C-3’]; 67.0 [C-5’]; 53.8 [C-α Glu]; 35.2, 35.1 [2x CH2CO myristoyl residues]; 
33.6 [CH2-γ Glu]; 31.3, 31.0, 30.8, 30.7, 30.7, 30.4, 28.8, 26.4, 24.2 [CH2-β Glu, 22x CH2 
myristoyl residues]; 15.0 [2x CH3].  
ESI-MS (positive ions): calcd. for C43H72N6O10 = 832.5310; found m/z = 871.50 [M + K
+
]. 
HRMS (MALDI-TOF): calcd. for C43H72N6O10Na = 855.5208; found m/z: 855.5253 [M + Na
+
]. 
 
Synthesis of compound 7c.  
6 (121 mg, 0.126 mmol) was dissolved in 1.0 mL of anhydrous DMF and then treated with 
the complex SO3∙Et3N (25 mg, 0.139 mmol). The solution was stirred at room temperature 
for 45 min and then the solvent was removed under reduced pressure. The residue was 
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purified on a silica gel column (eluent: AcOEt/CH3OH 95:5, v/v). The desired product 7c 
was obtained in the form of triethylammonium salt in 70% isolated yield (91 mg, 0.088 
mmol). 
7c: oil, Rf = 0.6 [AcOEt/CH3OH, 9:1 (v/v)].  
1
H NMR (CDCl3, 500 MHz): δ 10.85 [broad signal, 1H, (CH3CH2)3NH
+
]; 9.70 [s, 1H, H-8]; 
6.16 [d, J = 5.5 Hz, 1H, H-1’]; 5.74 [dd, J = 5.5 and 5.0 Hz, 1H, H-2’]; 5.65 [broad signal, 1H, 
H-3’]; 4.44 - 4.31 [overlapped signals, 3H, H-4’, H-5’a and H-5’b]; 3.15 [m, 6H, 
(CH3CH2)3NH
+
]; 2.32 - 2.25 [overlapped signals, 4H, 2x CH2CO myristoyl residues]; 1.61 - 
1.54 [overlapped signals, 27H, C(CH3)3, 2x OCOC(CH3)3]; 1.40 [t, J = 7.5 and 7.5 Hz, 9H, 
(CH3CH2)3NH
+
]; 1.28 - 1.24 [overlapped signals, 44H, 22x CH2]; 0.88 [overlapped triplet, J = 
6.5 and 6.0 Hz, 6H, 2x CH3].  
13
C NMR (CDCl3, 100 MHz): significant signals a δ 172.6, 172.2 [2x COCH2]; 87.2 [C-1’]; 
83.4 [C-4’]; 75.2 [C-2’]; 73.7 [C-3’]: 66.2 [C-5’]; 46.0 [N(CH2CH3)3]; 33.8 [2x CH2CO 
overlapped signals]; 31.8, 29.6, 29.2, 27.9, 27.5, 24.7, 22.6 [22x -CH2, C(CH3)3, 2x 
OCOC(CH3)3]; 14.0 [2x CH3]; 8.6 [N(CH2CH3)3].  
ESI-MS (negative ions): calcd. for C52H88N5O14S
-
 = 1038.6054; found m/z = 1037.42 [M
-
]. 
HRMS (MALDI-TOF): calcd. for C52H88N5O14S
-
 = 1038.6054; found m/z: 1038.6081 [M
-
]. 
 
Synthesis of compound G3.  
7c (91 mg, 0.088 mmol), dissolved in 0.90 mL of anhydrous CH2Cl2, was reacted with 0.10 
mL TFA. The solution was stirred at room temperature for 1.5 h, then the solvent was 
removed under reduced pressure and the residue coevaporated three times with i-PrOH. 
The desired product G3 was obtained in quantitative yield as a pure compound (69 mg, 
0.088 mmol). 
G3: amorphous solid, Rf = 0.2 [AcOEt/CH3OH, 9:1 (v/v)].  
1
H NMR (CD3OD, 500 MHz): δ 9.10 [broad signal, 1H, (CH3CH2)3NH
+
]; 8.73 [s, 1H, H-8]; 
6.18 d, J = 5.5 Hz, 1H, H-1’]; 5.87 [m, 1H, H-2’]; 5.66 [broad signal, 1H, H-3’]; 4.33 - 4.06 
[overlapped signals, 3H, H-4’, H-5’a and H-5’b]; 3.23 [m, 6H, (CH3CH2)3NH
+
]; 2.42 - 2.27 
[overlapped signals, 4H, 2x CH2CO]; 1.66 – 1.46 [broad signal, 4H, 2x CH2CH2CO]; 1.32 - 
1.18 [overlapped signals, 20H, 10x CH2]; 1.14 [m, 9H, (CH3CH2)3NH
+
]; 0.89 [overlapped 
triplets, J = 6.0 and 7.0 Hz, 6H, 2x CH3].  
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13
C NMR (CD3OD, 100 MHz): δ 174.5 [2x CO myristoyl residues]; 161.8 [C-6]; 155.5 [C-2]; 
152.1 [C-4]; 138.7 [C-8]; 119.4 [C-5]; 80.5 [C-1’]; 76.7 [C-4’]; 73.9 [C-2’]; 71.6 [C-3’]; 70.1 
[C-5’]; 48.4 [(CH3CH2)3NH
+
]; 35.3 [2x CH2CO]; 33.6 [2x CH2CH2CO]; 31.3, 31.1, 30.7, 29.5, 
28.8, 26.5, 24.2, 22.6, 22.1 [20x CH2]; 15.0 [2x CH3]; 9.7 [(CH3CH2)3NH
+
].  
ESI-MS (negative ions); calcd. for C38H64N5O10S
-
 = 782.4379; found m/z = 782.11 [M
-
]. 
HRMS (MALDI-TOF): calcd. for C38H64N5O10S
-
 = 782.4379; found m/z: 782.4354 [M
-
]. 
 
Synthesis of compound 7d.  
6 (71 mg, 0.074 mmol) was dissolved in 2.5 mL of anhydrous CH2Cl2. To the solution DCC 
(23 mg, 0.11 mmol), DMAP (1.0 mg, 0.0037 mmol) and Fmoc-Ser(OTrt)-OH (51 mg, 0.089 
mmol) were sequentially added. The solution was stirred at room temperature for 1.5 h, 
then the solvent was removed under reduced pressure and the residue was purified on a 
silica gel column (eluent: AcOEt/n-hexane 3:7, v/v). The desired product 7d was obtained 
in quantitative yield (112 mg, 0.074 mmol). 
7d: oil, Rf = 0.5 [AcOEt/n-hexane, 4:6 (v/v)].  
1
H NMR (CDCl3, 200 MHz): δ 7.98 [s, 1H, H-8]; 7.75 - 7.15 [overlapped signals, 23H, 
aromatic protons of Trt and Fmoc]; 6.00 [d, J = 4.2 Hz, 1H, H-1’]; 5.75 - 5.57 [overlapped 
signals, 2H, H-2’ and H-3’]; 4.66 - 4.21 [overlapped signals, 7H, H-4’, CH2 and CH Fmoc, CH-
α and CH2-β Ser]; 3.55 [m, 2H, H-5’a and H-5’b]; 2.40 - 2.22 [overlapped signals, 4H, 2x 
CH2CO myristoyl residues]; 1.71 [s, 9H, C(CH3)3]; 1.41 [s, 18H, 2x OCOC(CH3)3]; 1.36 - 1.16 
[overlapped signals, 44H, 22x CH2]; 0.88 [overlapped triplets, J = 6.0 and 6.8 Hz, 6H, 2x 
CH3].  
13
C NMR (CDCl3, 50 MHz): δ 171.9, 170.1 [3x COO myristoyl and Ser residues]; 160.9 [C-6]; 
155.9 [CO Fmoc]; 151.8, 151.5 [C-2 and C-4]; 150.6 [2x OCOC(CH3)3]; 143.7, 143.2, 140.7, 
128.4, 127.6, 127.2, 127.0, 125.1, 119.9 [Trt and Fmoc aromatic carbons]; 141.2 [C-8]; 
121.4 [C-5]; 86.8 [C-1’]; 84.0 [C(CH3)3]; 82.9 [C-4’]; 80.1 [2x OCOC(CH3)3]; 73.3 [C-2’]; 71.4 
[C-3’]; 67.3 [CH2 Fmoc]; 64.3 [C-5’]; 63.8 [C-β Ser]; 54.5 [C-α Ser]; 47.0 [CH Fmoc]; 33.7 [2x 
CH2CO myristoyl residues]; 31.9, 29.6, 29.4, 29.3, 28.3, 27.8, 24.7, 22.6 [22x -CH2, C(CH3)3, 
2x OCOC(CH3)3]; 14.0 [2x CH3].  
ESI-MS (positive ions): calcd. for C89H118N6O15 = 1510.8655; found m/z = 1550.21 [M + K
+
]. 
HRMS (MALDI-TOF): calcd. for C89H118N6O15Na = 1533.8553; found m/z: 1533.8582 [M + 
Na
+
]. 
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Synthesis of compound G4.  
7d (106 mg, 0.070 mmol), dissolved in 900 µL of anhydrous DMF, was treated with 100 µL 
of piperidine. The solution was stirred at room temperature for 40 min, then the solvent 
was removed under reduced pressure and the residue purified on a silica gel column 
(eluent: AcOEt/n-hexane 1:4, v/v). The obtained product was successively dissolved in 
0.90 mL of anhydrous CH2Cl2 and 0.10 mL of TFA and stirred at room temperature for 2 h. 
Successively the solvent was removed under reduced pressure, the residue coevaporated 
three times with i-PrOH and then washed with acetone. The desired product was 
obtained in 46% overall yield for the two steps (25 mg, 0.032 mmol). 
G4: amorphous solid,  Rf = 0.1 [AcOEt/CH3OH, 9:1 (v/v)].  
1
H NMR (DMSO-d6, 500 MHz): δ 10.8 [s, 1H, NH-1]; 7.96 [s, 1H, H-8]; 6.56 [broad signal, 
2H, NH2-2]; 5.97 [d, J = 6.5 Hz, 1H, H-1’]; 5.77 [dd, J = 6.0 and 6.5 Hz, 1H, H-2’]; 5.59 
[broad signal, 1H, OH]; 5.55 [apparent triplet, J = 4.0 Hz, 1H, H-3’]; 4.55 [m, 1H, H-4’]; 4.38 
[m, 2H, H-5’a and H-5’b]; 4.25 [broad signal, 1H, CH-α Ser]; 3.84 [m, 2H, CH2-β Ser]; 2.42 - 
2.22 [overlapped signals, 4H, 2x CH2CO myristoyl residues]; 1.55 - 1.44 [overlapped 
signals, 4H, CH2-β myristoyl residue]; 1.26 – 1.18 [overlapped signals, 44H, 22x CH2]; 0.85 
[overlapped triplets, J = 6.5 and 7.0 Hz, 6H, 2x CH3].  
13
C NMR (DMSO-d6, 125 MHz): δ 171.9, 171.6 [2x COO myristoyl residues]; 167.9 [COO 
Ser]; 156.6 [C-6]; 154.0 [C-2]; 151.2 [C-4]; 144.3 [C-8]; 116.7 [C-5]; 83.9 [C-1’]; 79.4 [C-4’]; 
71.8 [C-2’]; 69.6 [C-3’]; 64.9 [C-5’]; 59.5 [CH2-β Ser]; 54.2 [CH-α Ser]; 33.2, 33.0 [2x CH2CO 
myristoyl residues]; 32.9, 31.3, 29.0, 28.9, 28.8, 28.7, 28.5, 28.3, 24.4, 24.2, 22.1 [22x -
CH2]; 13.9 [2x CH3].  
ESI-MS (positive ions): calcd. for C41H70N6O9 = 790.5204; found m/z = 791.12 [M + H
+
]. 
HRMS (MALDI-TOF): calcd. for C41H70N6O9Na = 814.0191; found m/z: 814.0210 [M + Na
+
]. 
 
Synthesis of compound 8.  
Commercially available α,α’-D-trehalose 2xH2O (1.14 g, 3.33 mmol) was previously 
dehydrated by heating under vacuum at 100 °C for 30 min. Then the solid was cooled at 
room temperature in anhydrous N2 atmosphere and successively suspended in 10 mL of 
anhydrous DMF. To the stirred suspension imidazole (136 mg, 2.00 mmol) and TBDPSCl 
(432 µL, 1.66 mmol) were sequentially added. The reaction mixture was stirred at 0 °C for 
50 min, then the solvent was removed under vacuum and the residue purified on a silica 
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gel column (eluent: CHCl3/CH3OH 85:15, v/v). The desired product 8 was obtained in 86% 
isolated yield (828 mg, 1.43 mmol). 
8: amorphous solid, Rf = 0.6 [CHCl3/CH3OH, 7:3 (v/v)].  
1
H NMR (CD3OD, 500 MHz): δ 7.72-7.37 [overlapped signals, 10H, aromatic protons of 
TBDPS]; 5.18 [d, J = 3.7 Hz, 1H, H-1]; 5.16 [d, J = 3.7 Hz, 1H, H-1’]; 3.95 - 3.81 [overlapped 
signals, 7H, H-3, H-5, H-6a, H-6b, H-3’, H-5’, H-6’a]; 3.71 [dd, J = 5.5 and 5.5 Hz, 1H, H-6’b]; 
3.56-3.52 [overlapped signals, 2H, H-2, H-4]; 3.48 [dd, J = 3.5 and 3.5 Hz, 1H, H-2’]; 3.35 
[buried under the residual solvent signal, H-4’]; 1.03 [s, 9H, 3x SiC(CH3)3].  
13
C NMR (CD3OD, 125 MHz): δ 137.3, 137.2, 136.3, 135.6, 135.2, 131.2, 129.1, 121.9 
[aromatic carbons of TBDPS]; 95.4 [C-1]; 95.2 [C-1’]; 75.2 [C-3]; 75.1 [C-3’]; 74.5 [C-5]; 
74.3 [C-5’]; 73.7 [C-2]; 73.6 [C-2’]; 72.4 [C-4]; 72.2 [C-4’]; 64.8 [C-6]; 63.1 [C-6’]; 27.8 
[SiC(CH3)3]; 20.6 [SiC(CH3)3].  
ESI-MS (positive ions): calcd. for C28H40O11Si = 580.2340; found m/z = 604.12 [M + Na
+
]; 
650.00 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C28H40O11SiNa = 603.6859; found m/z: 
603.6880 [M + Na
+
]. 
 
Synthesis of compound 9.  
8 (363 mg, 0.62 mmol) was dissolved in 4 mL of anhydrous CH3CN and then DMAP (8.0 
mg, 0.062 mmol), TEA (1.4 mL, 9.92 mmol), and Boc2O (2.0 mL, 8.68 mmol) were 
sequentially added. The reaction mixture was stirred for 48 h at room temperature, then 
the solvent was removed under reduced pressure and the residue purified on a silica gel 
column (eluent: AcOE/n-hexane 1:4, v/v). The desired compound 9 was obtained in 58% 
isolated yield (460 mg, 0.36 mmol). 
9: oil, Rf = 0.4 [AcOEt/n-hexane, 1:4 (v/v)].  
1
H NMR (CDCl3, 500 MHz): δ 7.67 - 7.30 [overlapped signals, 10H, aromatic protons of 
TBDPS]; 5.33 [apparent triplet, J = 10.5 and 9.0, 1H, H-3’]; 5.27 [d, J = 4.0 Hz, 1H, H-1’]; 
5.22 [t, J = 10.5 and 10.0 Hz, 2H, H-5 and H-5’]; 5.18 [d, J = 4.0 Hz, 1H, H-1]; 4.94 [apparent 
triplet, J = 10.5 and 9.5 Hz, 1H, H-3]; 4.90 and 4.79 [dd’s, J = 4.0 and 10.0 Hz, 1H each, H-2 
and H-2’]; 4.36 [dd, J = 2.0 and 11.0 Hz, 1H, H-6’a]; 4.26 [d, J = 10.5 Hz, 1H, H-4]: 4.10 [d, J 
= 10.5 Hz, 1H, H-4’]; 4.01 [dd, J = 2.0 and 11.0 Hz, 1H, H-6’b]; 3.80 [dd, J = 2.0 and 11.0 Hz, 
1H, H-6a]; 3.63 [d, J = 11.0 Hz, 1H, H-6b]; 1.49, 1.47, 1.45 [singlets, 63H, 7x OCOC(CH3)3]; 
1.01 [s, 9H, SiC(CH3)3].  
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13
C NMR (CDCl3, 50 MHz): δ 153.1, 152.5, 152.1, 152.0, 151.9, 151.8 [7x OCOC(CH3)3]; 
135.6, 135.4, 133.4, 132.8, 129.4, 127.5 [aromatic carbons of TBDPS]; 94.3 [C-1]; 93.9 [C-
1’]; 82.7, 82.6, 82.5, 82.3, 82.2, 82.0 [7x OCOC(CH3)3]; 73.7, 72.9, 72.5, 72.0 [C-5, C-5’, C-3, 
C-3’]; 70.5, 70.3 [C-2 and C-2’]; 70.1 [C-4’]; 68.0 [C-4]; 63.5 [C-6]; 61.4 [C-6’]; 27.7, 27.6, 
27.5, 27.3 [7x OCOC(CH3)3]; 26.5 [SiC(CH3)3]; 19.2 [SiC(CH3)3].  
ESI-MS (positive ions): calcd. for C63H96O25Si = 1280.6010; found m/z = 1303.00 [M + Na
+
]; 
1320.00 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C63H96O25SiNa = 1303.5908; found m/z: 
1303.5933 [M + Na
+
]. 
 
Synthesis of compound 10.  
9 (460 mg, 0.36 mmol), dissolved in 2.0 mL of anhydrous THF, was reacted with Et3N⋅3HF 
(1.16 mL, 7.12 mmol). The solution was stirred at room temperature for 72 h, then the 
crude was washed three times with H2O/CH2Cl2; the collected organic phases were dried 
over anhydrous Na2SO4, concentrated under reduced pressure and purified on a silica gel 
column (eluent: n-hexane/AcOEt 4:1, v/v). The desired product 10 was obtained in 80% 
isolated yield (300 mg, 0.29 mmol). 
10: oil, Rf = 0.3 [AcOEt/n-hexane, 3:7 (v/v)].  
1
H NMR (CDCl3, 500 MHz): δ 5.28 - 5.24 [overlapped signals, 3H, H-1, H-1’, H-3’]; 5.20 
[apparent triplet, J = 10.5 and 9.5 Hz, 1H, H-3]; 4.96 [apparent triplet, J = 9.5 and 10.5 Hz, 
1H, H-4]; 4.84 - 4.79 [overlapped signals, 3H, H-2, H-2’, H-4’]; 4.36 [dd, J = 2.5 and 12.0 Hz, 
1H, H-6a]; 4.26 [d, J = 10.5 Hz, 1H, H-5]; 4.06 [d, J = 10.0 Hz, 1H, H-5’]; 4.00 [dd, J = 2.0 and 
12.0 Hz, 1H, H-6b]; 3.71-3.59 [m, 2H, H-6’a, H-6’b]; 1.50-1.44 [overlapped signals, 63H, 7x 
OCOC(CH3)3].  
13
C NMR (CDCl3, 125 MHz): δ 153.4, 153.1, 152.2, 152.1, 151.9, 151.8 [7x OCOC(CH3)3]; 
94.7 and 94.6 [C-1 and C-1’]; 83.4, 83.0, 82.7, 82.6, 82.4, 82.1 [7x OCOC(CH3)3]; 72.9, 72.4, 
72.2, 72.1, 71.1, 70.4, 70.3, 68.1 [C-3, C-3’, C-5, C-5’, C-2, C-2’, C-4, C-4’]; 63.3 [C-6]; 60.4 
[C-6’]; 27.6 [7x OCOC(CH3)3].  
ESI-MS (positive ions): calcd. for C47H78O25 = 1042.4832; found m/z = 1065.69 [M + Na
+
]; 
1082.42 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C47H78O25Na = 1065.4730; found m/z: 
1065.4754 [M + Na
+
]. 
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Synthesis of compound 11.  
10 (125 mg, 0.12 mmol) was dissolved in 1.0 mL of anhydrous THF. To the solution, DMAP 
(15 mg, 0.12 mmol) and succinic anhydride (24 mg, 0.24 mmol) were sequentially added 
and the resulting mixture was taken under stirring at room temperature. After 24 h the 
reaction mixture was taken to dryness and the crude, transferred into a separatory 
funnel, was washed three times with H2O/CH2Cl2; the collected organic phases were dried 
over anhydrous Na2SO4, concentrated under reduced pressure and purified on a silica gel 
column (eluent: n-hexane/AcOEt 3:7, v/v). The desired product 11 was obtained in 78% 
isolated yield (107 mg, 0.094 mmol). 
11: oil, Rf = 0.4 [AcOEt/n-hexane, 1:1 (v/v)].  
1
H NMR (CDCl3, 500 MHz): δ 5.24 - 5.22 [overlapped signals, 2H, H-1, H-1’]; 5.20, 5.17 
[triplets, J = 10.0 and 10.0 Hz, 1H each, H-3, H-3’]; 4.94 [overlapped triplets, J = 10.0 and 
9.5 Hz, 2H, H-4, H-4’]; 4.89 - 4.84 [overlapped signals, 2H, H-2, H-2’]; 4.41 - 4.35 
[overlapped signals, 2H, H-6a, H-6’a]; 4.28 - 4.22 [overlapped signals, 2H, H-5, H-5’]; 4.08 
[m, 1H, H-6’b]; 3.99 [m, 1H, H-6b]; 2.68 [m, 4H, CH2CH2COOH]; 1.48 - 1.42 [overlapped 
signals, 63H, 7x OCOC(CH3)3]. 
13
C NMR (CDCl3, 100 MHz): δ 175.5, 171.5 [2x OOCCH2CH2]; 153.0, 152.2, 151.8 [7x 
OCOC(CH3)3]; 94.2 [C-1, C-1’]; 82.9, 82.6, 82.3, 82.0 [7x OCOC(CH3)3]; 72.9 [C-3, C-3’]; 72.0 
[C-2, C-2’], 70.3 [C-4, C-4’]; 68.0 [C-5, C-5’]; 63.3 [C-6]; 61.2 [C-6’]; 29.5, 28.7 [2x 
COCH2CH2]; 28.5, 27.5 [7x OCOC(CH3)3].  
ESI-MS (positive ions): calcd. for C51H82O28 = 1142.4993; found m/z = 1144.10 [M + H
+
]; 
1166.06 [M + Na
+
]; 1182.03 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C51H82O28Na = 
1165.4890; found m/z: 1165.4910 [M + Na
+
]. 
 
Synthesis of compound 12.  
11 (88 mg, 0.077 mmol) was dissolved in 0.80 mL of anhydrous CH2Cl2 and to the resulting 
solution DCC (29 mg, 0.14 mmol), DMAP (1.0 mg, 0.077 mmol) and 6 (70 mg, 0.070 mmol) 
were sequentially added. The reaction mixture was stirred at room temperature for 3 h, 
then the solvent was removed under vacuum and the residue purified on a silica gel 
column (eluent: n-hexane/AcOEt 4:1, v/v). the desired product 12 was obtained in 86% 
isolated yield (124 mg, 0.066 mmol). 
12: oil, Rf = 0.4 [acetone/n-hexane, 35:65 (v/v)].  
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1
H NMR (CDCl3, 200 MHz): δ 8.03 [s, 1H, H-8]; 6.11 [d, J = 5.0 Hz, 1H, H-1’]; 5.74 [dd, J = 
5.6 and 5.0 Hz, 1H, H-2’]; 5.53 [m, 1H, H-3’]; 5.22 - 5.12 [overlapped signals, 4H, H-a, H-a’, 
H-c, H-c’]; 4.98 - 4.79 [overlapped signals, 4H, H-b, H-b’, H-d, H-d’]; 4.42 - 3.94 
[overlapped signals, 9H, H-4, H2-5’, H-fa, H-f’a, H-e, H-e’, H-fb, H-f’b]; 2.65 [s, 4H, 
OCCH2CH2CO succinic acid]; 2.28 [m, 4H, -CH2COO myristoyl residues]; 1.68 [s, 9H, 
C(CH3)3]; 1.59 - 1.12 [overlapped signals, 125H, 9x OCOC(CH3)3, 22x CH2]; 0.84 [overlapped 
signals, J = 5.8 and 5.8 Hz, 6H, 2x CH3].  
13
C NMR (CDCl3, 50 MHz): δ 171.8, 171.3 [2x CH2COO myristoyl and 2x CH2COO succinoyl 
residue]; 161.0 [C-6]; 153.1, 152.1, 151.8, 151.2, 150.5 [C-2, C-4, 9x OCOC(CH3)3]; 140.3 
[C-8]; 121.3 [C-5]; 94.1 [C-a, C-a’]; 86.4 [C-1’]; 83.8 [C-4’]; 82.6, 82.2, 81.9, 80.3 [C(CH3)3, 
9x OCOC(CH3)3]; 73.0 [C-c, C-c’, C-2’]; 72.2 [C-b, C-b’, C-3’]; 70.4 [C-d, C-d’]; 68.1 [C-e, C-
e’]; 63.5 [C-f, C-5’]; 61.4 [C-f’]; 33.7, 33.5, 31.7 [2x CH2COO myristoyl residues, 2x CH2COO 
succinoyl residue]; 29.4, 29.1, 28.5, 28.2, 27.7, 27.5, 25.4, 24.6, 24.5, 22.4 [22x CH2, -
C(CH3)3, 9x OCOC(CH3)3]; 13.8 [2x CH3].  
MALDI-TOF (positive ions): calcd. for C103H169N5O38 = 2084.1446; found m/z = 2085.18 [M 
+ H
+
]. HRMS (MALDI-TOF): calcd. for C103H169N5O38Na = 2107.1343; found m/z: 2107.1369 
[M + Na
+
]. 
 
Synthesis of compound G5.  
12 (111 mg, 0.053 mmol), dissolved in 0.90 mL of anhydrous CH2Cl2, was treated with 0.10 
mL of TFA. The solution was stirred at room temperature for 3 h; then the solvent was 
removed under vacuum and the residue coevaporated three times with i-PrOH. The 
desired product G5 was obtained in quantitative yield without further purification (60 mg, 
0.053 mmol). 
G5: amorphous solid, Rf = 0.1 [CHCl3/CH3OH, 7:3 (v/v)].  
1
H NMR (CD3OD, 500 MHz): δ 8.72 [s, 1H, NH-1]; 8.21 [s, 1H, H-8]; 6.09 [d, J = 4.5 Hz, 1H, 
H-1’]; 5.95 [t, J = 5.5 and 5.5 Hz, 1H, H-2’]; 5.66 [t, J = 5.0 and 5.0 Hz, 1H, H-3’]; 5.08 - 5.06 
[overlapped signals, 2H, H-a and H-a’]; 4.50 – 4.38 [overlapped signals, 4H, H-f’a, H-4’ and 
H2-5’]; 4.21 – 4.18 [m, 1H, H-f’b]; 4.01 [m, 1H, H-e’]; 4.00 – 3.78 [overlapped signals, 4H, 
H-fa, H-e, H-c and H-c’]; 3.68 – 3.47 [m, 1H, H-fb]; 3.49 – 3.43 [overlapped signals, 2H, H-b 
and H-b’]; 2.67 [s, 4H, COCH2CH2CO]; 2.44 - 2.32 [overlapped signals, 4H, 2x CH2COO 
myristoyl residues]; 1.86 – 1.54 [overlapped signals, 4H, 2x CH2CH2COO myristoyl 
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residues]; 1.38 - 1.10 [overlapped signals, 20H, 10x CH2 myristoyl residues]; 0.90 
[overlapped triplets, J = 6.5 and 7.0 Hz, 6H, 2x CH3]. H-d and H-d’ signals are buried under 
the residual solvent signal.  
13
C NMR (CD3OD, 100 MHz): significant signals at δ 174.5, 174.4, 174.3 [4x CH2COO]; 
138.5 [C-8]; 116.6 [C-5]; 95.8, 95.7 [C-a and C-a’]; 88.7 [C-1’]; 82.2 [C-4’]; 75.1 [C-2’]; 74.3, 
73.7 [C-e and C-e’]; 72.5 [C-b and C-b’]; 71.9 [C-3’]; 65.5 [C-d and C-d’]; 64.7 [C-5’]; 63.2 
[C-f and C-f’]; 35.3, 33.6 [2x CH2COO myristoyl residues]; 31.3, 31.0 [2x CH2COO succinoyl 
residue]; 27.2, 26.5, 24.2 [22x CH2]; 14.9 [CH3].  
ESI-MS (positive ions): calcd. for C54H89N5O20 = 1127.6101; found m/z = 1128.30 [M + H
+
]. 
HRMS (MALDI-TOF): calcd. for C54H89N5O20Na = 1150.5999; found m/z: 1150.5617 [M + 
Na
+
]. 
 
Synthesis of compound 13.  
3 (129 mg, 0.239 mmol) was dissolved in 1.0 mL of anhydrous CH2Cl2. To the solution DCC 
(222 mg, 1.98 mmol), DMAP (3 mg, 0.024 mmol) and CH3O(CH2CH2O)3CH2COOH 
[19]
 (212 
mg, 0.956 mmol) were sequentially added under stirring at room temperature. After 48 h 
the solvent was removed under vacuum and the residue purified on a silica gel column 
(eluent: acetone/n-hexane 55:45, v/v). The desired product 13 was obtained in 42% 
isolated yield (114 mg, 0.099 mmol). 
13: oil, Rf = 0.3 [acetone/n-hexane, 2:3 (v/v)].  
1
H NMR (CDCl3, 200 MHz): δ 8.16 [s, 1H, H-8]; 6.17 [d, J = 5.4 Hz, 1H, H-1’]; 5.97 [dd, J = 
5.2 and 5.6 Hz, 1H, H-2’]; 5.68 [m, 1H, H-3’]; 4.43 [overlapped signals, 3H, H-4’, H-5’a and 
H-5’b]; 4.21 - 4.11 [overlapped signals, 6H, 3x OCH2CO]; 3.70 - 3.49 [overlapped signals, 
36H, 9x OCH2CH2O]; 3.34 and 3.33 [singlets, 9H, 3x OCH3]; 1.67 [s, 9H, C(CH3)3]; 1.39 [s, 
18H, 2x OCOC(CH3)3].  
13
C NMR (CDCl3, 50 MHz): δ 169.6, 169.1, 168.9 [3x OCH2COO]; 160.6 [C-6]; 151.9 [C-2]; 
151.2 [C-4]; 150.5 [2x OCOC(CH3)3]; 140.8 [C-8]; 121.2 [C-5]; 85.9 [C-1’]; 84.1 [C-4’]; 82.9 
[C(CH3)3]; 80.1 [2x OCOC(CH3)3]; 73.0 [C-2’]; 71.7, 71.1, 70.9, 70.4 [C-3’, 9x OCH2CH2O]; 
68.4, 68.0, 67.8 [3x OCH2CO]; 63.4 [C-5’]; 58.8 [3x OCH3]; 28.1 [C(CH3)3] 27.7 [2x 
OCOC(CH3)3].  
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ESI-MS (positive ions): calcd. for C51H85N5O24 = 1151.5584; found m/z = 1152.77 [M + H
+
]; 
1174.71 [M + Na
+
]; 1190.77 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C51H85N5O24Na = 
1174.5482; found m/z: 1174.5501 [M + Na
+
]. 
 
Synthesis of compound G6.  
13 (108 mg, 0.090 mmol), dissolved in 0.90 mL of anhydrous CH2Cl2, was treated with 0.10 
mL of TFA. The solution was stirred at room temperature for 3 h, then taken to dryness 
and coevaporated three times with i-PrOH. The desired product G6 was obtained in 
quantitative yield without further purification (81 mg, 0.090 mmol). 
G6: oil, Rf = 0.2 [AcOEt/CH3OH, 7:3 (v/v)].  
1
H NMR (CDCl3, 200 MHz): δ 8.77 [s, 1H, H-8]; 6.79 [broad signal, 2H, NH2-2]; 6.12 [d, J = 
5.6 Hz, 1H, H-1’]; 5.97 [m, 1H, H-2’]; 5.67 [m, 1H, H-3’]; 5.47 [m, 1H, H-4’]; 4.24 - 4.10 
[overlapped signals, 8H, H-5’a and H-5’b, 3x OCH2COO]; 3.70 - 3.49 [overlapped signals, 
36H, 9x OCH2CH2O]; 3.38 - 3.35 [overlapped signals, 9H, 3x OCH3].  
13
C NMR (CDCl3, 50 MHz): δ 172.0, 169.3, 169.2 [3x OCH2COO]; 159.5 [C-6]; 155.4 [C-2]; 
153.6 [C-4]; 136.2 [C-8]; 117.8 [C-5]; 87.6 [C-1’]; 81.2 [C-4’]; 73.1 [C-2’]; 71.7 [C-3’]; 70.7, 
70.2 [9x OCH2CH2O]; 68.5, 68.0 [3x OCH2COO]; 63.0 [C-5’]; 58.8 [3x OCH3].  
ESI-MS (positive ions): calcd. for C37H61N5O20 = 895.3910; found m/z = 896.2 [M + H
+
]; 
918.2 [M + Na
+
]; 934.2 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C37H61N5O20Na = 918.3808; 
found m/z: 918.3831 [M + Na
+
]. 
 
Synthesis of compound 14.  
4 (87 mg, 0.11 mmol) was dissolved in 0.50 mL of anhydrous CH2Cl2. To the solution DCC 
(68 mg, 0.33 mmol), DMAP (3 mg, 0.022 mmol) and CH3O(CH2CH2O)3CH2COOH 
[19] 
(73 mg, 
0.33 mmol) were sequentially added and stirred at room temperature for 1 h; then the 
solvent was removed under vacuum and the residue purified on a silica gel column 
(eluent: acetone/n-hexane 1:1, v/v). The desired product 14 was obtained in 80% isolated 
yield (105 mg, 0.088 mmol). 
14: oil, Rf = 0.8 [acetone/n-hexane, 2:3 (v/v)].  
1
H NMR (CDCl3, 200 MHz): δ 8.16 [s, 1H, H-8]; 7.67 - 7.31 [overlapped signals, 10H, TBDPS 
aromatic protons]; 6.30 [d, J = 6.8 Hz, 1H, H-1’]; 5.81 [apparent triplet, J = 5.2 and 6.6 Hz, 
1H, H-2’]; 5.70 [m, 1H, H-3’]; 4.25 - 4.22 [m, 1H, H-4’]; 4.14, 4.08 [singlets, 2H each, 2x 
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OCH2CO]; 3.89 [m, 2H, H-5’a and H-5’b]; 3.71 - 3.48 [overlapped signals, 24H, 6x 
OCH2CH2O]; 3.35, 3.33 [singlets, 3H each, 2x OCH3]; 1.69 [s, 9H, C(CH3)3]; 1.38 [s, 18H, 2x 
OCOC(CH3)3]; 1.09 [s, 9H, SiC(CH3)3].  
13
C NMR (CDCl3, 50 MHz): δ 169.3, 168.8 [2x OCH2COO]; 160.9 [C-6]; 152.3 [C-2]; 151.3 [C-
4]; 150.5 [2x OCOC(CH3)3]; 139.7 [C-8]; 135.5, 135.3, 132.2, 131.8, 130.0, 129.9 [TBDPS 
aromatic carbons]; 120.9 [C-5]; 84.1 [C-1’]; 84.0 [C-4’]; 83.3 [C(CH3)3]; 82.8 [2x 
OCOC(CH3)3]; 73.8 [C-2’]; 71.8, 71.2, 70.9, 70.8, 70.4 [C-3’, 6x OCH2CH2O]; 68.5, 68.0, 67.7 
[2x OCH2CO]; 63.2 [C-5’]; 58.8 [2x OCH3]; 33.8 [SiC(CH3)3]; 28.2 [C(CH3)3] 27.7 [2x 
OCOC(CH3)3]; 11.4 [SiC(CH3)3].  
ESI-MS (positive ions): calcd. for C58H87N5O19Si = 1185.5765; found m/z = 1186.28 [M + 
H
+
]; 1208.13 [M + Na
+
]; 1224.15 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C58H87N5O19SiNa 
= 1208.5662; found m/z: 1208.5688 [M + Na
+
]. 
 
Synthesis of compound 15.  
14 (100 mg, 0.080 mmol), dissolved in 0.30 mL of anhydrous THF, was reacted with 
Et3N٠3HF (260 μL, 1.6 mmol). The solution was stirred at room temperature for 18 h, 
then the solvent was removed under vacuum and the residue purified on a silica gel 
column (eluent: acetone/n-hexane 1:1, v/v). The desired product 15 was obtained in 56% 
isolated yield (47 mg, 0.045 mmol). 
15: oil, Rf = 0.2 [acetone/n-hexane, 3:2 (v/v)].  
1
H NMR (CDCl3, 200 MHz): δ 8.04 [s, 1H, H-8]; 6.07 [overlapped signals, 2H, H-1’ and H-2’]; 
5.73 [broad signal, 1H, H-3’]; 4.34 [broad signal, 1H, H-4’]; 4.23 [broad signal, 4H, 2x 
OCH2CO]; 4.06 [m, 2H, H-5’a and H-5’b]; 3.72 - 3.50 [overlapped signals, 24H, 6x 
OCH2CH2O]; 3.35, 3.33 [singlets, 3H each, 2x OCH3]; 1.69 [s, 9H, C(CH3)3]; 1.40 [s, 18H, 2x 
OCOC(CH3)3].  
13
C NMR (CDCl3, 50 MHz): δ 169.8, 168.8 [2x OCH2COO]; 161.7 [C-6]; 152.3 [C-2]; 151.3 [C-
4]; 150.7 [2x OCOC(CH3)3]; 142.6 [C-8]; 122.7 [C-5]; 88.1 [C-1’]; 86.0 [C-4’]; 84.9 [C(CH3)3]; 
83.5 [2x OCOC(CH3)3]; 73.8 [C-2’]; 73.0 [C-3’]; 72.1, 71.2, 70.7, 70.6 [6x OCH2CH2O]; 68.5, 
68.1 [2x OCH2COO]; 62.5 [C-5’]; 59.2 [2x OCH3]; 28.5 [C(CH3)3] 28.1 [2x OCOC(CH3)3].  
ESI-MS (positive ions): calcd. for C42H69N5O19 = 947.4587; found m/z =  948.07 [M + H
+
]; 
969.85 [M + Na
+
]; 985.94 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C42H69N5O19Na = 
970.4484; found m/z: 970.4509 [M + Na
+
]. 
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Synthesis of compound 16.  
15 (29 mg, 0.030 mmol) was dissolved in 0.80 mL of anhydrous CH2Cl2, then was added 
DCC (18 mg, 0.090 mmol), DMAP (0.4 mg, 0.0030 mmol) and myristic acid (10 mg, 0.045 
mmol). The solution was stirred for 2 h at room temperature, then the solvent was 
removed under vacuum and the residue purified on a silica gel column (eluent: 
acetone/n-hexane 1:1 v/v). The desired product 16 was obtained in quantitative yield (36 
mg, 0.030 mmol). 
16: oil, Rf = 0.8 [acetone/n-hexane, 6:4 (v/v)].  
1
H NMR (CDCl3, 200 MHz): δ 8.04 [s, 1H, H-8]; 6.16 [d, J = 4.8 Hz, 1H, H-1’]; 5.90 [apparent 
triplet, J = 5.2 and 4.8 Hz, 1H, H-2’]; 5.67 [apparent triplet, J = 5.2 and 4.8 Hz, 1H, H-3’]; 
4.45 - 4.38 [overlapped signals, 3H, H-4’, H-5’a and H-5’b]; 4.20, 4.14 [singlets, 2H each, 2x 
OCH2COO]; 3.70 - 3.51 [overlapped signals, 24H, 6x OCH2CH2O]; 3.36, 3.35 [singlets, 3H 
each, 2x OCH3]; 2.35 [t, J = 7.4 and 7.4 Hz, 2H, CH2COO-C5’]; 1.69 [broad signal, 9H, 
C(CH3)3]; 1.40 [s, 18H, 2x OCOC(CH3)3; 1.24 [broad signal, 22H, 11x CH2]; 0.86 [t, J = 6.6 
and 6.6 Hz, 3H, CH3].  
13
C NMR (CDCl3, 50 MHz): δ 172.9 [CH2COO-C5’]; 169.8, 168.8 [2x OCH2COO]; 161.0 [C-6]; 
152.3 [C-2]; 151.7 [C-4]; 150.5 [2x OCOC(CH3)3]; 140.4 [C-8]; 121.3 [C-5]; 86.2 [C-1’]; 84.1 
[C-4’]; 82.9 [C(CH3)3]; 80.1 [2x OCOC(CH3)3]; 73.4 [C-2’]; 71.8 [C-3’]; 70.9, 70.4 [6x 
OCH2CH2O]; 68.0, 67.8 [2x OCH2COO]; 62.8 [C-5’]; 58.8 [2x OCH3]; 48.9 [CH2COO-C5’]; 
33.8, 31.8, 29.5, 29.2, 28.9, 28.1, 27.7, 25.5, 24.8, 24.6, 22.5 [C(CH3)3; 2x OCOC(CH3)3; 11x 
CH2]; 13.9 [CH3].  
ESI-MS (positive ions); calcd. for C56H95N5O20 = 1157.6570; found m/z = 1158.38 [M + H
+
]; 
1180.30 [M + Na
+
]; 1196.28 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C56H95N5O20Na = 
1180.6468; found m/z: 1180.6490 [M + Na
+
]. 
 
Synthesis of compound G7.  
16 (31 mg, 0.027 mmol) was dissolved in 0.90 mL of anhydrous CH2Cl2 and 0.10 mL of TFA. 
The solution was stirred at room temperature for 2.5 h, the solvent removed under 
vacuum and coevaporated three times with i-PrOH. The desired product G7 was obtained 
in quantitative yield without further purification (24 mg, 0.027 mmol). 
G7: oil Rf = 0.2 [AcOEt/CH3OH, 8:2 (v/v)].  
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1
H NMR (CDCl3, 200 MHz): δ 8.04 [s, 1H, H-8]; 6.03 [d, J = 4.8 Hz, 1H, H-1’]; 5.90 [apparent 
triplet, J = 5.2 and 4.8 Hz, 1H, H-2’]; 5.67 [apparent triplet, J = 5.2 and 4.8 Hz, 1H, H-3’]; 
4.45 - 4.38 [overlapped signals, 3H, H-4’, H-5’a and H-5’b]; 4.20 - 4.14 [overlapped signals, 
4H, 2x OCH2CO]; 3.70 - 3.51 [overlapped signals, 24H, 6x OCH2CH2O]; 3.36, 3.35 [singlets, 
3H each, 2x OCH3]; 2.35 [t, J = 7.4 and 7.4 Hz, 2H, CH2COO-C5’]; 1.24 [broad signals, 22H, 
11x CH2]; 0.86 [t, J = 6.6 and 6.6 Hz, 3H, CH3].  
13
C NMR (CDCl3, 100 MHz): δ 173.4, 173.3 [2x OCH2COO]; 169.8 [CH2COO-C5’]; 161.5 [C-
6]; 156.7 [C-2]; 153.6 [C-4]; 140.8 [C-8]; 118.3 [C-5]; 88.8 [C-1’]; 84.1 [C-4’]; 73.4 [C-2’]; 
72.7 [C-3’]; 71.7, 70.7, 70.3 [6x OCH2CH2O]; 68.4, 68.1 [2x OCH2COO]; 62.8 [C-5’]; 58.8 [2x 
OCH3]; 49.1 [CH2COO-C5’]; 33.8, 31.8, 30.2, 29.5, 29.2, 25.5, 24.8, 22.5 [11x CH2]; 13.9 
[CH3].  
ESI-MS (positive ions): calcd. for C42H71N5O16 = 901.4896; found m/z = 901.92 [M + H
+
]; 
923.98 [M + Na
+
]; 939.94 [M + K
+
]. HRMS (MALDI-TOF): calcd. for C42H71N5O16Na = 
924.4794; found m/z: 924.4808 [M + Na
+
]. 
 
Synthesis of compound 17. 
15 (7.0 mg, 0.0075 mmol) was dissolved in 200 µL of anhydrous CH2Cl2. DCC (2.9 mg, 
0.014 mmol), DMAP (0.10 mg, 0.00070 mmol) and 5-doxyl-stearic acid (3.8 mg, 0.010 
mmol) were sequentially added to the solution, which was stirred at room temperature. 
After 3 h the solvent was removed under reduced pressure and the residue purified on a 
silica gel column, eluted with acetone/n-hexane (1:1, v/v). The desired product 17 was 
obtained in quantitative yields (10 mg, 0.0070 mmol). 
17: oil, Rf = 0.6 [acetone/n-hexane 6:4 (v/v)]. 
1
H NMR (CDCl3, 500 MHz): relevant signals at δ 8.06 [s, 1H, H-8]; 6.16 [d, J = 5.0 Hz, 1H, H-
1’]; 5.94 [dd, J = 5.0 and J = 5.5 Hz, 1H, H-2’]; 5.69 [bs, 1H, H-3’]; 4.44 - 4.39 [overlapped 
signals, 3H, H-4’, H-5’a and H-5’b]; 4.22 - 4.14 [overlapped signals, 4H, 2x -OCH2CO-]; 3.74 - 
3.64 [overlapped signals, 24H, 6x -OCH2CH2O-]; 3.54 [bs, 2H, -CH2 doxyl]; 3.38, 3.36 
[overlapped singlet, 6H, 2x -OCH3]; 2.40 – 2.35 [broad signals, 2H, CH2-α stearic acid]; 1.95 
- 1.84 [broad signals, 2H, CH2-β stearic acid]; 1.71 [s, 18H, 2x -OCOC(CH3)3]; 1.58 [s, 9H, -
C(CH3)3]; 1.48 - 1.23 [overlapped signals, 26H, 13x -CH2-]; 1.17 - 1.10 [overlapped signals, 
6H, 2x CH3 doxyl]; 0.87 [t, J = 6.5 and 6.5 Hz, 3H, -CH3]. 
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13
C NMR (CDCl3, 100 MHz): relevant signals  δ 168.9, 168.7 [3x -CO-]; 160.8 [C-6]; 151.5 
[C-2]; 151.0 [C-4]; 150.3 [2x -OCOC(CH3)3]; 121.3 [C-5]; 86.4 [C-1’]; 83.9 [C-4’]; 82.7 
[C(CH3)3]; 80.0 [2x -OCOC(CH3)3]; 73.6 [C-2’]; 71.7 [C-3’]; 71.1, 70.3 [6x -OCH2CH2O-]; 68.4, 
67.8 [2x -OCH2CO-, -CH2CO-]; 63.4 [C-5’]; 58.8 [2x -OCH3]; 48.8 [CH2COO-C5’]; 33.6, 31.6, 
30.3, 29.4, 29.0, 28.0, 27.8, 25.3, 24.6, 22.4 [14x -CH2-, -C(CH3)3, 2x -OCOC(CH3)3, 2x CH3 
doxile]; 13.8 [CH3]. 
ESI-MS (positive ions): calcd. for C64H109N6O22= 1313.7595; found m/z= 1314.40 [M + H
+
]; 
1336.44 [M + Na
+
]; 1352.34 [M + K
+
]. 
 
Synthesis of G8. 
17 (9.3 mg, 0.0070 mmol) was dissolved in 225 µL of anhydrous CH2Cl2 and 25 µL of TFA. 
The solution was stirred at room temperature for 2.5 h, the solvent removed under 
vacuum and coevaporated three times with i-PrOH. The desired product G8 was obtained 
as a pure compound, not requiring further purification, in quantitative yields (7.4 mg, 
0.0070 mmol). 
G8 : solid, Rf = 0.3 [AcOEt/CH3OH, 8:2 (v/v)]. 
1
H NMR (CDCl3, 500 MHz): relevant signals at δ 8.12 - 8.06 [broad signals, 1H, H-8]; 6.19 - 
6.07 [broad signals, 1H, H-1’]; 6.07 – 6.02 [dd, J = 4.5 and 5.0 Hz, 1H, H-2’]; 5.80 – 5.73 
[broad signals, 1H, H-3’]; 4.49 - 4.21 [broad signals, 5H, H-4’, H2-5’, 2x -OCH2CO-]; 3.75 - 
3.47 [overlapped signals, 26H, 6x -OCH2CH2O-, -CH2 doxyl]; 3.37, 3.34 [singlets, 6H, 2x -
OCH3]; 2.50 - 2.35 [broad signals, 2H, CH2-α stearic acid]; 1.86 - 1.67 [broad signals, 2H, 
CH2-β stearic acid]; 1.61 - 1.02 [overlapped signals, 34H, 14x CH2, 2x CH3 doxyl]; 0.96 - 
0.88 [broad signals, 3H, -CH3]. 
13
C NMR (CDCl3, 100 MHz): relevant signals at δ 174.9 [-CH2CO-]; 171.8, 171.6 [2x -
OCH2CO-]; 160.3 [C-6]; 140.3 [C-8]; 88.5 [C-1’]; 81.9 [C-4’]; 80.0, 79.9 [2x -OCOC(CH3)3]; 
75.0 [C-2’]; 73.4 [C-3’]; 72.5, 72.0 [6x -OCH2CH2O-]; 69.6 [2x -OCH2CO-]; 69.5 [-CH2CO-]; 
64.5 [C-5’]; 59.6 [2x -OCH3]; 44.0 [-OCH2- doxyl]; 35.2, 34.4, 33.6, 32.1, 31.2, 28.9, 25.4, 
24.2, 20.4 [14x -CH2-, -C(CH3)3, 2x -OCOC(CH3)3, 2x CH3 doxyl]; 14.9 [-CH3]. 
ESI-MS (positive ion): calcd. for C50H85N6O18= 1057.5920; found m/z= 1059.91 [M + H
+
]; 
1094.86 [M + K
+
]. 
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Chapter 6. 
 
On the Use of Boc as a Thymine Protecting Group  
for the Synthesis of Deoxyribose-Alkylated Thymidine 
Analogs 
 
 
1. Introduction 
 
Boc is a widely used protecting group, [1] first developed for the peptide synthesis 
and successively exploited in a wide range of synthetic organic chemistry elaborations. Its 
application in nucleoside or oligonucleotide chemistry and related mimics has been 
reported only in sporadic cases, as for the protection of exocyclic amino groups in 
cytidine, adenosine and guanosine derivatives [2] and the synthesis of modified PNA. [3] 
To the best of our knowledge, its use for masking the thymine base has been 
reported only by Moon et al., who exploited N-3 Boc-protected thymidine building blocks 
to obtain a 3’-deoxy, 3’-[18F]fluorinated thymidine analog in high radiochemical yield. [4] 
These researchers prepared the Boc-protected nucleoside by reaction with Boc anhydride 
in the presence of stoichiometric amounts of DMAP in THF, which required long reaction 
times (5 h) and led to the target compound in only 53% yields. 
More efficient procedures to protect thymine and uracil, useful to give synthetic 
access to a variety of sugar-modified thymidine and uridine analogs, have been explored 
by other research groups. Among others, benzyl (removable by catalytic hydrogenation)
A similar protocol was used 
by Yu et al. to protect uracil in the synthesis of 5-fluoro (FaraU) and (E)-5-(2-fluorovinyl) 
arabinosyl uridine (FVAU) via 5-trimethylstannyl and (E)-5-(2-tributylstannylvinyl) 
arabinosyl uridine analogs. [5] Also in this case, insertion of the Boc group was obtained 
in low overall yields (50 %), leading to a mixture of N- and O-derivatized nucleosides. 
 
[6], p-methoxybenzyl (removable by ceric ammonium nitrate treatment) [7] and p-
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nitrophenylethyl (removable by treatment with DBU in pyridine) [8] groups have been 
adopted to this purpose. 
In the context of studies on nucleoside analogs, a novel protection for the thymine 
base in nucleoside and oligonucleotide synthetic elaborations was recently developed in 
this laboratory, based on the 2-(phenylthio)ethyl group, inserted at the 3-N position by a 
Mitsunobu reaction with 2-(phenylthio)ethanol. [9] In an efficient “two-stage” system, 
after oxidation of the thioether to sulfone, this protecting group could be totally removed 
by a β-elimination mechanism using 0.1 M NaOH aq. solution. The use of 2-
(phenylthio)ethyl, stable to strongly basic conditions, allowed to selectively achieve O-
alkylation of the ribose moieties in satisfactory yields, [10] and thus to efficiently obtain 
the anti-HIV active Hotoda’s  5’TGGGAG3’ sequence, [11] alkylated at the 5’-OH of the 
thymidine unit with the 3,4-dibenzyloxybenzyl group. 
Aiming at expanding the repertoire of available sugar-alkylated thymidine analogs, 
of interest as potential thymidine kinase inhibitors [12] and functional building blocks for 
the synthesis of sugar-modified oligonucleotides, we were intrigued by fast and simple 
synthetic methods to prepare easy-to-handle nucleoside scaffolds. Following the 
renovated interest in Boc protection, stimulated by the discovery of novel, very mild 
procedures for its removal, [13] we decided to re-investigate its applicability as a thymine 
protecting group in nucleoside analogs chemistry. 
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2. Use of Boc as a thymine protecting group in nucleoside 
chemistry 
 
As model compounds for this study we chose 5’-O-DMT, 3’-O-acetyl-thymidine (1, 
Scheme 1) and 5’-O-TBDMS, 3’-O-acetyl-thymidine (4, Scheme 2), which allowed us to 
explore the compatibility of Boc with the most commonly used protecting groups in 
nucleoside manipulations, i.e. the acid-labile 4,4’-dimethoxytriphenylmethyl (DMT), the 
fluoride-labile tert-butyl dimethylsilyl (TBDMS) and the base-labile acetyl (Ac) group. 
Insertion of the Boc group was first optimized on 1, testing a very simple 
procedure, involving the use of 2 equiv of Boc anhydride in the presence of TEA (3 equiv) 
and catalytic amounts of DMAP in different solvents. [14] At this stage the solvent was 
found to dramatically affect the course of the reaction. When the above mentioned 
reagents were dissolved in dioxane or acetonitrile, no transformation occurred, even 
forcing the system conditions; in fact, no benefit could be obtained by prolonging the 
reaction times, or using high temperatures, or adding to the mixtures bases stronger than 
TEA, as DIPEA. On the contrary, in a large variety of other solvents, the Boc protection 
was always complete in 1 h at r.t., with very good-to-excellent yields (see Table 1). [15] In 
the latter cases, target compound 2 was isolated as a stable compound after a simple 
work-up, in yields always higher than 90%. 
O
OAc
N
NH
O
O
O
OAc
DMTO
N
N
O
O
O
O
O
OAc
HO
N
N
O
O
O
O
Boc2O, TEA, 
DMAP, r.t.
ZnBr2, DCM 
1.5 h, r.t.
1 2
3a
O
OAc
HO
N
NH
O
O
3b
DMTO
 
Table 1. Yields of insertion of Boc group on 1 
as a function of the used solvent 
Solvent Yields 
Acetonitrile 0% 
Benzene 92% 
1,2-Dichloroethane 92% 
Dichloromethane 92% 
Diethyl ether 90% 
N,N-Dimethylformamide 90% 
1,4-Dioxane 0% 
Pyridine 99% 
Scheme 1. Synthesis of Boc-protected 5’-O-DMT-thymidine 
derivative 2 and conversion into its detritylated analog 3a. 
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The best conditions for the Boc installation on 1 were then extended to 5’-O-TBDMS, 
3’-O-acetyl-thymidine 4. This nucleoside, dissolved in pyridine, was therefore reacted 
with Boc anhydride (2 equiv) and TEA (3 equiv) in the presence of 0.5 equiv of DMAP, 
leading to the target compound 5 in almost quantitative yields. 
1H and 13C NMR spectra of 2 and 5 clearly indicated that the Boc group was selectively 
inserted on the 3-N position. In fact, no signal attributable to the N-H group could be 
found in the 1H NMR spectra of these nucleosides dissolved in DMSO-d6; in parallel, the 
13C NMR spectra of both these compounds showed a unique signal at ca. 148 ppm, clearly 
attributable to the sp2 carbon of the Boc carbonyl linked to a nitrogen atom, with the 
concomitant absence of signals at ca. 155 ppm, expected in case of its attachment to an 
oxygen atom. In contrast with previous findings, [5] we never observed migration of the 
Boc group from the N-3 to the O-4 or O-2 position, both in this and all the successive 
manipulations. In addition, no transposition of carbamates to the corresponding O-tert-
butyl derivatives [2b] was observed, as confirmed by MS analysis of the reaction crudes 
and of the isolated reaction products. 
With the two Boc-protected thymidine derivatives in hand, we searched, as a first goal, 
for efficient conditions allowing the selective removal of the DMT group from 2. Having a 
priori discarded the use of even diluted, weak protic acids - not able to guarantee the 
requested selectivity between the two acid-labile protecting groups Boc and DMT - 
anhydrous Lewis acids, and particularly ZnBr2 [16] and CuSO4
 [17] were investigated in a 
variety of reaction systems. The use of the latter reagent always caused partial cleavage 
of the Boc group. On the contrary, satisfactory results were obtained with anhydrous 
ZnBr2, which led to 3a in 83% yields. The isolation of only traces of 3b from the reaction 
mixture essentially confirmed that this treatment did not markedly affect the Boc group. 
The best conditions for the preparation of 3a involved the use of 2 equiv of ZnBr2 in 
anhydrous CH2Cl2, taking the reaction mixture under stirring at r.t. for 1.5 h. Prolonging 
the reaction times, even using a lower excess of the Lewis acid, was detrimental for the 
success of the reaction, causing also partial Boc removal; similar results were obtained 
when anhydrous CH3OH was used in lieu of CH2Cl2 as the solvent (see Table 2). 
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Table 2. Conditions tested for the DMT removal from nucleoside 2 and relative yields 
equiv. ZnBr Solvent 2 Reaction Time (h) Isolated yield (%) 
3a 3b 
2.5 DCM 1.5 80 10 
3.0 DCM 2.5 60 32 
1.5 DCM 2.5 60 32 
2.5 CHa 3 1.25 OH 55
 0 
a ZnBr2
 
Removal of TBDMS from 5 was carried out first by treatment with standard 1 M 
TBAF solution in THF, which, quite unexpectedly, was found to partially cleave the Boc 
group. On the contrary, full selectivity was obtained with the milder desilylating reagent 
Et
 was added as a saturated methanolic solution 
3
O
OAc
TBDMSO
N
NH
O
O
O
OAc
TBDMSO
N
N
O
O
O
O
O
OAc
HO
N
N
O
O
O
O
Boc2O, TEA, 
DMAP, rt
Et3N  HF, 
THF, rt
4 5
3a
N∙3HF, [18] which gave the desired Boc-protected nucleoside 3a in quantitative yields. 
 
 
Scheme 2. Synthesis of Boc-protected 5’-O-TBDMS-thymidine derivative 5 and its conversion into 3a. 
 
In order to prepare 3’-O-alkylated thymidine analogs, the acetyl group at the 3’-
OH group had to be removed first. For this step, a standard treatment with conc. aq. 
ammonia was tested on 2, which after 2.5 h at r.t. fully converted the starting material 
into desired 6. A model reaction for the 3’-OH alkylation was carried out first by reacting 6 
with benzyl bromide and NaH (1.2 equiv each) in DMF, giving the target adduct 7 in 85% 
isolated yields. Then, the alkylation reaction on 6 was carried out with methyl 
chloroacetate. Due to the lower reactivity of alkyl chlorides with respect to bromides, a 
higher excess of the alkylating agent and the base (2.5 equiv) was here required for the 
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reaction to go to completion, which after chromatography gave methyl ester 8 in 82% 
yields. Hydrolysis with 1 M NaOH (30 min, r.t.) led to target 3’-O-carboxymethyl derivative 
9, sodium salt, obtained in 82% yields as a pure compound by TLC and NMR after a simple 
extraction (66% overall yields for 4 steps starting from 1). This thymidine analog, as a 
convenient precursor of 3’-O-carboxymethyl-thymidine, [19] is of interest as a versatile 
building block for backbone-modified oligonucleotides; for example it can be attached at 
the NH2
O
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9 R = O-Na+
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THF, rt
-end of a PNA chain in the synthesis of DNA-PNA chimera. [20] 
 
 
Scheme 3. Synthesis of 3’-O-alkylated thymidine analogs 7, 8 and 9. 
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3. Conclusions  
 
In this study we have described the use of Boc to conveniently protect thymine for 
a simple and general synthetic access to a large variety of sugar-alkylated thymidine 
analogs. Conditions for its quantitative installation on sugar-protected thymidine 
derivatives were found, as well as for the selective removal of commonly used protecting 
groups as DMTr, TBDMS and acetyl group on Boc-protected nucleosides. These high-
yielding procedures in principle allow to easily obtain useful and versatile nucleoside 
building blocks of use in a variety of base-promoted sugar modifications. To demonstrate 
the feasibility of this approach, two sugar-alkylated thymidine analogs, 5 and 7, have 
been synthesized and characterized. The use of 9 as a useful monomer linker to be 
attached at the NH2-end of a PNA chain in the synthesis of DNA-PNA chimera is currently 
underway in our laboratory. 
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4. Experimental section 
 
Materials and Methods. 
TLC analyses were carried out on silica gel plates from Merck (60, F254). Reaction 
products on TLC plates were visualized by UV light and then by treatment with a 10 % 
Ce(SO4)2/H2SO4 aqueous solution. For column chromatography, silica gel from Merck 
(Kieselgel 40, 0.063-0.200 mm) was used. For the ESI MS analyses a Waters Micromass ZQ 
instrument – equipped with an Electrospray source – was used in the positive and/or 
negative mode. NMR spectra were recorded on Bruker WM-400 or Varian XR-200 
spectrometers. All the chemical shifts are expressed in ppm with respect to the residual 
solvent signal; J values are given in Hz. The following abbreviations were used to explain 
the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; b = broad; 
dd = double doublet. Peak assignments have been carried out on the basis of standard 1H-
1H COSY and HSQC experiments. 
 
General procedure for the insertion of Boc on 1: synthesis of 2. 
5’-O-DMT-3’-O-acetyl-thymidine 1 (53 mg, 0.090 mmol), dissolved in the appropriate 
solvent, was reacted with Boc anhydride (40 mg, 0.18 mmol), TEA (38 µL, 0.27 mmol) and 
DMAP (5.5 mg, 0.045 mmol). After 1 h under stirring at r.t., the solvent was removed 
under reduced pressure and the residue was purified on a silica gel column (eluent: n-
hexane/AcOEt 7:3, v/v). The yields obtained for each reaction are shown in Table 1 in the 
main text. 
2. foam. Rf = 0.6 (n-hexane/AcOEt 1:1, v/v). 
1H NMR (CDCl3, 200 MHz): δ 7.55 (d, J = 1.2 Hz, 1H, H-6); 7.44-6.84 (overlapped signals, 
13H, aromatic protons of DMT), 6.40 (dd, J = 7.4 and 6.0 Hz, 1H, H-1’); 4.61 (m, 1H, H-3’); 
4.08 (m, 1H, H-4’); 3.82 (s, 9H, 2 x –OCH3), 3.10 (ABX system, J = 2.8 and 10.4 Hz, 2H, H-5’a 
and H-5’b); 2.42 (m, 2H, H-2’a and H-2’b); 2.10 (s, 3H, CH3 acetyl); 1.63 [s, 9H, -C(CH3)3]; 
1.45 (d, J = 1.0 Hz, 3H, -CH3 Thy). 
13C NMR (CDCl3, 50 MHz): δ 161.1 (C-4); 158.7, 144.2, 135.0, 130.0, 128.1, 128.0, 127.1, 
113.2 (aromatic carbons of DMT), 148.5 (C-2); 148.0 (CO carbamate); 135.3 (C-6); 110.9 
(C-5); 86.9 (quaternary carbon of DMT); 86.6 [-C(CH3)3]; 86.2 (C-1’); 85.0 (C-4’); 72.1 (C-
3’); 63.4 (C-5’); 55.2 (-OCH3); 41.1 (C-2’); 27.4 [-C(CH3)3]; 21.0 (COCH3); 11.7 (-CH3 Thy). 
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ESI-MS (positive ions): for C38H42N2O10, calculated 686.28; found m/z: 686.09 [M+H
+]. 
 
Procedure for the removal of the DMT group from 5’-O-DMT-3’-O-acetyl-3-N-Boc-
thymidine: synthesis of 3a. 
5’-O-DMT-3’-O-acetyl-3-N-Boc-thymidine 2 (30 mg, 0.044 mmol) was dissolved in 1 mL of 
anhydrous DCM, then dry ZnBr2 (25 mg, 0.110 mmol) was added. The mixture was stirred 
at rt for 1.5 h, then the reaction was quenched by addition of few drops of MeOH. The 
crude, diluted with DCM, was washed twice with H2O; the organic phase was dried over 
anhydrous Na2SO4, concentrated under reduced pressure and purified on a silica gel 
column (eluent: n-hexane/AcOEt 2:3, v/v). Products 3a and 3b were isolated in 80 and 10 
% isolated yield, respectively. 
Other reaction conditions were tested (see Table 2), but lower yields were always 
observed. 
3a oil. Rf = 0.4 (n-hexane/AcOEt 3:7, v/v). 
1H NMR (CDCl3, 200 MHz): δ 7.55 (d, J = 1.2 Hz, 1H, H-6); 6.25 (dd, J = 7.4 and 6.8 Hz, 1H, 
H-1’); 5.33 (m, 1H, H-3’); 4.10 (m, 1H, H-4’); 3.92 (m, 2H, H-5’a and H-5’b); 2.39 (m, 2H, H-
2’a and H-2’b); 2.09 (s, 3H, CH3 acetyl); 1.93 (d, J = 1.4 Hz, 3H, -CH3 Thy); 1.60 [s, 9-H, -
C(CH3)3]. 
13C NMR (CDCl3, 100 MHz): δ 170.6 (C=O); 161.1 (C-4); 148.5 (C-2); 147.7 (C carbamate); 
135.3 (C-6); 110.9 (C-5); 86.7 [-C(CH3)3]; 86.0 (C-1’); 85.0 (C-4’); 74.5 (C-3’); 62.4 (C-5’); 
37.3 (C-2’); 27.3 [-C(CH3)3]; 20.8 (COCH3); 12.5 (-CH3 Thy). 
ESI-MS (positive ions): for C17H24N2O8, calculated 384.15; found m/z: 407.1 [M+Na
+]; 
423.0 [M+K+]; 791.2 [2xM+Na+
5’-O-DMT-3’-O-acetyl-3-N-Boc-thymidine 2 (61 mg, 0.089 mmol) was dissolved in 800 µL 
of CH
]. 
3b was identified by TLC and NMR comparison with an authentic sample. 
 
Procedure for the removal of the acetyl group from 5’-O-DMT-3’-O-acetyl-3-N-Boc-
thymidine: synthesis of 4. 
3OH and 200 µL of a NH4OH solution (29.1 % p.p.) were added to the solution. After 
stirring for 2.5 h at r.t., the reaction mixture was concentrated under reduced pressure. 
The crude was then washed with DCM/H2O; the organic phase was dried over anhydrous 
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Na2SO4 and concentrated under reduced pressure. The desired product 4 was obtained in 
almost quantitative yields without any observable side reaction. 
4. oil. Rf = 0.4 (n-hexane/AcOEt 1:1, v/v). 
1H NMR (CDCl3, 200 MHz): δ 7.55 (d, J = 1.2 Hz, 1H, H-6); 7.44-6.84 (overlapped signals, 
13H, aromatic protons of DMT ), 6.40 (dd, J = 7.4 and 6.0 Hz, 1H, H-1’); 4.61 (m, 1H, H-3’); 
4.08 (m, 1H, H-4’); 3.82 (s, 9H, 2 x –OCH3), 3.10 (ABX system, J = 2.8 and 10.4 Hz, 2H, H-5’a 
and H-5’b); 2.42 (m, 2H, H-2’a and H-2’b); 1.63 [s, 9-H, -C(CH3)3]; 1.45 (d, J = 1.0 Hz, 3H, -
CH3 Thy). 
13C NMR (CDCl3, 50 MHz): δ 161.1 (C-4); 158.7, 144.2, 135.0, 130.0, 128.1, 128.0, 127.1, 
113.2 (aromatic carbons of DMT), 148.5 (C-2); 148.0 (C carbamate); 135.3 (C-6); 110.9 (C-
5); 86.9 (quaternary carbon of DMT); 86.65 [-C(CH3)3]; 86.2 (C-1’); 85.0 (C-4’); 72.1 (C-3’); 
63.4 (C-5’); 55.2 (-OCH3); 41.1 (C-2’); 27.4 [-C(CH3)3]; 11.7 (-CH3 Thy). 
ESI-MS (positive ions): for C36H40N2O9, calculated 644.27; found m/z: 644.97 [M+H
+]; 
666.94 [M+Na+]; 672.95 [M+K+
5’-O-DMT-3-N-Boc-thymidine 4 (50 mg, 0.078 mmol) was dissolved in 400 µL of 
anhydrous DMF and cooled at 0 °C. After 5 min BnBr (11 µL, 0.094 mmol) and NaH (60% 
p.p., 4.0 mg, 0.094 mmol) were added in the order. The mixture was stirred at r.t. for 4 h, 
then a few drops of CH3OH were added at 0 °C to quench the reaction. The suspension 
was concentrated under reduced pressure and the crude was then washed with 
DCM/H2O; the organic phase was dried over anhydrous Na2SO4, concentrated under 
reduced pressure and purified on a silica gel column (eluent: n-hexane/AcOEt 2:3, v/v). 
The desired product 5 was obtained in 85% isolated yield (49 mg, 0.066 mmol). 
]. 
 
Procedure for synthesis of  5’-O-DMT-3’-O-benzyl-3-N-Boc-thymidine (5). 
5. oil. Rf = 0.8 (n-hexane/AcOEt 1:1, v/v). 
1H NMR (CDCl3, 200 MHz): δ 7.63 (d, J = 1.2 Hz, 1H, H-6); 7.36-6.79 (overlapped signals, 
18H, aromatic protons of DMT and Bn), 6.34 (dd, J = 7.6 and 5.8 Hz, 1H, H-1’); 4.58-4.40 
(AB system, J= 11.8 Hz, 2H, -OCH2Bn); 4.32 (m, 1H, H-3’); 4.18 (m, 1H, H-4’); 3.79 (s, 9H, 2 
x –OCH3), 3.30 (ABX system, J = 2.9 and 10.6 Hz, 2H, H-5’a and H-5’b); 2.61-2.17 (m, 2H, H-
2’a and H-2’b); 1.61 [s, 9-H, -C(CH3)3]; 1.42 (d, J = 1.0 Hz, 3H, -CH3 Thy). 
13C NMR (CDCl3, 50 MHz): δ 161.3 (C-4); 158.7, 144.2, 137.3, 130.0, 128.1, 128.5, 128.1, 
127.9, 127.6, 127.1, 113.2 (aromatic carbons of DMT and Bn), 148.5 (C-2); 148.0 (C 
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carbamate); 135.3 (C-6); 110.9 (C-5); 86.9 (quaternary carbon of DMT); 86.2 (C-1’); 85.2 [(-
C(CH3)3)]; 84.2 (C-4’); 78.3 (CH2Ph), 71.3 (C-3’); 63.4 (C-5’); 55.2 (-OCH3); 46.2 (C-2’); 27.4 
(-C(CH3)3); 11.4 (-CH3). 
ESI-MS (positive ions): for C43H46N2O9, calculated 734.32; found m/z: 735.91 [M+H
+]; 
756.77 [M+Na+]; 772.67 [M+K+]. 
 
General procedure for the insertion of Boc on 8: synthesis of 9. 
5’-O-TBDMS-3’-O-acetyl-thymidine 8 (53 mg, 0.090 mmol) was dissolved in 1 mL of dry 
pyridine, then Boc-anhydride (40 mg, 0.180 mmol), TEA (38 µl, 0.270 mmol) and DMAP 
(5.5 mg, 0.045 mmol) were added in the order. The mixture was stirred at r.t. for 1 h, the 
solvent was removed under reduced pressure and the residue was purified on a silica gel 
column (n-hexane/AcOEt 7:3, v/v). The desired compound 9 was obtained in 98% isolated 
yield (60 mg, 0.088 mmol). 
9. oil. Rf = 0.8 (n-hexane/AcOEt 4:6, v/v). 
1H NMR (CDCl3, 200 MHz): δ 7.54 (d, J = 1.2 Hz, 1H, H-6); 6.33 (dd, J = 5.2, 1H, H-1’); 5.23 
(m, 1H, H-3’); 4.10 (m, 1H, H-4’); 3.90 (m, 2H, H-5’a and H-5’b); 2.42 (m, 2H, H-2’a and H-
2’b); 2.08 (s, 3H, CH3 acetyl); 1.93 (d, J = 1.2 Hz, 3H, -CH3); 1.61 [s, 9-H, -C(CH3)3]; 0.92 [s, 
9H, -SiC(CH3)3]; 0.13 [s, 6H, -Si(CH3)2]. 
13C NMR (CDCl3, 100 MHz): δ 170.6 (C=O); 161.2 (C-4); 148.5 (C-2); 147.9 (C carbamate); 
134.3 (C-6); 110.9 (C-5); 86.7 [-C(CH3)3]; 85.4 (C-1’); 85.0 (C-4’); 75.3 (C-3’); 63.5 (C-5’); 
37.3 (C-2’); 27.3 [-C(CH3)3]; 25.9 [-SiC(CH3)3]; 20.9 (CH3 acetyl); 18.3 [-SiC(CH3)3]; 12.5 (-CH3 
Thy); -5.6 [-Si(CH3)2].  
ESI-MS (positive ions): for C23H38N2O8Si, calculated 498.23; found m/z: 499.14 [M+H
+]; 
520.92 [M+Na+]; 536.82 [M+K+
5’-O-TBDMS-3’-O-acetyl-3-N-Boc-thymidine 9 (20 mg, 0.040 mmol), dissolved in 200 µL of 
anhydrous THF, was reacted with triethylamine trihydrofluoride (20 µL, 0.120 mmol). The 
reaction mixture was stirred at r.t. for 1 h, then the solution, diluted with DCM, was 
washed twice with H2O; the organic phase was dried over anhydrous Na2SO4, 
concentrated under reduced pressure and purified on a silica gel column (eluent: n-
]. 
 
Procedure for the removal of TBDMS group from 5’-O-TBDMS-3’-O-acetyl-3-N-Boc-
thymidine (9). 
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hexane/AcOEt 2:3, v/v). The desired product was obtained in quantitative yield, and 
proved to be identical to nucleoside 3a, isolated from the detritylation of 2. 
 
Procedure for synthesis of  5’-O-DMT-3’-O-methoxycarbonylmethyl-3-N-Boc-thymidine 
(6). 
5’-O-DMT-3-N-Boc-thymidine 4 (40 mg, 0.062 mmol) was dissolved in 0.5 mL of dry DMF, 
then methyl chloroacetate (14 µL, 0.15 mmol) and NaH (60% p.p., 8.0 mg, 0.19 mmol) 
were added. The reaction mixture was stirred at r.t. for 24 h, then a few drops of CH3OH 
were added at 0 °C to quench the reaction. The suspension was taken to dryness, then 
the crude was redissolved in DCM and washed twice with H2O; the organic phase was 
dried over anhydrous Na2SO4, concentrated under reduced pressure and purified on a 
silica gel column (eluent: n-hexane/AcOEt 3:7, v/v). The desired ester 6 was obtained in 
80% isolated yield (36 mg, 0.050 mmol). 
6. oil. Rf = 0.5 (n-hexane/AcOEt 1:1, v/v). 
1H NMR (CDCl3, 200 MHz): δ 7.63 (s, H-6); 7.44-6.84 (overlapped signals, 13H, aromatic 
protons of DMT), 6.33 (dd, J = 5.6 and 6.0 Hz, 1H, H-1’); 4.33-4.10 (overlapped signals, 4H, 
H-3’, H-4’, and CH2COOCH3); 3.81 (s, 9H, 2 x –OCH3), 3.75 (s, 3H, COOCH3); 3.41 (ABX 
system, J = 2.8 and 10.4 Hz, 2H, H-5’a and H-5’b); 2.58-2.26 (m, 2H, H-2’a and H-2’b); 1.61 
[s, 9-H, -C(CH3)3]; 1.44 (s, 3H, -CH3 Thy). 
13C NMR (CDCl3, 50 MHz): δ 170.7 (C=O); 161.1 (C-4); 158.7, 144.2, 135.0, 130.0, 128.1, 
128.0, 127.1, 113.2 (aromatic carbons of DMT), 148.5 (C-2); 147.3 (C carbamate); 135.3 
(C-6); 110.6 (C-5); 86.8 (quaternary carbon of DMT); 84.9 [-C(CH3)3]; 84.2 (C-1’); 80.2 (C-
4’); 79.2 (C-3’); 63.4 (C-5’); 55.2 (-OCH3); 37.1 (C-2’); 27.4 [-C(CH3)3]; 12.6 (-COOCH3); 11.8 
(-CH3 Thy). 
ESI-MS (positive ions): for C39H44N2O11, calculated 716,29; found m/z: 716.94 [M+H
+]; 
738.73 [M+Na+]; 754.75 [M+K+
5’-O-DMT-3’-O-methoxycarbonylmethyl-3-N-Boc-thymidine 6 (12 mg, 0.017 mmol) was 
dissolved in 100 µL of dry THF, then NaOH (0.7 mg, 0.019 mmol) in 20 µL of water was 
added. The reaction was kept under stirring at r.t. for 30 min, then the mixture was taken 
]. 
 
Procedure for the synthesis of 5’-O-DMT-3’-O-carboxymethyl-3-N-Boc-thymidine, 
sodium salt (7). 
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to dryness, redissolved in DCM and washed twice with H2O; the organic phase was dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The desired salt 7 was 
obtained in 80% isolated yield (10 mg, 0.014 mmol). 
7. oil. Rf = 0.1 (AcOEt). 
1H NMR (CDCl3, 400 MHz): δ 7.61 (s, 1H, H-6); 7.31- 6.77 (overlapped signals, 13H, 
aromatic protons of DMT); 6.34 (broad signal, 1H, H-1’); 4.17 (overlapped signals, 2H, H-3’ 
and H-4’); 3.79 (s, 2H, CH2CO); 3.73 (s, 6H, 2 x OCH3); 3.30 (m, 2H, H-5a’ and H-5b’); 2.55 – 
2.14 (m, 2H, H-2a’ and H-2b’); 1.49 [(s, 9H, -C(CH3)3)]; 1.25 (s, 3H, -CH3 Thy).  
13C NMR (CDCl3, 50 MHz): δ 175.6 (C=O); 161.1 (C-4); 158.7, 144.0, 129.9, 127.9, 127.0, 
113.2 (aromatic carbons of DMT), 148.6 (C-2); 147.8 (C carbamate); 135.3 (C-6); 111.1 (C-
5); 86.9 (quaternary carbon of DMT); 86.5 [-C(CH3)3]; 85.2 (C-1’); 83.9 (C-4’); 80.9 (C-3’); 
63.8 (C-5’); 55.1 (-OCH3); 37.3 (C-2’); 27.2 [-C(CH3)3]; 11.5 (-CH3 Thy). 
ESI-MS (negative ions): for C38H41N2O11
-, calculated 701.27; found m/z: 700.88 [M-]. 
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Summary 
 
My PhD thesis has been focused on the synthesis and characterization of a 
number of novel amphiphilic nucleolipids.  
In a first part of my work, preliminary to all the successive investigations, novel 
thymidine- or uridine-based nucleolipids, containing one hydrophilic oligo(ethylene 
glycol) chain and one or two oleic acid residues (called ToThy, HoThy, DoHu and 
ToThyChol), have been synthesized with the aim to develop biocompatible nanocarriers 
for drug delivery and/or produce pro-drugs. Studies of microstructural characterization of 
the corresponding aggregates have been carried out in pure water and in pseudo-
physiological conditions through DLS and SANS experiments. For ToThy, HoThy and DoHu 
stable vesicles, with mean hydrodynamic radii ranging between 120 nm and 250 nm have 
been revealed. In the case of ToThyChol, stable micelles were observed under the same 
experimental conditions, with mean hydrodynamic radii of 100 nm. Biological validation 
of the nucleolipidic nanocarriers was ensured by evaluation of their toxicological profiles, 
performed by administration of the nanoaggregates to a panel of different cell lines. 
ToThy exhibited a weak cytotoxicity and, at high concentration, some ability to interfere 
with cell viability and/or proliferation. In contrast, DoHu, HoThy and ToThyChol exhibited 
no toxicological relevance, behaving similarly to POPC-based liposomes, widely used for 
systemic drug delivery. Taken together, these results show that the here synthesized 
nucleolipid-based nanocarriers are finely tunable, self-assembling materials, potentially 
suitable for the in vivo transport of biomolecules or drugs.  
In a successive study, these nucleosidic nanovectors have been exploited as 
multifunctional ligands to obtain the corresponding ruthenium(III) salts, of interest as 
potential anticancer drugs. The obtained amphiphilic nucleosidic complexes were then 
studied in their self-aggregation properties by DLS and SANS techniques in aqueous 
solutions and in pseudo-physiological conditions. In analogy with the behaviour reported 
in the literature for the known Ru(III) complexes, the studied complexes ToThyRu, 
HoThyRu, DoHuRu and ToThyCholRu showed a limited stability in aqueous solutions, 
producing in few hours green precipitates. Therefore we studied how to achieve the 
complete stabilization in physiological media of these compounds. This goal was 
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accomplished by use of the nucleosidic Ru(III) complexes in formulation with POPC in 
molar ratio 15:85. Under these conditions, the complexes were completely stable in 
pseudo-physiological solutions for several weeks. A complete and comprehensive study 
on the in vitro bioactivity was performed on the synthesized complexes in POPC 
formulation, particularly examining their growth inhibition ability on MCF-7 and WiDr cell 
lines. Most remarkably, very promising results were observed on ToThyRu/POPC and 
HoThyRu/POPC formulations, showing IC50 values of 9 and 15 µM, respectively, on MCF-7 
cell lines. In vitro bioscreening studies on other cancer cell lines are currently in progress, 
with the peculiar aim to evaluate specificity effects. 
To investigate the in vivo mechanism of action of the synthesized compounds, a 
novel amphiphilic nucleosidic Ru(III)-complex, bearing the fluorescent dansyl group, was 
designed and synthesized, essentially built around the same basic skeleton present in 
HoThyRu, for applications in fluorescence microscopy.  
In a successive work, I have then investigated a novel design for the amphiphilic 
nucleosidic complexes starting from a highly functionalized uridine-based nucleolipid. In 
this optimized scaffold, the pyridine ligand for the metal complexation was attached on 
the sugar skeleton, in lieu of the N-3 position on the nucleobase, as in the case of 
ToThyRu, HoThyRu, DoHuRu and ToThyCholRu complexes.  
A modified nucleoside, 3-azido-3-deoxy-1-β-D-xylofuranosyluracil - here prepared 
following a new, simple and very convenient synthetic procedure - was also here 
exploited as a suitable key intermediate to obtain a cationic aminoacylnucleolipid, of 
interest per se, as a model compound of a valuable class of novel biocompatible, highly 
functionalized nucleolipids, and to be used in mixture with the naturally negatively 
charged ruthenium(III) complexes, thus producing catanionic vesicles.  
 In the frame of the design, synthesis and characterization of novel nucleolipids, a 
relevant part of my efforts have been then addressed to the study of guanosine-
containing amphiphiles, almost unexplored compounds of interest in the development of 
For all the latter compounds, including the nucleolipid-ruthenium(III) complexes 
and the cationic aminoacynucleolipid, a detailed microstructural characterization as well 
as biological activity assays are currently underway, in collaboration with specialized 
laboratories, and the related results will be presented in due course. 
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smart, novel self-assembling materials as well as for their potential biological activity. A 
small library of sugar-modified guanosine derivatives has been prepared, starting from a 
common intermediate, fully protected on the nucleobase. Insertion of myristoyl chains 
and of diverse hydrophilic groups, such as an oligoethylene glycol, an amino acid or a 
disaccharide chain, connected through in vivo reversible ester linkages, or of a charged 
functional group provided different examples of amphiphilic guanosine analogs, named 
G1-G7 herein. All of the sugar-modified derivatives were positive in the potassium picrate 
test, showing a marked ability to form G-tetrads. CD spectra demonstrated that, as dilute 
solutions in CHCl3, distinctive G-quadruplex systems may be formed, with spatial 
organisations dependent upon the structural modifications. Two compounds, G1 and G2, 
proved to be good low-molecular-weight organogelators in polar organic solvents, such as 
methanol, ethanol and acetonitrile. Ion transportation experiments through phospholipid 
bilayers were carried out to evaluate their ability to mediate H+ transportation, with G5 
showing the highest activity within the investigated series. Moreover, G3 and G5 
exhibited a significant cytotoxic profile against human MCF-7 cancer cells in in vitro 
bioassays with IC50 values in the 20 µM range, while no cytotoxic activity was observed on 
normal, control cells. 
Finally, to expand the knowledge about the available protective groups for 
nucleosides, the use of Boc as a thymine protecting group in the synthesis of sugar-
alkylated (or, more generally, sugar-modified) thymidine analogs was here described. Boc 
was easily inserted at the 3-N position in high yields and found to be stable to standard 
treatments for the removal of acetyl and TBDMS groups, as well as to ZnBr2
From the full comprehension of the structure-activity relationships of the here 
described compounds, a relevant contribution to the knowledge of nucleolipid 
ruthenium(III)-complexes, as promising anticancer agents, and more generally of novel 
-mediated 
DMTr deprotection. Boc protection proved to be completely resistant to the strong basic 
conditions required to selectively achieve 3’-O-alkylation. This acid-labile group, 
unprecedentedly used for the masking of pyrimidine nucleobases, was then here 
exploited to allow the synthesis of 3-azido-3-deoxy-1-β-D-xylofuranosyluracil in six, high 
yielding steps from uridine, previously mentioned as a valuable starting material for the 
synthesis of  novel, highly functionalized nucleolipids. 
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nucleoside-based amphiphiles as attractive, bioinspired building blocks of use in the 
production of innovative, smart materials for biomedical applications is expected. 
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List of Abbreviations 
 
The following abbreviations were used throughout the text:  
 
Ac = acetyl 
AcOEt = ethyl acetate  
Bn = benzyl 
Boc = tert-butoxycarbonyl  
Boc2O = Di-tert-butyl dicarbonate 
DCC = dicyclohexylcarbodiimide 
DIAD = diisopropylazodicarboxylate  
DMAP = 4-(N,N-dimethylamino)pyridine  
DMF = N,N-dimethylformamide 
DMSO = dimethylsulfoxide 
DMT = 4,4-dimethoxy-triphenylmethyl 
DPPA = diphenylphosphorylazide 
EtOH = ethanol 
Fmoc = 9-fluorenylmethoxycarbonyl 
HEG = hexaethylene glycol 
HEPES = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPTS = (8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt 
Im = imidazole 
i-PrOH = isopropanol 
MMTr = 4-monomethoxytriphenylmethyl  
Py = pyridine 
Pic = picrate 
t-Bu = tert-butyl 
TBDMS = tert-butyldimethylsilyl  
TBDPS =  tert-butyldiphenylsilyl 
TCA = trichloroacetic acid 
TEA = triethylamine 
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TEG = triethylene glycol 
TFA = trifluoroacetic acid  
THF = tetrahydrofuran 
Thy = thymidine residue 
TIS = triisopropylsilane 
Trt = trityl 
